Bausch Health Companies (BHC) 10-K 19 Feb 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Feb. 13, 2020	Jun. 30, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-14956
Entity Registrant Name	Bausch Health Companies Inc.
Entity Incorporation, State or Country Code	A1
Entity Address, Country	CA
Entity Tax Identification Number	98-0448205
Entity Address, Address Line One	2150 St. Elzéar Blvd. West
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H7L 4A8
City Area Code	514
Local Phone Number	744-6792
Title of 12(b) Security	Common Shares, No Par Value
Trading Symbol	BHC
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Smaller Reporting Company	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 7,880,919,845
Entity Common Stock, Shares Outstanding (in shares)		352,704,400
Documents Incorporated by Reference	Part III incorporates certain information by reference from the registrant’s proxy statement for the 2020 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant’s fiscal year ended December 31, 2019 .
Entity Central Index Key	0000885590
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,243	$ 721
Restricted cash	1	2
Trade receivables, net	1,839	1,865
Inventories, net	1,107	934
Prepaid expenses and other current assets	779	689
Total current assets	6,969	4,211
Property, plant and equipment, net	1,466	1,353
Intangible assets, net	10,201	12,001
Goodwill	13,126	13,142
Deferred tax assets, net	1,690	1,676
Other non-current assets	411	109
Total assets	33,863	32,492
Current liabilities:
Accounts payable	503	411
Accrued and other current liabilities	4,511	3,197
Current portion of long-term debt and other	1,234	228
Total current liabilities	6,248	3,836
Acquisition-related contingent consideration	262	298
Non-current portion of long-term debt	24,661	24,077
Deferred tax liabilities, net	705	885
Other non-current liabilities	851	581
Total liabilities	32,727	29,677
Commitments and contingencies (Notes 21 and 22)
Equity
Common shares, no par value, unlimited shares authorized, 352,562,636 and 349,871,102 issued and outstanding at December 31, 2019 and 2018, respectively	10,172	10,121
Additional paid-in capital	429	413
Accumulated deficit	(7,452)	(5,664)
Accumulated other comprehensive loss	(2,086)	(2,137)
Total Bausch Health Companies Inc. shareholders’ equity	1,063	2,733
Noncontrolling interest	73	82
Total equity	1,136	2,815
Total liabilities and equity	$ 33,863	$ 32,492

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	352,562,636	349,871,102
Common stock, shares outstanding (in shares)	352,562,636	349,871,102

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues
Revenue	$ 8,601,000,000	$ 8,380,000,000	$ 8,724,000,000
Expenses
Selling, general and administrative	2,554,000,000	2,473,000,000	2,582,000,000
Research and development	471,000,000	413,000,000	361,000,000
Amortization of intangible assets	1,897,000,000	2,644,000,000	2,690,000,000
Goodwill impairments	0	2,322,000,000	312,000,000
Asset impairments	75,000,000	568,000,000	714,000,000
Restructuring and integration costs	31,000,000	22,000,000	52,000,000
Acquisition-related contingent consideration	12,000,000	(9,000,000)	(289,000,000)
Other expense (income), net	1,414,000,000	(20,000,000)	(348,000,000)
Total expenses	8,804,000,000	10,764,000,000	8,622,000,000
Operating (loss) income	(203,000,000)	(2,384,000,000)	102,000,000
Interest income	12,000,000	11,000,000	12,000,000
Interest expense	(1,612,000,000)	(1,685,000,000)	(1,840,000,000)
Loss on extinguishment of debt	(42,000,000)	(119,000,000)	(122,000,000)
Foreign exchange and other	8,000,000	23,000,000	107,000,000
Loss before benefit from income taxes	(1,837,000,000)	(4,154,000,000)	(1,741,000,000)
Benefit from income taxes	54,000,000	10,000,000	4,145,000,000
Net (loss) income	(1,783,000,000)	(4,144,000,000)	2,404,000,000
Net income attributable to noncontrolling interest	(5,000,000)	(4,000,000)	0
Net (loss) income attributable to Bausch Health Companies Inc.	$ (1,788,000,000)	$ (4,148,000,000)	$ 2,404,000,000
(Loss) earnings per share attributable to Bausch Health Companies Inc.
Basic (in dollars per share)	$ (5.08)	$ (11.81)	$ 6.86
Diluted (in dollars per share)	$ (5.08)	$ (11.81)	$ 6.83
Weighted-average common shares
Basic (in shares)	352.1	351.3	350.2
Diluted (in shares)	352.1	351.3	351.8
Product sales
Revenues
Revenue	$ 8,489,000,000	$ 8,271,000,000	$ 8,595,000,000
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	2,297,000,000	2,309,000,000	2,506,000,000
Other revenues
Revenues
Revenue	112,000,000	109,000,000	129,000,000
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 53,000,000	$ 42,000,000	$ 42,000,000

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (1,783)	$ (4,144)	$ 2,404
Pension and postretirement benefit plan adjustments:
Net actuarial (loss) gain arising during the year	(8)	(7)	20
Amortization of prior service credit	(4)	(4)	(4)
Amortization or settlement recognition of net loss	2	1	2
Income tax (expense) benefit	(2)	3	(4)
Foreign currency impact	(2)	0	1
Net pension and postretirement benefit plan adjustments	(14)	(7)	15
Foreign currency translation adjustment	64	(237)	202
Net unrealized holding loss on sale of assets and businesses:
Arising in period	0	0	(26)
Reclassification to net (loss) income	0	0	26
Other comprehensive income (loss)	50	(244)	217
Comprehensive (loss) income	(1,733)	(4,388)	2,621
Comprehensive income attributable to noncontrolling interest	(4)	(1)	(4)
Comprehensive (loss) income attributable to Bausch Health Companies Inc.	$ (1,737)	$ (4,389)	$ 2,617

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Bausch Health Companies Inc. Shareholders' Equity	Noncontrolling Interest
Beginning Balance (in shares) at Dec. 31, 2016		347,800,000
Beginning Balance at Dec. 31, 2016	$ 3,258	$ 10,038	$ 351	$ (5,129)	$ (2,108)	$ 3,152	$ 106
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		900,000
Common shares issued under share-based compensation plans	0	$ 52	(52)			0
Share-based compensation	87		87			87
Share-based awards tax withholding	(4)		(4)			(4)
Acquisition of noncontrolling interest	(9)		(2)		(1)	(3)	(6)
Noncontrolling interest distributions	(9)						(9)
Net (loss) income	2,404			2,404		2,404	0
Other comprehensive income (loss)	217				213	213	4
Ending Balance (in shares) at Dec. 31, 2017		348,700,000
Ending Balance at Dec. 31, 2017	5,944	$ 10,090	380	(2,725)	(1,896)	5,849	95
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		1,200,000
Common shares issued under share-based compensation plans	2	$ 31	(29)			2
Share-based compensation	87		87			87
Share-based awards tax withholding	(10)		(10)			(10)
Acquisition of noncontrolling interest	(18)		(15)			(15)	(3)
Noncontrolling interest distributions	(11)						(11)
Net (loss) income	(4,144)			(4,148)		(4,148)	4
Other comprehensive income (loss)	$ (244)				(241)	(241)	(3)
Ending Balance (in shares) at Dec. 31, 2018	349,871,102	349,900,000
Ending Balance at Dec. 31, 2018	$ 2,815	$ 10,121	413	(5,664)	(2,137)	2,733	82
Increase (Decrease) in Shareholders' Equity
Effect of application of new accounting standard: Income taxes	1,209			1,209		1,209
Common shares issued under share-based compensation plans (in shares)		2,700,000
Common shares issued under share-based compensation plans	5	$ 51	(46)			5
Share-based compensation	102		102			102
Share-based awards tax withholding	(40)		(40)			(40)
Noncontrolling interest distributions	(13)						(13)
Net (loss) income	(1,783)			(1,788)		(1,788)	5
Other comprehensive income (loss)	$ 50				51	51	(1)
Ending Balance (in shares) at Dec. 31, 2019	352,562,636	352,600,000
Ending Balance at Dec. 31, 2019	$ 1,136	$ 10,172	$ 429	$ (7,452)	$ (2,086)	$ 1,063	$ 73

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities
Net (loss) income	$ (1,783,000,000)	$ (4,144,000,000)	$ 2,404,000,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization of intangible assets	2,075,000,000	2,819,000,000	2,858,000,000
Amortization and write-off of debt discounts and debt issuance costs	63,000,000	79,000,000	151,000,000
Asset impairments	75,000,000	568,000,000	714,000,000
Goodwill impairment	0	2,322,000,000	312,000,000
Acquisition-related contingent consideration	12,000,000	(9,000,000)	(289,000,000)
Allowances for losses on trade receivables and inventories	75,000,000	69,000,000	119,000,000
Deferred income taxes	(230,000,000)	(144,000,000)	(4,386,000,000)
(Gain) loss on disposal of assets and businesses	(31,000,000)	6,000,000	(579,000,000)
Additions (reductions) to accrued legal settlements	1,401,000,000	(27,000,000)	226,000,000
Insurance proceeds for legal settlement	0	0	60,000,000
Payments of accrued legal settlements	(15,000,000)	(224,000,000)	(221,000,000)
Share-based compensation	102,000,000	87,000,000	87,000,000
Foreign exchange loss (gain)	7,000,000	(19,000,000)	(106,000,000)
Interest expense on cross-currency swaps	(9,000,000)	0	0
Loss on extinguishment of debt	42,000,000	119,000,000	122,000,000
Payments of contingent consideration adjustments, including accretion	(1,000,000)	(2,000,000)	(4,000,000)
Other	36,000,000	(17,000,000)	(22,000,000)
Changes in operating assets and liabilities:
Trade receivables	39,000,000	216,000,000	417,000,000
Inventories	(209,000,000)	(5,000,000)	7,000,000
Prepaid expenses and other current assets	1,000,000	(72,000,000)	33,000,000
Accounts payable, accrued and other liabilities	(149,000,000)	(121,000,000)	387,000,000
Net cash provided by operating activities	1,501,000,000	1,501,000,000	2,290,000,000
Cash Flows From Investing Activities
Acquisition of businesses, net of cash acquired	(180,000,000)	5,000,000	0
Acquisition of intangible assets and other assets	(8,000,000)	(78,000,000)	(165,000,000)
Purchases of property, plant and equipment	(270,000,000)	(157,000,000)	(171,000,000)
Purchases of marketable securities	(16,000,000)	(7,000,000)	(7,000,000)
Proceeds from sale of marketable securities	10,000,000	7,000,000	2,000,000
Proceeds from sale of assets and businesses, net of costs to sell	45,000,000	34,000,000	3,253,000,000
Other	0	0	(25,000,000)
Net cash (used in) provided by investing activities	(419,000,000)	(196,000,000)	2,887,000,000
Cash Flows From Financing Activities
Issuance of long-term debt, net of discounts	5,960,000,000	8,944,000,000	9,424,000,000
Repayments of long-term debt	(4,406,000,000)	(10,101,000,000)	(14,203,000,000)
Borrowings of short-term debt	12,000,000	0	1,000,000
Repayments of short-term debt	(12,000,000)	(3,000,000)	(8,000,000)
Payment of share-based awards tax withholding	(40,000,000)	(10,000,000)	(4,000,000)
Payments of contingent consideration	(35,000,000)	(37,000,000)	(45,000,000)
Payments of deferred consideration	0	(18,000,000)	0
Payments of financing costs	(28,000,000)	(102,000,000)	(110,000,000)
Other	(8,000,000)	(26,000,000)	(18,000,000)
Net cash provided by (used in) financing activities	1,443,000,000	(1,353,000,000)	(4,963,000,000)
Effect of exchange rate changes on cash and cash equivalents	(4,000,000)	(26,000,000)	41,000,000
Net increase (decrease) in cash and cash equivalents and restricted cash	2,521,000,000	(74,000,000)	255,000,000
Cash and cash equivalents and restricted cash, beginning of year	723,000,000	797,000,000	542,000,000
Cash and cash equivalents and restricted cash, end of year	3,244,000,000	723,000,000	797,000,000
Cash and cash equivalents, end of year	3,243,000,000	721,000,000	720,000,000
Restricted cash, end of year	1,000,000	2,000,000	77,000,000
Cash and cash equivalents and restricted cash, end of year	$ 3,244,000,000	$ 797,000,000	$ 797,000,000

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the “Company”), formerly known as Valeant Pharmaceuticals International, Inc., is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. In preparing the Company’s Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation. Acquisitions Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. Fair Value of Financial Instruments The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. Fair Value of Derivative Instruments The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period. The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the risk-free interest rate and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps, is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the year 2019 . The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations. Cash and Cash Equivalents Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities and trade receivables. The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months . Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties. The Company’s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company’s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. In November 2016, as a result of the Egyptian government’s decision to float the Egyptian pound and un-peg it to the U.S. Dollar, the Egyptian pound was significantly devalued. The Company's exposure to the Egyptian pound is with respect to the Amoun Pharmaceutical Company S.A.E. business acquired in October 2015, which represented approximately 3% , 2% and 2% of the Company's total revenues in each of the years 2019, 2018 and 2017 , respectively. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company’s trade receivables outstanding in these countries. As of December 31, 2019 , the Company’s three largest U.S. wholesaler customers accounted for approximately 41% of net trade receivables. In addition, as of December 31, 2019 and 2018 , the Company’s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Turkey, Ukraine and Venezuela amounted to $128 million and $105 million , respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90 days amounted to $1 million , as of December 31, 2019 , a portion of which is comprised of public hospitals. Based on analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three- year period ended December 31, 2019 , the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves. Allowance for Credit Losses An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be collected. Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were $48 million and $47 million as of December 31, 2019 and 2018 , respectively. Inventories Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand. Property, Plant and Equipment Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives: Land improvements 15 - 30 years Buildings and improvements Up to 40 years Machinery and equipment 3 - 20 years Other equipment 3 - 10 years Equipment on operating lease Up to 5 years Leasehold improvements Lesser of term of lease or 10 years Intangible Assets Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives: Product brands 2 - 20 years Corporate brands 7 - 20 years Product rights 3 - 15 years Partner relationships 7 - 9 years Out-licensed technology and other 8 - 10 years Divestitures of Products The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net . Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable. IPR&D The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. IPR&D assets are tested for impairment at least annually or when triggering events are identified. The fair value of an IPR&D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. Indefinite-lived intangible assets, which includes acquired IPR&D and the corporate trademark acquired in the acquisition of Bausch & Lomb Holdings Incorporated (the ‘‘B&L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value. Goodwill Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values. Prior to January 1, 2018, the goodwill impairment test consisted of two steps. In step one, the Company compared the carrying value of each reporting unit to its fair value. In step two, if the carrying value of a reporting unit exceeded its fair value, the Company would measure goodwill impairment as the excess of the carryi ng value of the reporting unit’s goodwill over the fair value of its goodwill, if any. The fair value of goodwill was derived as the excess of the fair value of the reporting unit over the fair value of the reporting unit’s identifiable assets and liabilities. Effective January 1, 2018, the Company elected to early adopt guidance issued by the Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. Further, an entity is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit. Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility. Foreign Currency Translation The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders’ equity. Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized in Net (loss) income . Revenue Recognition Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. Based upon review of current customer contracts, the Company concluded the implementation of the new guidance did not have a material quantitative impact on its Consolidated Financial Statements as the timing of revenue recognition for product sales did not significantly change. The Company adopted this guidance using the modified retrospective approach, and therefore, revenue reported for the year 2017 has not been restated. Although the new guidance did result in additional disclosures as to the nature, amounts and concentrations of revenue, it did not have a material impact on the Company's significant accounting policies. The revenue recognition policies as enumerated below reflect the Company's accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition. The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 23, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Product Sales A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed further below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products. Product Sales Provisions As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period. Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. The following table presents the activity and ending balances of the Company’s variable consideration provisions for years ended December 31, 2019 and 2018 . (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balance, January 1, 2018 $ 167 $ 863 $ 1,094 $ 274 $ 148 $ 2,546 Current period provision 865 293 2,551 1,966 212 5,887 Payments and credits (857 ) (343 ) (2,621 ) (2,031 ) (197 ) (6,049 ) Reserve balance, December 31, 2018 175 813 1,024 209 163 2,384 Acquisition of Synergy — 3 12 — 1 16 Current period provision 776 113 2,265 1,938 195 5,287 Payments and credits (769 ) (238 ) (2,374 ) (1,979 ) (277 ) (5,637 ) Reserve balance, December 31, 2019 $ 182 $ 691 $ 927 $ 168 $ 82 $ 2,050 Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $29 million and $26 million as of December 31, 2019 and 2018 , respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets. The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or an adjustment related to past sales, or both. If the actual amounts paid vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variance becomes known. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration. Cash Discounts and Allowances Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability. Returns Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns. In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $84 million for the year 2019 . The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not differ from original estimates of provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems. Over the last several years the Company increased its focus on maximizing operational efficiencies and reducing product returns. The Company continually takes actions to address product returns including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions resulted in improved sales return experience related to current branded products and previously genericized products. As a result, for the year 2019 as compared to 2018 , the provision for sales returns improved by a net of $180 million . During the three months ended September 30, 2019 and 2018 we recorded a reduction in variable consideration for sales returns of approximately $80 million and $30 million , respectively, related to past sales. Rebates and Chargebacks Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates. The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $83 million for 2019 . Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods. Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share. Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. In estimating provisions for

ACQUISITIONS AND LICENSING AGRE

ACQUISITIONS AND LICENSING AGREEMENTS	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
ACQUISITIONS AND LICENSING AGREEMENTS	ACQUISITIONS AND LICENSING AGREEMENTS Acquisition Agreement for Synergy Pharmaceuticals Inc. On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance ® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies. Assets Acquired and Liabilities Assumed The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date: (in millions) Accounts receivable $ 7 Inventories 24 Prepaid expenses and other current assets 5 Product brand intangible assets (estimated useful life - 7 years) 159 Accounts payable (1 ) Accrued expenses (17 ) Total identifiable net assets 177 Goodwill 3 Total fair value of consideration transferred $ 180 Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes. Revenue and Operating Results Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million . Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the years 2019 and 2018 were not material. Included in Other expense (income), net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services. Noncontrolling Interest in Medpharm a On October 16, 2018, using cash on hand, the Company acquired the 40% noncontrolling interest of Medpharma Pharmaceutical & Chemical Industries LLC (“Medpharma”) for $18 million . The difference between the carrying value and the price paid for the noncontrolling interest in Medpharma of $15 million , is a reduction of additional paid-in capital. There were no other material business combinations in 2019, 2018 or 2017. The measurement period for all acquisitions has closed. Licensing Agreement In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA, (iii) covered by third-party payors or (iv) profitable for distribution cannot be fairly predicted. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated. On February 21, 2017, EyeGate Pharmaceuticals, Inc. (“EyeGate”) granted a subsidiary of the Company the exclusive worldwide licensing rights to manufacture and sell the EyeGate ® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. Under the terms of the licensing agreement, EyeGate was responsible for the continued development of this product candidate in the U.S. for the treatment of post-operative pain and inflammation in ocular surgery patients, and all associated costs, and the Company had the right to further develop the product in the field outside of the U.S. at its cost. In connection with the licensing agreement, the Company paid an initial license fee of $4 million during the three months ended March 31, 2017 and was obligated to make future payments of: (i) up to $34 million upon the achievement of certain development and regulatory milestones, of which $3 million was paid, (ii) up to $65 million upon the achievement of certain sales-based milestones and (iii) royalties. Based on early stage of development of the asset, and lack of acquired significant inputs, the Company concluded this was an asset acquisition. On December 14, 2018, the Company issued a notice voluntarily terminating this licensing agreement dated February 21, 2017 and another license agreement dated July 9, 2015 with EyeGate, such termination was effective March 14, 2019. Following the termination of these agreements on March 14, 2019, the Company relinquished all rights to the EyeGate ® II Delivery System and EGP-437 combination product. During the three months ended September 30, 2018, the Company fully impaired the EyeGate ® II Delivery System and EGP-437 combination product intangible assets and reduced the carrying value of the contingent consideration liabilities associated with these licensing agreements to zero . All payments due to EyeGate for reimbursement of certain out-of-pocket costs incurred in connection with development work have been provided for in the Company's Consolidated Financial Statements.

DIVESTITURES

DIVESTITURES	12 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURES	DIVESTITURES During 2019, the Company reclassified certain products as held for sale. During 2018, the Company did no t make any material divestitures. During 2017, the Company divested certain businesses and assets, which, in each case, was not aligned with its core business objectives. 2019 Assets Held for Sale The Company has identified certain products in the Bausch + Lomb/International segment and one product in the Diversified Products segment for disposal as of December 31, 2019 . The products and the related assets and liabilities of this disposal group qualify as a business. Revenues associated with this business were $14 million and $19 million for the years 2019 and 2018 , respectively. The carrying value of the business, including inventories, intangible assets, goodwill and deferred income taxes, was adjusted to its estimated fair value less costs to sell and reclassified as held for sale as of December 31, 2019 . Included in Asset impairments in 2019 is a charge of $8 million associated with these assets held for sale. 2017 CeraVe ® , AcneFree ™ and AMBI ® skincare brands On March 3, 2017, the Company completed the sale of its interests in the CeraVe ® , AcneFree ™ and AMBI ® skincare brands for $1,300 million in cash (the “Skincare Sale”). The CeraVe ® , AcneFree ™ and AMBI ® skincare business was part of the Bausch + Lomb/International segment and was reclassified as held for sale as of December 31, 2016. Included in Other expense (income), net for the year 2017 is the Gain on the Skincare Sale of $309 million , as adjusted. Dendreon Pharmaceuticals LLC On June 28, 2017, the Company completed the sale of all outstanding equity interests in Dendreon Pharmaceuticals LLC (formerly Dendreon Pharmaceuticals, Inc.) (“Dendreon”) for $845 million in cash (the “Dendreon Sale”), as adjusted. Dendreon was part of the former Branded Rx segment and was reclassified as held for sale as of December 31, 2016. Included in Other expense (income), net for the year 2017 is the Gain on the Dendreon Sale of $97 million , as adjusted. iNova Pharmaceuticals On September 29, 2017, the Company completed the sale of its Australian-based iNova Pharmaceuticals (“iNova”) business for $938 million in cash (the “iNova Sale”), as adjusted. iNova markets a diversified portfolio of weight management, pain management, cardiology and cough and cold prescription and OTC products in more than 15 countries, with leading market positions in Australia and South Africa, as well as an established platform in Asia. The Company continues to operate in these geographies through the Bausch + Lomb franchise. The iNova business was part of the Bausch + Lomb/International segment and was reclassified as held for sale as of December 31, 2016. Included in Other expense (income), net for the year 2017 is the Gain on the iNova Sale of $309 million , as adjusted. Obagi Medical Products, Inc. On November 9, 2017, certain of the Company's affiliates completed the sale its Obagi Medical Products, Inc. (“Obagi”) business for $190 million in cash (the “Obagi Sale”). Obagi is a global specialty skin care pharmaceutical business with products focused on premature skin aging, skin damage, hyperpigmentation, acne and sun damage which are primarily available through dermatologists, plastic surgeons and other skin care professionals. The Obagi business was part of the former U.S. Diversified Products segment and was reclassified as held for sale as of March 31, 2017. The carrying value of the Obagi business, including associated goodwill, was adjusted to its estimated fair value less costs to sell and an impairment of $103 million was recognized in Asset impairments in the Consolidated Statement of Operations. Included in Other expense (income), net for the year 2017 is a $13 million loss related to this transaction. Sprout Pharmaceuticals, Inc. On December 20, 2017 , the Company completed the sale of Sprout to a buyer affiliated with certain former shareholders of Sprout (the “Sprout Sale”), in exchange for a 6% royalty on global sales of Addyi ® (flibanserin 100 mg) beginning June 2019. In connection with the completion of the Sprout Sale, the terms of the October 2015 merger agreement relating to the Company's acquisition of Sprout were amended to terminate the Company's ongoing obligation to make future royalty payments associated with the Addyi ® product, as well as certain related provisions (including the obligation to make certain marketing and other expenditures). In connection with the completion of the Sprout Sale, the litigation against the Company, initiated on behalf of the former shareholders of Sprout, which disputed the Company's compliance with certain contractual terms of that same merger agreement with respect to the use of certain diligent efforts to develop and commercialize the Addyi ® product (including a disputed contractual term with respect to the spend of no less than $200 million in certain expenditures), was dismissed with prejudice. In connection with the completion of the Sprout Sale, the Company issued the buyer a five -year $25 million loan for initial operating expenses. Addyi ® , a once-daily, non-hormonal tablet approved for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, is Sprout's only approved and commercialized product. Sprout was part of the former Branded Rx segment and was reclassified as held for sale as of September 30, 2017. The carrying value of the Sprout business, including associated goodwill, was adjusted to its estimated fair value less costs to sell and a $351 million impairment was recognized in Asset impairments in the year ended December 31, 2017. Upon consummation of the transaction, a loss of $98 million was recognized in Other expense (income), net . Beginning in June 2019, the Company has been recognizing the agreed upon 6% royalty of global sales of Addyi ® as these royalties become due, as the Company does not recognize contingent payments until such amounts are realizable.

RESTRUCTURING AND INTEGRATION C

RESTRUCTURING AND INTEGRATION COSTS	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND INTEGRATION COSTS	RESTRUCTURING AND INTEGRATION COSTS The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. The expenses associated with the implementation of these cost savings programs include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. Cost-rationalization and integration initiatives relating to the acquisition of Salix Pharmaceuticals, Ltd. ("Salix Ltd.") in April 2015 (the "Salix Acquisition") were substantially completed by mid-2016. The remaining liability associated with all cost-rationalization and integration initiatives as of December 31, 2019 was $27 million . During 2019, the Company incurred $31 million of restructuring and integration-related costs. These costs included: (i) $11 million of severance costs and other costs associated with the acquisition of certain assets of Synergy, (ii) $11 million of facility closure costs and (iii) $9 million of other severance costs. The Company made payments of $31 million during 2019. During 2018, the Company incurred $22 million of restructuring and integration-related costs. These costs included: (i) $11 million of severance costs, (ii) $10 million of facility closure costs and (iii) $1 million of other costs. The Company made payments of $33 million during 2018. During 2017, the Company incurred $52 million of restructuring and integration-related costs. These costs included: (i) $16 million of integration consulting, transition service and other costs, (ii) $16 million of severance costs and (iii) $20 million of facility closure costs. The Company made payments of $85 million

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value measurements are estimated based on valuation techniques and inputs categorized as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities; • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and 2018 : 2019 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 2,696 $ 2,646 $ 50 $ — $ 197 $ 166 $ 31 $ — Liabilities: Acquisition-related contingent consideration $ 316 $ — $ — $ 316 $ 339 $ — $ — $ 339 Cross-currency swaps $ 13 $ — $ 13 $ — $ — $ — $ — $ — There were no transfers between Level 1, Level 2 or Level 3 during 2019 and 2018 . Cross-currency Swaps During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million , to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. Prior to 2019, the Company had no derivative instruments for any period presented. The fair value of the Company’s cross-currency swaps liability as of December 31, 2019 was $13 million . Included in Other non-current liabilities is $22 million of cross-currency swaps liability and included in Prepaid expenses and other current assets is $9 million of earned interest within the Consolidated Balance Sheets. The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for the year 2019 : (in millions) Loss recognized in Gain excluded from assessment of hedge effectiveness Location of gain in income of excluded component Cross-currency swaps $ 22 $ 9 Interest expense During 2019 , there were no payments or receipts in settlement of the Company’s cross-currency swaps as the settlement dates occur in February and August of each year, with the first settlement in February 2020. Future settlements of the Company’s cross-currency swaps will be reported as investing activities in the Consolidated Statement of Cash Flows. Acquisition-related Contingent Consideration Obligations The fair value measurement of acquisition-related contingent consideration arising from business combinations is determined via a probability-weighted discounted cash flow analysis or Monte Carlo Simulation (if deemed appropriate), using unobservable (Level 3) inputs. These inputs may include: (i) the estimated amount and timing of projected cash flows, (ii) the probability of the achievement of the factor(s) on which the contingency is based, (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows and (iv) volatility of projected performance (Monte Carlo Simulation). Significant increases (decreases) in any of those inputs in isolation could result in a significantly lower (higher) fair value measurement. At December 31, 2019 , the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 5% to 25% . The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for 2019 and 2018 : (in millions) 2019 2018 Beginning balance, January 1, $ 339 $ 387 Adjustments to Acquisition-related contingent consideration: Accretion for the time value of money $ 22 $ 24 Fair value adjustments due to changes in estimates of future payments (10 ) (33 ) Acquisition-related contingent consideration adjustments 12 (9 ) Payments / Settlements (36 ) (39 ) Foreign currency translation adjustment included in other comprehensive loss 1 — Ending balance, December 31, 316 339 Current portion 54 41 Non-current portion $ 262 $ 298 Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis: December 31, 2019 December 31, 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Other non-current assets: Non-current assets held for sale $ 39 $ — $ — $ 39 $ — $ — $ — $ — Non-current assets held for sale of $39 million included in the Consolidated Balance Sheets as of December 31, 2019 were remeasured to estimated fair values less costs to sell. Included in Asset impairments in 2019 is a charge of $8 million associated with these assets held for sale. The estimated fair values of these assets less costs to sell were determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. See Note 4, "DIVESTITURES" for additional details regarding these assets held for sale. Fair Value of Long-term Debt The fair value of long-term debt as of December 31, 2019 and 2018 was $27,520 million and $23,357 million , respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, net of allowance for obsolescence, as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Raw materials $ 319 $ 275 Work in process 149 95 Finished goods 639 564 $ 1,107 $ 934

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT The major components of property, plant and equipment as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Land $ 79 $ 81 Buildings 696 693 Machinery and equipment 1,606 1,527 Other equipment and leasehold improvements 369 366 Equipment on operating lease 56 46 Construction in progress 301 162 3,107 2,875 Less accumulated depreciation (1,641 ) (1,522 ) $ 1,466 $ 1,353 Depreciation expense was $178 million , $175 million and $168 million for 2019 , 2018 and 2017 , respectively.

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	INTANGIBLE ASSETS AND GOODWILL Intangible Assets The major components of intangible assets as of December 31, 2019 and 2018 consist of: Weighted- Average Remaining Useful Lives (Years) 2019 2018 (in millions) Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Gross Carrying Amount Accumulated Net Carrying Amount Finite-lived intangible assets: Product brands 7 $ 21,011 $ (13,544 ) $ 7,467 $ 20,891 $ (11,958 ) $ 8,933 Corporate brands 8 930 (338 ) 592 926 (263 ) 663 Product rights/patents 4 3,297 (2,887 ) 410 3,292 (2,658 ) 634 Partner relationships 2 166 (165 ) 1 168 (166 ) 2 Technology and other 3 209 (189 ) 20 208 (173 ) 35 Total finite-lived intangible assets 25,613 (17,123 ) 8,490 25,485 (15,218 ) 10,267 Acquired IPR&D not in service NA 13 — 13 36 — 36 B&L Trademark NA 1,698 — 1,698 1,698 — 1,698 $ 27,324 $ (17,123 ) $ 10,201 $ 27,219 $ (15,218 ) $ 12,001 Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. Asset impairments for 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&D not in service. Asset impairments in 2018 included impairments of: (i) $348 million reflecting decreases in forecasted sales for the Uceris ® Tablet product in the Company's Salix reporting unit and other product lines due to generic competition, (ii) $132 million reflecting decreases in forecasted sales for the Arestin ® product in the Company's Dentistry reporting unit and other product lines due to changing market conditions, (iii) $55 million , in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses, (iv) $28 million to Acquired IPR&D not in service related to a certain product and (v) $5 million related to assets being classified as held for sale. Asset impairments in 2017 included impairments of: (i) $351 million related to the Sprout business being classified as held for sale, (ii) $151 million reflecting decreases in forecasted sales for other product lines, (iii) $114 million to other assets classified as held for sale, primarily related to the Obagi business, (iv) $95 million , in aggregate, to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core business and (v) $3 million related to acquired IPR&D. The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs. Periodically, the Company’s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity, due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company’s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material. As a result of the launch of a generic competitor in July 2018, the Company revised its near and long term financial projections of the Uceris ® Tablet-related intangible assets. As of June 30, 2018, the carrying value of the Uceris ® Tablet-related intangible assets exceeded the undiscounted expected cash flows from the Uceris ® Tablet. As a result, the Company recognized an impairment of $263 million to reduce the carrying value of the Uceris ® Tablet-related intangible assets to their estimated fair value. As of December 31, 2019 , the remaining carrying value of the Uceris ® Tablet-related intangible assets was $47 million . Prior to its launch, the Company initiated infringement proceedings against this generic competitor. The Company continues to believe that its Uceris ® Tablet related patents are enforceable and is proceeding in the ongoing litigation between the Company and the generic competitor; however, the ultimate outcome of the matter is not predictable. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. In review of the Company’s finite-lived intangible assets, management revised the estimated useful lives of certain intangible assets in 2018 and 2017. In review of the Company’s finite-lived intangible assets, management revised the estimated useful lives of certain intangible assets in the third and fourth quarters of 2017. As a result, the useful lives of certain product brands, with an aggregate carrying value of $7,618 million as of December 31, 2017, were revised from an average of seven years to four years primarily due to revisions in forecasted sales as a result of revisions to the date each product is expected to lose exclusivity. In addition, the useful life of the Salix Brand, with a carrying value of $569 million as of December 31, 2017, was revised from seventeen years to ten years , due to a change in the forecasted sales of its product portfolio. Effective September 12, 2018, the Company changed the estimated useful life of its Xifaxan ® -related intangible assets due to the positive impact of an agreement between the Company and Actavis Laboratories FL, Inc. ("Actavis") resolving the intellectual property litigation regarding Xifaxan ® tablets, 550 mg. Under the agreement, the parties agreed to dismiss all litigation related to Xifaxan ® tablets, 550 mg and all intellectual property protecting Xifaxan ® will remain intact and enforceable. As a result, the useful life of the Xifaxan ® -related intangible assets was extended from 2024 to January 1, 2028. As this change in the estimated useful life is a change in an accounting estimate, amortization expense is impacted prospectively. The change in the estimated useful life of the Xifaxan ® -related intangible assets resulted in a decrease to the Net loss attributable to Bausch Health Companies Inc. of $473 million and $143 million , and a decrease to the Basic and Diluted Loss per share attributable to Bausch Health Companies Inc. of $1.34 and $0.41 for the years 2019 and 2018 , respectively. As of December 31, 2019, the net carrying value of the Xifaxan ® -related intangible assets was $4,309 million . Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows: (in millions) 2020 2021 2022 2023 2024 Thereafter Total Amortization $ 1,624 $ 1,375 $ 1,224 $ 1,079 $ 950 $ 2,238 $ 8,490 Goodwill The changes in the carrying amounts of goodwill during the years ended December 31, 2019, 2018 and 2017 were as follows: (in millions) Bausch + Lomb/ International Branded Rx U.S. Diversified Products Salix Ortho Dermatologics Diversified Products Total Balance, January 1, 2017 $ 5,499 $ 7,265 $ 3,030 $ — $ — $ — $ 15,794 Realignment of segment goodwill 264 (264 ) — — — — — Goodwill reclassified to assets held for sale and subsequently disposed (30 ) (61 ) (84 ) — — — (175 ) Impairment of the former Branded Rx reporting unit — (312 ) — — — — (312 ) Foreign exchange and other 283 3 — — — — 286 Balance, December 31, 2017 6,016 6,631 2,946 — — — 15,593 Impairment of the Salix and Ortho Dermatologics reporting units — (2,213 ) — — — — (2,213 ) Realignment of Global Solta reporting unit goodwill (82 ) 115 (33 ) — — — — Goodwill reclassified to assets held for sale and subsequently disposed (2 ) — — — — — (2 ) Realignment of segment goodwill — (4,533 ) (2,913 ) 3,156 1,267 3,023 — Impairment of the Dentistry reporting unit — — — — — (109 ) (109 ) Foreign exchange and other (127 ) — — — — — (127 ) Balance, December 31, 2018 5,805 — — 3,156 1,267 2,914 13,142 Acquisition of certain assets of Synergy — — — 3 — — 3 Goodwill reclassified to assets held for sale (Note 4) (18 ) — — — — — (18 ) Foreign exchange and other (1 ) — — — — — (1 ) Balance, December 31, 2019 $ 5,786 $ — $ — $ 3,159 $ 1,267 $ 2,914 $ 13,126 Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The Company performed its annual impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount (Step 0). Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit (Step 1). The quantitative fair value test was performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. The Company forecasts cash flows for each reporting unit and takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts were based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. 2017 2017 Realignment of Segment Structure Effective January 1, 2017, revenues and profits from the Company's operations in Canada were reclassified from the former Branded Rx segment to the Bausch + Lomb/International segment. In connection with this change, the prior-period presentation of segment goodwill has been recast to conform to the then-current reporting structure, of which $264 million of goodwill as of December 31, 2016 was reclassified from the former Branded Rx segment to the Bausch + Lomb/International segment. No facts or circumstances were identified in connection with this change in alignment that would suggest an impairment existed. As detailed in Note 4, "DIVESTITURES" , the Sprout business was classified as held for sale as of September 30, 2017. As the Sprout business represented only a portion of a former Branded Rx reporting unit, the Company assessed the remaining reporting unit for impairment and determined the carrying value of the remaining reporting unit exceeded its fair value. After completing step two of the impairment testing, the Company determined and recorded a goodwill impairment charge of $312 million during the three months ended September 30, 2017. 2017 Annual Goodwill Impairment Test The Company conducted its annual goodwill impairment test as of October 1, 2017 and determined that the carrying value of the Salix reporting unit exceeded its fair value and, as a result, the Company proceeded to perform step two of the goodwill impairment test for the Salix reporting unit. After completing step two of the impairment testing, the Company determined that the carrying value of the unit's goodwill did not exceed its implied fair value and, therefore, no impairment was identified to the goodwill of the Salix reporting unit. As of the date of testing, the Salix reporting unit had an estimated fair value of $10,660 million and a carrying value of $13,404 million , including goodwill of $5,127 million . The Company's remaining reporting units passed step one of the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was no impairment to goodwill. Subsequent to the annual impairment test, the Company considered events occurring after October 1 st to determine if further testing was required. The Company considered the impact of the changes in the Tax Cuts and Jobs Act (the “Tax Act”) on its reporting units, including the impact on the carrying value, for changes in deferred tax assets and liabilities, and changes in assumptions related to the tax rate when assessing the fair value. The Company concluded that the fair value continued to exceed the carrying value for all reporting units, except Salix, after considering the impact of the changes in the Tax Act. Further, the Step 2 impairment test for Salix continued to support the carrying value of goodwill. As a result, no additional impairment charges were recorded. 2018 Adoption of New Accounting Guidance for Goodwill Impairment Testing In January 2017, the FASB issued guidance which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. The Company elected to adopt this guidance effective January 1, 2018. Upon adopting the new guidance, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value. As a result of the adoption of new accounting guidance, the Company recognized a goodwill impairment of $1,970 million associated with the Salix reporting unit. As of October 1, 2017, the date of the 2017 annual goodwill impairment test, the fair value of the Ortho Dermatologics reporting unit exceeded its carrying value. However, at January 1, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as: (i) changes in the dermatology sector, (ii) increased pricing pressures from third-party payors, (iii) additional risks to the exclusivity of certain products and (iv) an expected longer launch cycle for a new product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of October 1, 2017, when the Company performed its 2017 annual goodwill impairment test. In response to these adverse business indicators, as of January 1, 2018, the Company reduced its near and long term financial projections for the Ortho Dermatologics reporting unit. As a result of the reductions in the near and long term financial projections, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at January 1, 2018 and the Company recognized a goodwill impairment of $243 million . 2018 Realignment of Solta Business Effective March 1, 2018, revenues and profits from the U.S. Solta business included in the former U.S. Diversified Products segment in prior periods and revenues and profits from the international Solta business included in the Bausch + Lomb/ International segment in prior periods, are reported in the new Global Solta reporting unit, which, at that time, was a part of the former Branded Rx segment. As a result of this change, $115 million of goodwill was reallocated to the new Global Solta reporting unit and the Company assessed the impact on the fair values of each of the reporting units affected. After considering, among other matters: (i) the limited period of time between last impairment test (January 1, 2018) and the realignment (March 1, 2018), (ii) the results of the last impairment test and (iii) the amount of goodwill reallocated to the new Global Solta reporting unit, the Company did not identify any indicators of impairment at the time of the realignment. 2018 Realignment of Segment Structure In the second quarter of 2018, the Company began operating in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The Bausch + Lomb/International segment consists of the: (i) U.S. Bausch + Lomb and (ii) International reporting units. The Salix segment consists of the Salix reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. There was no triggering event which would require the Company to test goodwill for impairment as a result of the second quarter realignment of the segment structure as it did not result in a change in the reporting units. 2018 Interim Goodwill Impairment Assessments - Salix As a result of the change in accounting policy for goodwill impairment testing and the resulting impairment to the goodwill of the Salix reporting unit as of January 1, 2018, the carrying value of the Salix reporting unit approximated its fair value at that time. Therefore, during the three months ended March 31, 2018, June 30, 2018 and September 30, 2018, the Company performed qualitative assessments of the Salix reporting unit to determine if testing was warranted. As part of these qualitative assessments, management considered the revisions made to its forecasts for the Salix reporting unit and compared the reporting unit’s revised operating results to its original forecasts through the date of each assessment. The revisions to the forecasts reflected, among other matters: (i) the launch of a generic competitor in July 2018 to the Company’s Uceris ® Tablet product, (ii) the improved performance of the remaining Salix product portfolio, including the Xifaxan ® products, (iii) the positive impact of the settlement agreement between the Company and Actavis resolving the intellectual property litigation regarding Xifaxan ® tablets, 550 mg and (iv) certain other assumptions used in preparing its discounted cash flow model. As part of these qualitative assessments, management also considered the sensitivity of its conclusions as they related to changes in the estimates and assumptions used in the latest forecast available for each period. Based on these qualitative assessments, management believed that the carrying value of the Salix reporting unit did not exceed its fair value and, therefore, concluded a quantitative assessment was not required for the Salix reporting unit. 2018 Interim Goodwill Impairment Assessments and Testing - Ortho Dermatologics As a result of the change in accounting policy for goodwill impairment testing and the resulting impairment to the goodwill of the Ortho Dermatologics reporting unit as of January 1, 2018, the carrying value of the Ortho Dermatologics reporting unit approximated its fair value at that time. Therefore, during the three months ended March 31, 2018, June 30, 2018 and September 30, 2018, the Company performed qualitative assessments of the Ortho Dermatologics reporting unit to determine if testing was warranted. As part of the qualitative assessment as of March 31, 2018, management compared the reporting unit’s operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit as of January 1, 2018. Based on the qualitative assessment, management believed that the carrying value of Ortho Dermatologics reporting unit did not exceed its fair value and, therefore, concluded a quantitative assessment was not required at March 31, 2018. During the three months ended June 30, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as changes in the dermatology sector, additional risks to the exclusivity of certain products and a longer than originally expected launch cycle for a certain product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of January 1, 2018, when the Company performed its last goodwill impairment test. In response to these adverse business indicators, the Company performed a goodwill impairment test of the Ortho Dermatologics reporting unit. Based on the goodwill impairment test performed, the estimated fair value of the Ortho Dermatologics reporting unit exceeded its carrying value at the date of testing by approximately 5% and, therefore, there was no impairment to goodwill. As part of the qualitative assessment as of September 30, 2018, management compared the reporting unit’s operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit as of June 30, 2018. Based on the qualitative assessment, management believed that the carrying value of Ortho Dermatologics reporting unit did not exceed its fair value and, therefore, concluded a quantitative assessment was not required at September 30, 2018. 2018 Annual Goodwill Impairment Test The Company conducted its annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million for the Dentistry reporting unit, representing the full amount of goodwill for the reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results. The Company is taking steps to address these changing market and business conditions. The Company's remaining reporting units passed the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was no impairment to goodwill for any reporting unit other than the Dentistry reporting unit. In order to evaluate the sensitivity of its fair value calculations on the goodwill impairment test, the Company compared the carrying value of each reporting unit to its fair value as of October 1, 2018, the date of testing. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15% . 2019 2019 Interim Goodwill Impairment Assessment No events occurred or circumstances changed during the period October 1, 2018 through September 30, 2019 that would indicate that the fair value of any reporting unit might be below its carrying value. Based on the results of the October 1, 2018 annual goodwill impairment test, the Company performed qualitative interim assessments of the carrying value and fair value of the Ortho Dermatologics reporting unit on a quarterly basis to determine if quantitative fair value testing was warranted. As part of these qualitative assessments, management considered the totality of all relevant events or circumstances that affect the carrying amount or fair value of the reporting unit, including comparing the reporting unit’s operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit as of October 1, 2018. Based on the qualitative assessments, management believed that the carrying value of Ortho Dermatologics reporting unit did not exceed its fair value and, therefore, concluded a quantitative assessment was not required for any period. 2019 Annual Goodwill Impairment Test The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit. As a result, there was no impairment to the goodwill of any reporting unit. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. Specifically, the Company continues to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as compared to their respective projections and will perform qualitative interim assessments of the carrying value and fair value on a quarterly basis to determine if impairment testing of goodwill will be warranted. The Company performed quantitative fair value tests for the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019, utilizing long-term growth rates of 2.0% and 1.5% , and discount rates of 9.8% and 9.0% , respectively, in estimation of the fair value of these reporting units. Accumulated goodwill impairment charges through December 31, 2019 were $3,711 million .

ACCRUED AND OTHER CURRENT LIABI

ACCRUED AND OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
ACCRUED AND OTHER CURRENT LIABILITIES	ACCRUED AND OTHER CURRENT LIABILITIES Accrued and other current liabilities as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Legal matters and related fees $ 1,397 $ 11 Product rebates 898 998 Product returns 691 813 Interest 305 273 Employee compensation and benefit costs 304 301 Income taxes payable 196 167 Other 720 634 $ 4,511 $ 3,197

FINANCING ARRANGEMENTS

FINANCING ARRANGEMENTS	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2019 and 2018 consists of the following: 2019 2018 (in millions) Maturity Principal Amount Net of Premiums, Discounts and Issuance Costs Principal Amount Net of Premiums, Discounts and Issuance Costs Senior Secured Credit Facilities: 2023 Revolving Credit Facility June 2023 — — 75 75 June 2025 Term Loan B Facility June 2025 3,869 3,768 4,394 4,269 November 2025 Term Loan B Facility November 2025 1,275 1,257 1,481 1,456 Senior Secured Notes: 6.50% Secured Notes March 2022 1,250 1,242 1,250 1,239 7.00% Secured Notes March 2024 2,000 1,983 2,000 1,979 5.50% Secured Notes November 2025 1,750 1,733 1,750 1,730 5.75% Secured Notes August 2027 500 493 — — Senior Unsecured Notes: 5.625% December 2021 — — 700 697 5.50% March 2023 402 400 1,000 995 5.875% May 2023 1,448 1,441 3,250 3,229 4.50% euro-denominated debt May 2023 1,682 1,674 1,720 1,709 6.125% April 2025 3,250 3,230 3,250 3,226 9.00% December 2025 1,500 1,473 1,500 1,469 9.25% April 2026 1,500 1,484 1,500 1,482 8.50% January 2027 1,750 1,756 750 738 7.00% January 2028 750 741 — — 5.00% January 2028 1,250 1,234 — — 7.25% May 2029 750 740 — — 5.25% January 2030 1,250 1,234 — — Other Various 12 12 12 12 Total long-term debt and other $ 26,188 25,895 $ 24,632 24,305 Less: Current portion of long-term debt and other 1,234 228 Non-current portion of long-term debt $ 24,661 $ 24,077 Covenant Compliance The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00 :1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill. As of December 31, 2019 , the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company’s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate. Senior Secured Credit Facilities On February 13, 2012, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Third Amended Credit Agreement”) with a syndicate of financial institutions and investors, as lenders. As of January 1, 2017, the Third Amended Credit Agreement provided for: (i) a $1,500 million Revolving Credit Facility maturing on April 20, 2018 (the "2018 Revolving Credit Facility") and (ii) $9,939 million in a series of term loans maturing during the years 2018 through 2022. There was $875 million outstanding under the 2018 Revolving Credit Facility as of January 1, 2017. 2017 Activity During 2017, the Company repaid $3,221 million of outstanding debt under its Senior Secured Credit Facilities using the net proceeds from the Skincare Sale, Dendreon Sale, iNova Sale, Obagi Sale and the divestiture of a manufacturing facility in Brazil. During 2017, the Company also repaid another $786 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand. On March 21, 2017, the Company entered into Amendment No. 14 to the Third Amended Credit Agreement, which, among other changes, provided additional financing from an incremental term loan under the Company's Series F Tranche B Term Loan Facility (the “Series F Tranche B Term Loan Facility”), the proceeds of which, combined with the proceeds from the issuance of the March 2022 Secured Notes (as defined below) and the March 2024 Secured Notes (as defined below) and cash on hand, were used to: (i) refinance $4,962 million of term loans under the Senior Secured Credit Facilities (the “March 2017 Refinanced Debt”), (ii) repurchase $1,100 million in principal amount of 6.75% senior unsecured notes due August 2018 (the " August 2018 Unsecured Notes "), (iii) repay $350 million of amounts outstanding under the Company's 2018 Revolving Credit Facility and (iv) pay related fees and expenses (collectively, the “March 2017 Refinancing Transactions”). On March 28, 2017, the Company entered into Amendment No. 15 to the Third Amended Credit Agreement which provided for the extension of the maturity date of $1,190 million of revolving credit commitments under the 2018 Revolving Credit Facility from April 20, 2018 to April 20, 2020 (the “2020 Revolving Credit Facility”). On November 21, 2017, the Company entered into Amendment No. 16 to the Third Amended Credit Agreement to reprice the then outstanding term loans under its Senior Credit Facilities. In connection with the repayments of debt and amendments to its Senior Secured Credit Facilities during 2017, the Company recognized $66 million in aggregate losses on extinguishment of debt representing: (i) the difference between the amounts paid to settle extinguished debt and its carrying value (the stated principal amount net of unamortized discount and debt issuance costs) and (ii) prepayment penalties. Third-party expenses of $3 million associated with the modification of certain debt under the Senior Secured Credit Facilities were expensed as incurred and included in Interest expense during 2017. 2018 Activity During 2018, the Company repaid (net of additional borrowings) $571 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand. On June 1, 2018, the Company entered into a Restatement Agreement in respect of a Fourth Amended and Restated Credit and Guaranty Agreement (the “Restated Credit Agreement”) which restated in full the Third Amended Credit Agreement. The Restated Credit Agreement replaced the 2020 Revolving Credit Facility with a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and replaced the Series F Tranche B Term Loan Facility principal amount outstanding of $3,315 million with a new seven year Tranche B Term Loan Facility of $4,565 million (the “ June 2025 Term Loan B Facility ”) borrowed by the Company’s subsidiary, Bausch Health Americas, Inc. ("BHA") (formerly Valeant Pharmaceuticals International). The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million . Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars, Canadian dollars or euros. On June 1, 2018, the Company issued an irrevocable notice of redemption for the remaining outstanding principal amounts of: (i) $691 million of the March 2020 Unsecured Notes (as defined below), (ii) $578 million of 6.75% Senior Unsecured Notes due August 2021 (the “August 2021 Unsecured Notes”), (iii) $550 million of 7.25% Senior Unsecured Notes due July 2022 (the “July 2022 Unsecured Notes”) and (iv) $146 million of 6.375% Senior Unsecured Notes due October 2020 (the March 2020 Unsecured Notes (as defined below), together with the August 2021 Unsecured Notes, the July 2022 Unsecured Notes and the 6.375% Senior Unsecured Notes due October 2020 the “June 2018 Unsecured Refinanced Debt”). On June 1, 2018, using the remaining net proceeds from the June 2025 Term Loan B Facility , the net proceeds from the issuance of $750 million in aggregate principal amount of 8.50% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") by BHA and cash on hand, the Company prepaid the remaining Series F Tranche B Term Loan Facility and redeemed the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged (collectively, the “ June 2018 Refinancing Transactions ”). The Restated Credit Agreement was accounted for as a modification of debt, to the extent the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to the same creditor, and as an extinguishment of debt if: (i) the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to a different creditor, (ii) a portion of the unamortized deferred financing fees was allocated to debt that was paid down or (iii) the borrowing capacity declined when issuing a new revolving credit facility. The following was accounted for as an extinguishment of debt: (i) the difference between the amounts paid to redeem the June 2018 Unsecured Refinanced Debt and the June 2018 Unsecured Refinanced Debt’s carrying value, (ii) the replacement of the Series F Tranche B Term Loan Facility with the June 2025 Term Loan B Facility to the extent any unamortized deferred financing fees were associated with the portion of the Series F Tranche B Term Loan Facility that was paid down and (iii) the replacement of the 2020 Revolving Credit Facility with the 2023 Revolving Credit Facility to the extent any unamortized deferred financing fees were associated with the decline in borrowing capacity. For amounts accounted for as an extinguishment of debt, the Company incurred a loss on extinguishment of debt of $48 million . Payments made to the lenders and a portion of payments made to third parties of $74 million associated with the June 2018 Refinancing Transactions were capitalized and are being amortized as interest expense over the remaining terms of the debt, ranging from 2023 through 2027. Third-party expenses of $4 million associated with the modification of debt were expensed as incurred and included in Interest expense. On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500 million (the " November 2025 Term Loan B Facility ") and used the net proceeds, and cash on hand, to repay $1,483 million of 7.50% Senior Unsecured Notes due July 2021 (the “ July 2021 Unsecured Notes ”) in a tender offer (the " November 2018 Refinancing Transactions "). On December 27, 2018, the Company redeemed, using cash on hand, the remaining outstanding principal amount of $17 million of the July 2021 Unsecured Notes . The repayment of the July 2021 Unsecured Notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $43 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Payments made to the lenders and other third parties of $25 million associated with the issuance of the November 2025 Term Loan B Facility were capitalized and are being amortized as interest expense over the remaining term of the November 2025 Term Loan B Facility . 2019 Activity During 2019, the Company repaid (net of additional borrowings) $806 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand. As of December 31, 2019 , the Company had no outstanding borrowings, $170 million of issued and outstanding letters of credit, and remaining availability of $1,055 million under its 2023 Revolving Credit Facility. Current Description of Senior Secured Credit Facilities Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00% ) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin. Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00% ) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization. The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75% , respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75% , respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2019 , the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 4.74% and 4.49% per annum, respectively. The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2019 , the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $1,126 million through November 1, 2025. The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50% - 2.00% with respect to base rate or prime rate borrowings and 2.50% - 3.00% with respect to eurocurrency rate or BA rate borrowings. As of December 31, 2019 , the stated rate of interest on the 2023 Revolving Credit Facility was 4.74% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees. The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50 :1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50 :1.00 or an interest coverage ratio of not less than 2.00 :1.00. Senior Secured Notes The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral. Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest. 6.50% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024 - March 2017 Refinancing Transactions As part of the March 2017 Refinancing Transactions, the Company issued $1,250 million aggregate principal amount of 6.50% senior secured notes due March 15, 2022 (the “ March 2022 Secured Notes ”) and $2,000 million aggregate principal amount of 7.00% senior secured notes due March 15, 2024 (the “ March 2024 Secured Notes ”), in a private placement, the proceeds of which, when combined with the proceeds from the Series F Tranche B Term Loan Facility and cash on hand, were used to: (i) repay the March 2017 Refinanced Debt, (ii) repurchase $1,100 million in principal amount of August 2018 Unsecured Notes , (iii) repay $350 million of amounts outstanding under the 2018 Revolving Credit Facility and (iv) pay related fees and expenses. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15. The March 2022 Secured Notes are redeemable at the option of the Company, in whole or in part, at the redemption prices set forth in the indenture. The March 2024 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after March 15, 2020, at the redemption prices set forth in the indenture. The Company may redeem some or all of the March 2024 Secured Notes prior to March 15, 2020 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to March 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the March 2024 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture. 5.50% Senior Secured Notes due 2025 - October 2017 Refinancing Transactions and November 2017 Refinancing Transactions On October 17, 2017, the Company issued $1,000 million aggregate principal amount of 5.50% Senior Secured Notes due November 2025 (the “ November 2025 Secured Notes ”), in a private placement, the proceeds of which were used to repurchase $1,000 million in aggregate principal amount of previously outstanding senior unsecured notes (the “October 2017 Refinancing Transactions”). The related fees and expenses were paid using cash on hand. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1. The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after November 1, 2020, at the redemption prices set forth in the indenture. The Company may redeem some or all of the November 2025 Secured Notes prior to November 1, 2020 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to November 1, 2020, the Company may redeem up to 40% of the aggregate principal amount of the November 2025 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture. On November 21, 2017 , the Company issued $750 million aggregate principal amount of the November 2025 Secured Notes in a private placement. These are additional notes and form part of the same series as the Company’s existing November 2025 Secured Notes . The proceeds were used to prepay $750 million of its Series F Tranche B Term Loan Facility. The related fees and expenses were paid using cash on hand (collectively, the “November 2017 Refinancing Transactions”). 5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes”) and (iv) pay all fees and expenses associated with these transactions (collectively, the “ March 2019 Refinancing Transactions ”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15. The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture. Senior Unsecured Notes The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest. 5.625% Senior Unsecured Notes due 2021 On December 2, 2013, the Company issued $900 million aggregate principal amount of December 2021 Unsecured Notes in a private placement. The December 2021 Unsecured Notes accrued interest at the rate of 5.625% per year and were subsequently repaid in full: (i) using cash on hand of $200 million in December 2018 and (ii) as part of the March 2019 Refinancing Transactions . 5.50% Senior Unsecured Notes due 2023 On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. The March 2023 Unsecured Notes accrue interest at the rate of 5.50% per year, payable semi-annually in arrears. The Company may redeem all or a portion of the remaining March 2023 Unsecured Notes at the applicable redemption prices set forth in the March 2023 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. 5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.50% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025 On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the " March 2020 Unsecured Notes "), $3,250 million aggregate principal amount of 5.875% Senior Unsecured Notes due 2023 (the " May 2023 Unsecured Notes "), €1,500 million aggregate principal amount of 4.50% Senior Unsecured Notes due 2023 (the "Euro Notes”) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the " April 2025 Unsecured Notes " and, together with the March 2020 Unsecured Notes , the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement. In addition, the VRX Issuer entered into an escrow and security agreement (the “Escrow Agreement”) dated as of March 27, 2015, with an escrow agent. Pursuant to the Escrow Agreement, the proceeds from the issuance of the VRX Notes, together with cash sufficient to fund certain accrued and unpaid interest on the VRX Notes, totaling $10,340 million in the aggregate, were deposited into escrow accounts and held as security for the VRX Issuer’s obligations until the consummation of the Salix Acquisition, which occurred on April 1, 2015. At the time of the closing of the Salix Acquisition, (1) the VRX Issuer was voluntarily liquidated and all of its obligations were assumed by, and all of its assets were distributed to, the Company, (2) the Company assumed all of the VRX Issuer's obligations under the VRX Notes and the related indenture and (3) the funds previously held in escrow were released to the Company and were used to finance the Salix Acquisition (as such, the $10,340 million referenced in this paragraph was released from restricted cash and cash equivalents in April 2015.) The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of: (i) the December 2017 Refinancing Transactions (as defined below), (ii) the March 2018 Refinancing Transactions (as defined below) and (iii) the June 2018 Refinancing Transactions . The May 2023 Unsecured Notes , the Euro Notes and the April 2025 Unsecured Notes accrue interest at the rate of 5.875% , 4.50% and 6.125% per year, respectively, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On December 18, 2019, the Company issued a conditional notice of redemption to redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020. On December 30, 2019, the Company received the proceeds associated with the December 2019 Financing and Refinancing Transactions (as defined below), satisfying the condition included in this conditional notice of redemption. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of May 2023 Unsecured Notes . The Company may redeem all or a portion of the April 2025 Unsecured Notes at any time prior to April 15, 2020 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. The Company may redeem all or a portion of the May 2023 Unsecured Notes or the Euro Notes and, on or after April 15, 2020, the Company may redeem all or a portion of the April 2025 Unsecured Notes , at the redemption prices applicable to each series of such notes, as set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption. 9.00% Senior Unsecured Notes due 2025 - December 2017 Refinancing Transactions On December 18, 2017, the Company issued $1,500 million aggregate principal amount of 9.00% Senior Unsecured Notes due 2025 (the “ December 2025 Unsecured Notes ”) in a private placement, the net proceeds of which were used to repurchase $1,500 million in aggregate principal amount of previously outstanding senior unsecured notes (the “December 2017 Refinancing Transactions”). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.00% per year, payable semi-annually in arrears on each of June 15 and December 15. The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole”

PENSION AND POSTRETIREMENT EMPL

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch & Lomb Holdings Incorporated (‘‘B&L’’) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees. In addition to the B&L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. Accounting for Pension Benefit Plans and Postretirement Benefit Plan The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of other comprehensive income (loss). The amounts included in Accumulated other comprehensive loss as of December 31, 2019 , and 2018 were as follows: Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 2019 2018 Unrecognized actuarial losses $ (20 ) $ (31 ) $ (65 ) $ (50 ) $ (2 ) $ (1 ) Unrecognized prior service credits $ — $ — $ 26 $ 27 $ 14 $ 17 Of the December 31, 2019 amounts, the Company expects to recognize $3 million and $1 million of unrecognized prior service credits related to the U.S. postretirement benefit plan and the non-U.S. defined benefit plans, respectively, in net periodic (benefit) cost during 2020 . In addition, the Company expects to recognize $2 million of unrecognized actuarial losses related to the non-U.S. pension benefit plans in net periodic (benefit) cost during 2020 . Net Periodic (Benefit) Cost The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2019 , 2018 and 2017 : Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2017 2019 2018 2017 2019 2018 2017 Service cost $ 2 $ 2 $ 2 $ 3 $ 3 $ 3 $ — $ — $ — Interest cost 8 7 8 5 5 5 1 1 2 Expected return on plan assets (13 ) (15 ) (13 ) (5 ) (5 ) (5 ) — — — Amortization of net loss — — — 1 1 2 — — — Amortization of prior service credit — — — (1 ) (1 ) (1 ) (2 ) (2 ) (3 ) Other — — — 1 — — — — — Net periodic (benefit) cost $ (3 ) $ (6 ) $ (3 ) $ 4 $ 3 $ 4 $ (1 ) $ (1 ) $ (1 ) Benefit Obligation, Change in Plan Assets and Funded Status The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2019 and 2018 : Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 2019 2018 Change in Projected Benefit Obligation Projected benefit obligation, beginning of year $ 214 $ 234 $ 235 $ 254 $ 41 $ 48 Service cost 2 2 3 3 — — Interest cost 8 7 5 5 1 1 Employee contributions — — — — 1 1 Settlements — — (2 ) (2 ) — — Benefits paid (15 ) (16 ) (8 ) (5 ) (4 ) (5 ) Actuarial losses (gains) 18 (13 ) 30 (10 ) 2 (4 ) Currency translation adjustments — — (4 ) (10 ) — — Projected benefit obligation, end of year 227 214 259 235 41 41 Change in Plan Assets Fair value of plan assets, beginning of year 187 206 147 155 — — Actual return on plan assets 42 (11 ) 17 (2 ) — — Employee contributions — — — — 1 1 Company contributions 2 8 10 7 3 4 Settlements — — (2 ) (2 ) — — Benefits paid (15 ) (16 ) (8 ) (5 ) (4 ) (5 ) Currency translation adjustments — — (3 ) (6 ) — — Fair value of plan assets, end of year 216 187 161 147 — — Funded Status at end of year $ (11 ) $ (27 ) $ (98 ) $ (88 ) $ (41 ) $ (41 ) Recognized as: Accrued and other current liabilities $ — $ — $ (2 ) $ (2 ) $ (5 ) $ (5 ) Other non-current liabilities $ (11 ) $ (27 ) $ (96 ) $ (86 ) $ (36 ) $ (36 ) A number of the Company’s pension benefit plans were underfunded as of December 31, 2019 and 2018 , having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows: U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 Projected benefit obligation $ 227 $ 214 $ 259 $ 235 Accumulated benefit obligation 227 214 251 225 Fair value of plan assets 216 187 161 147 The Company’s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2020 , the Company expects to contribute $3 million , $9 million and $5 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2020 . Estimated Future Benefit Payments Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: (in millions) Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans 2020 $ 14 $ 5 $ 5 2021 18 6 4 2022 18 6 4 2023 17 6 4 2024 16 6 3 2025-2029 77 33 13 Assumptions The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2019, 2018 and 2017 were as follows: Pension Benefit Plans U.S. Postretirement Benefit Plan 2019 2018 2017 2019 2018 2017 For Determining Net Periodic (Benefit) Cost U.S. Plans: Discount rate 4.25 % 3.56 % 4.04 % 4.16 % 3.47 % 3.85 % Expected rate of return on plan assets 7.25 % 7.50 % 7.50 % — — — Rate of compensation increase — — — — — — Non-U.S. Plans: Discount rate 2.39 % 2.29 % 2.08 % Expected rate of return on plan assets 3.46 % 3.66 % 3.84 % Rate of compensation increase 2.89 % 2.87 % 2.64 % Pension Benefit Plans U.S. Postretirement Benefit Plan 2019 2018 2019 2018 For Determining Benefit Obligation U.S. Plans: Discount rate 3.16 % 4.25 % 3.04 % 4.16 % Rate of compensation increase — — — — Non-U.S. Plans: Discount rate 1.68 % 2.39 % Rate of compensation increase 3.05 % 2.89 % The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company’s U.S. pension plan for 2019 was 7.25% . The expected return on plan assets for the Company’s Ireland pension plans was 3.50% for 2019 . The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants. The 2020 expected rate of return for the U.S. pension benefit plan will be 6.25% . The 2020 expected rate of return for the Ireland pension benefit plans will be 3.00% . Pension Benefit Plans Assets Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2019 and 2018 : 2019 2018 U.S. Plan Equity securities 55 % 52 % Fixed income securities 44 % 47 % Other 1 % 1 % Non-U.S. Plans Cash and cash equivalents 6 % 5 % Equity securities 25 % 20 % Fixed income securities 64 % 69 % Other 6 % 6 % The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches. The Company’s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities. Fair Value of Plan Assets The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 6, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy. The table below presents total plan assets by investment category as of December 31, 2019 and 2018 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2019 and 2018 . Pension Benefit Plans - U.S. Plans December 31, 2019 December 31, 2018 (in millions) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash and cash equivalents $ 1 $ — $ — $ 1 $ 2 $ — $ — $ 2 Commingled funds: Equity securities: U.S. broad market — 64 — 64 — 51 — 51 Emerging markets — 15 — 15 — 13 — 13 Worldwide developed markets — 26 — 26 — 21 — 21 Other assets — 15 — 15 — 13 — 13 Fixed income securities: Investment grade — 95 — 95 — 87 — 87 $ 1 $ 215 $ — $ 216 $ 2 $ 185 $ — $ 187 Pension Benefit Plans - Non-U.S. Plans December 31, 2019 December 31, 2018 (in millions) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents $ — $ 9 $ — $ 9 $ — $ 7 $ — $ 7 Commingled funds: Equity securities: Emerging markets — 2 — 2 — 1 — 1 Worldwide developed markets — 38 — 38 — 29 — 29 Fixed income securities: Investment grade — 9 — 9 — 9 — 9 Global high yield — 3 — 3 — 2 — 2 Government bond funds 1 90 — 91 — 90 — 90 Other assets — 8 1 9 — 9 — 9 $ 1 $ 159 $ 1 $ 161 $ — $ 147 $ — $ 147 Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 95% of the non-U.S. commingled funds in 2019 and 2018 . The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds. The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. Defined Contribution Plans The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries. Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $41 million , $36 million and $22 million to these plans during the years ended December 31, 2019, 2018 and 2017 , respectively.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	LEASES Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2019 as follows: (in millions) Right-of-use assets included in: Other non-current assets $ 271 Lease liabilities included in: Accrued and other current liabilities $ 53 Other non-current liabilities 240 Total lease liabilities $ 293 As of December 31, 2019 , the Company's finance leases were no t material and for the year 2019 sub-lease income and short-term lease expense were no t material. Lease expense for the year 2019 includes: (in millions) Operating lease costs $ 62 Variable operating lease costs $ 16 Other information related to operating leases for 2019 is as follows: (dollars in millions) Cash paid from operating cash flows for amounts included in the measurement of lease liabilities $ 73 Right-of-use assets obtained in exchange for new operating lease liabilities $ 47 Weighted-average remaining lease term 8.2 years Weighted-average discount rate 6.2 % Right-of-use assets obtained in exchange for new operating lease liabilities during the year ended December 31, 2019 of $47 million in the table above does not include $282 million of right-of-use assets recognized upon adoption of the new standard for accounting for leases on January 1, 2019. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" for further detail regarding the impact of adoption. As of December 31, 2019 , future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows: (in millions) 2020 $ 70 2021 55 2022 42 2023 37 2024 30 Thereafter 149 Total 383 Less: Imputed interest 90 Present value of remaining lease payments 293 Less: Current portion 53 Non-current portion $ 240 Upon adopting the new lease guidance, the Company elected the modified retrospective approach without revising prior periods. Accordingly, rental expense related to operating lease agreements was $92 million and $102 million for 2018 and 2017, respectively, and the Company is providing the following table of future payments under noncancelable operating leases as of December 31, 2018, for each of the five succeeding years ending December 31 and thereafter as previously disclosed under prior accounting guidance: (in millions) 2019 2020 2021 2022 2023 Thereafter Total Future payments $ 78 $ 60 $ 44 $ 39 $ 32 $ 166 $ 419

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan is equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. Effective April 30, 2018, the Company amended and restated the 2014 Plan (the “Amended and Restated 2014 Plan”). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company’s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis. During 2017, the Company introduced a new long-term incentive program with the objective of realigning the share-based awards granted to senior management with the Company’s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (“TSR”) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company’s return on tangible capital (“ROTC”). Approximately 9,864,000 common shares were available for future grants as of December 31, 2019 . The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans. The components and classification of share-based compensation expense related to stock options and RSUs for the years 2019 , 2018 and 2017 were as follows: (in millions) 2019 2018 2017 Stock options $ 21 $ 23 $ 18 RSUs 81 64 69 Share-based compensation expense $ 102 $ 87 $ 87 Research and development expenses $ 9 $ 9 $ 8 Selling, general and administrative expenses 93 78 79 Share-based compensation expense $ 102 $ 87 $ 87 Stock Options Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share preceding the date of grant. Stock options generally vest 33% and 25% each year over a three -year and four -year period, respectively, on the anniversary of the date of grant. The fair values of all stock options granted for the years 2019 , 2018 and 2017 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: 2019 2018 2017 Expected stock option life (years) 3.0 3.0 3.0 Expected volatility 46.5 % 54.0 % 67.3 % Risk-free interest rate 2.5 % 2.7 % 1.8 % Expected dividend yield — % — % — % The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option’s exercise price and expected annual dividend rate at the time of grant. The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company’s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values. The following table summarizes stock option activity during 2019 : (in millions, except per share amounts) Options Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2019 5.9 $ 27.88 Granted 1.7 $ 23.19 Exercised (0.3 ) $ 16.03 Expired or forfeited (0.2 ) $ 37.27 Outstanding, December 31, 2019 7.1 $ 26.99 7.5 $ 61 Vested and expected to vest, December 31, 2019 6.7 $ 27.43 7.4 $ 57 Vested and exercisable, December 31, 2019 3.6 $ 34.27 6.5 $ 24 The weighted-average fair values of all stock options granted in 2019, 2018 and 2017 were $8.45 , $7.83 and $5.97 , respectively. The total intrinsic values of stock options exercised in 2019, 2018 and 2017 were $3 million , $1 million and $1 million , respectively. Proceeds received on the exercise of stock options in 2019, 2018 and 2017 were $5 million , $2 million and $1 million , respectively. As of December 31, 2019 , the total remaining unrecognized compensation expense related to non-vested stock options amounted to $11 million , which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. The total fair value of stock options vested in 2019, 2018 and 2017 were $18 million , $17 million and $20 million , respectively. RSUs RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three -year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company’s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited. To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company’s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company’s common shares on the vesting date. The Company’s current intent is to settle vested RSUs through the issuance of common shares. Time-Based RSUs Each vested time-based RSU represents the right of a holder to receive one of the Company’s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company’s common shares on the date of grant. The following table summarizes non-vested time-based RSU activity during 2019 : (in millions, except per share amounts) Time-Based RSUs Weighted- Average Grant-Date Fair Value Per Share Non-vested, January 1, 2019 5.8 $ 18.29 Granted 3.1 $ 24.13 Vested (1.9 ) $ 17.88 Forfeited (0.9 ) $ 23.77 Non-vested, December 31, 2019 6.1 $ 20.54 As of December 31, 2019 , the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $56 million , which will be amortized over the weighted-average remaining requisite service period of approximately 1.6 years. The total fair value of time-based RSUs vested in 2019, 2018 and 2017 were $34 million , $30 million and $58 million , respectively. Performance-Based RSUs Each vested performance-based RSU represents the right of a holder to receive a number of the Company’s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company’s performance is below a specified performance level, no common shares will be paid. The fair value of each TSR performance-based RSU granted during 2019 , 2018 and 2017 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company’s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company’s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. The fair values of TSR performance-based RSUs granted during 2019 , 2018 and 2017 were estimated with the following assumptions: 2019 2018 2017 Contractual term (years) 3.0 3.0 3.0 Expected Company share volatility 46.5% 54.2% 67.2% - 77.2% Risk-free interest rate 2.5% 2.7% 1.7% - 1.8% The expected company share volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the contractual term of the performance-based RSUs. The following table summarizes non-vested performance-based RSU activity during 2019 : (in millions, except per share amounts) Performance-based RSUs Weighted- Average Grant-Date Fair Value Per Share Non-vested, January 1, 2019 1.5 $ 34.06 Granted 1.0 $ 29.52 Vested (0.3 ) $ 48.42 Forfeited (0.2 ) $ 91.76 Non-vested, December 31, 2019 2.0 $ 25.80 During 2019 , the Company granted approximately 959,000 performance-based RSUs, consisting of approximately 454,000 units of TSR performance-based RSUs with an average grant date fair value of $34.53 per RSU and approximately 505,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $25.03 per RSU. As of December 31, 2019 , the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $28 million , which will be amortized over the weighted-average remaining requisite service period of approximately 1.6 years. A maximum of approximately 3,486,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2019 . In connection with the 2018 grant of long-term incentive awards with an aggregate value of $10 million , approximately 933,000 performance-based RSUs received by the Company’s Chief Executive Officer ("CEO") upon his hire in 2016 were canceled, and the shares underlying those performance-based RSUs were permanently retired and are not available for future grants under the 2014 Plan. The CEO's long-term incentive award was accounted for as an award modification whereby the Company continues to recognize the unamortized compensation associated with the original award plus the incremental fair value of the new award measured at the date of grant, over the vesting period of the new award.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED OTHER COMPREHENSIVE LOSS Accumulated other comprehensive loss as of December 31, 2019 and 2018 consists of: (in millions) 2019 2018 Foreign currency translation adjustment $ (2,046 ) $ (2,111 ) Pension adjustment, net of tax (40 ) (26 ) $ (2,086 ) $ (2,137 ) Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company’s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	12 Months Ended
	Dec. 31, 2019
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2019 , 2018 and 2017 consists of: (in millions) 2019 2018 2017 Product related research and development $ 434 $ 376 $ 328 Quality assurance 37 37 33 Research and development $ 471 $ 413 $ 361

OTHER EXPENSE (INCOME), NET

OTHER EXPENSE (INCOME), NET	12 Months Ended
	Dec. 31, 2019
Other Income and Expenses [Abstract]
OTHER EXPENSE (INCOME), NET	OTHER EXPENSE (INCOME), NET Other expense (income), net for the years 2019 , 2018 and 2017 consists of: (in millions) 2019 2018 2017 Gain on the Skincare Sale $ — $ — $ (309 ) Gain on the iNova Sale — — (309 ) Gain on the Dendreon Sale — — (97 ) Loss on the Sprout Sale — — 98 Net (gain) loss on other sales of assets (31 ) 6 37 Litigation and other matters 1,401 (27 ) 226 Acquired in-process research and development costs 41 1 5 Acquisition-related costs 8 1 — Other, net (5 ) (1 ) 1 Other expense (income), net $ 1,414 $ (20 ) $ (348 ) In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter (which is subject to final court approval) . In 2018, Litigation and other matters of $27 million includes a favorable adjustment of $40 million related to the Salix legacy litigation matter. In 2017, Litigation and other matters of $226 million includes: (i) $96 million related to the settlement of the Allergan shareholder class actions, (ii) $93 million related to the settlement of the Solodyn ® antitrust class actions litigation and (iii) $20 million related to the Mimetogen Pharmaceuticals litigation. These matters and other significant matters are discussed in further detail in Note 21, "LEGAL PROCEEDINGS" . In 2019, Net (gain) loss on other sales of assets includes $20 million related to the achievement of a milestone related to a certain product. In 2019, Acquired in-process research and development costs includes $38 million of in-process research and development costs associated with the upfront payments to enter into certain exclusive licensing agreements.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The components of Loss before benefit from income taxes for 2019 , 2018 and 2017 consist of: (in millions) 2019 2018 2017 Domestic $ (2,396 ) $ (1,475 ) $ (2,032 ) Foreign 559 (2,679 ) 291 $ (1,837 ) $ (4,154 ) $ (1,741 ) The components of Benefit from income taxes for 2019 , 2018 and 2017 consist of: (in millions) 2019 2018 2017 Current: Domestic $ (12 ) $ — $ (20 ) Foreign (116 ) (327 ) (146 ) (128 ) (327 ) (166 ) Deferred: Domestic (5 ) 17 (2 ) Foreign 187 320 4,313 182 337 4,311 $ 54 $ 10 $ 4,145 The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2019 , 2018 and 2017 as follows: (in millions) 2019 2018 2017 Loss before benefit from income taxes $ (1,837 ) $ (4,154 ) $ (1,741 ) Benefit from income taxes Expected benefit from income taxes at Canadian statutory rate $ 494 $ 1,117 $ 468 Non-deductible amount of share-based compensation (7 ) (10 ) (37 ) Adjustments to tax attributes (99 ) (4 ) (242 ) Impact of changes in enacted income tax rates — — 747 Change in valuation allowance related to foreign tax credits and NOLs 21 (3 ) 139 Change in valuation allowance on Canadian deferred tax assets and tax rate changes (142 ) (875 ) (360 ) Change in uncertain tax positions (350 ) (47 ) (65 ) Foreign tax rate differences 186 (3 ) 933 Non-deductible portion of Goodwill impairments — (488 ) (139 ) Tax differences on divestitures of businesses — — 203 Tax benefit on intra-entity transfers — 356 2,480 Other (49 ) (33 ) 18 $ 54 $ 10 $ 4,145 Deferred tax assets and liabilities as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Deferred tax assets: Tax loss carryforwards $ 2,911 $ 2,886 Provisions 641 519 Research and development tax credits 155 143 Scientific Research and Experimental Development pool 52 52 Tax credit carryforwards 25 46 Deferred revenue 5 4 Unrealized FX on U.S. dollar debt and other financing cost 94 262 Prepaid expenses 41 44 Share-based compensation 19 24 Other 23 — Total deferred tax assets 3,966 3,980 Less valuation allowance (2,831 ) (2,913 ) Net deferred tax assets 1,135 1,067 Deferred tax liabilities: Intangible assets 53 163 Plant, equipment and technology 56 55 Outside basis differences 41 29 Other — 29 Total deferred tax liabilities 150 276 Net deferred tax asset (liability) $ 985 $ 791 On December 22, 2017, the Tax Act was signed into law and included a number of changes in the U.S. tax law, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The Tax Act also implemented a modified territorial tax system that included a one-time transition tax on the accumulated previously untaxed earnings of foreign subsidiaries (the “Transition Toll Tax”) equal to 15.5% (reinvested in liquid assets) or 8% (reinvested in non-liquid assets). At the taxpayer's election, the Transition Toll Tax can be paid over an eight -year period without interest, starting in 2018. The Company elected not to use this option and instead used a portion of its U.S. net operating losses ("NOLs") to offset this income inclusion. The Tax Act also includes two U.S. tax base erosion provisions: (i) the base-erosion and anti-abuse tax (“BEAT”) and (ii) the global intangible low-taxed income (“GILTI”). BEAT provides a minimum tax on U.S. tax deductible payments made to related foreign parties after December 31, 2017. GILTI requires an entity to include in its U.S. taxable income the earnings of its foreign subsidiaries in excess of an allowable return on each foreign subsidiary’s depreciable tangible assets. Accounting guidance provides that the impacts of GILTI can be included in the consolidated financial statements either by recording the impacts in the period in which GILTI has been incurred or by adjusting deferred tax assets or liabilities in the period of enactment related to basis differences expected to reverse as a result of the GILTI provisions in future years. The Company elected to provide for the GILTI tax in the period in which it is incurred and, therefore, the 2017 benefit for income taxes did not include a provision for GILTI. Income tax expense for years after 2017 includes the effects of the Tax Act including both GILTI and BEAT. As part of the Tax Act, the Company’s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. The Company considered such provisions in 2018 and 2019 and expects to fully utilize any interest carry forwards in future periods. The Company’s Benefit from income taxes for the year 2017 included provisional net tax benefits of $975 million attributable to the Tax Act which included: (i) the re-measurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future of $774 million , (ii) the one-time Transition Toll Tax of $88 million and (iii) the decrease in deferred tax assets attributable to certain legal accruals, the deductibility of which is uncertain for U.S. federal income tax purposes, of $10 million . The Company utilized NOLs to offset the provisionally determined $88 million Transition Toll Tax and therefore no amount was recorded as payable. The Company previously provided for residual U.S. federal income tax on its outside basis differences in certain foreign subsidiaries which, due to the Tax Act, are no longer taxable. As such, the Company's residual U.S. federal income tax liability of $299 million prior to the Tax Act was reversed and the Company recognized a deferred tax benefit of $299 million in the fourth quarter of 2017. The provisional amounts included in Benefit from income taxes for the year 2017, including the Transition Toll Tax, were finalized during 2018. Differences between the provisional net income tax benefits provided for the year 2017 attributable to the Tax Act of $975 million , as previously disclosed, and the benefit for income taxes as finalized are included in the Benefit from income taxes for 2018 and were not material to the Company’s financial results for the year 2018. The Company has provided for income taxes, including the impacts of the Tax Act, in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. In 2017, the Company liquidated its top U.S. subsidiary (Biovail Americas Corp.) in a taxable transaction that resulted in a taxable loss which was of a character that offset certain gains from internal restructurings and third-party divestitures, the excess of which was, under U.S. tax law, able to be carried back to offset previously recognized gains in 2016, 2015 and 2014. This carryback resulted in an increase in the deferred tax asset for NOLs previously utilized against such gains. In connection with this taxable transaction, the Company recognized a net income tax benefit of approximately $400 million related to the carryback of losses and reversed a previously established deferred tax liability of approximately $1,900 million . The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. As a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings, the valuation allowance decreased by $82 million during 2019 and increased by $912 million during 2018. Given the Company’s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (“ITC”) and pooled Scientific Research and Experimental Development Tax Incentive (“SR&ED”) expenditures. The Canadian valuation allowance represents a material portion of the Company's total valuation allowance. As of December 31, 2019 and 2018 , the Company had accumulated taxable losses available to offset future years’ federal and provincial taxable income in Canada of approximately $7,441 million and $5,655 million , respectively. As of December 31, 2019 and 2018 , unclaimed ITCs available to offset future federal taxes in Canada were approximately $34 million and $34 million , respectively, which expire in the years 2020 through 2036. In addition, as of December 31, 2019 and 2018 , pooled SR&ED expenditures available to offset against future taxable income in Canada were approximately $192 million and $192 million , respectively, which may be carried forward indefinitely. As of December 31, 2019 and 2018 , a full valuation allowance against the net Canadian deferred tax assets has been provided of $2,461 million and $2,470 million , respectively. As of December 31, 2019 and 2018 , the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $636 million and $1,552 million , respectively, including acquired losses which expire in the years 2021 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2019 and 2018 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $106 million and $97 million , respectively, which includes acquired research and development credits and which expire in the years 2021 through 2038. The Company intends to amend prior U.S. tax filings in order to deduct foreign taxes rather than take a foreign tax credit. Therefore, during 2017, the Company reversed the deferred tax asset and associated valuation allowance of approximately $342 million in U.S. foreign tax credits, including acquired U.S. foreign tax credits. The Company recorded a deferred tax benefit of $84 million for such deduction and adjusted its expected NOL carryforward accordingly. In conjunction with the Sprout Sale in 2017, the Company recognized a capital loss and established a valuation allowance on the portion of the loss for which a benefit is not expected to be realized. Previously valued capital loses utilized during 2019 were not material. As of December 31, 2019 and 2018, the Company had accumulated taxable losses available to offset future years’ taxable income in Ireland of approximately $6,765 million and $5,495 million , respectively. As of December 31, 2019 and 2018, the Company recognized a capital loss and established a valuation allowance on the portion of the loss for which a benefit is not expected to be realized. The Company provides for Canadian tax on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S. subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2019 , the Company estimates there will be no tax liability attributable to the permanently reinvested U.S. earnings. As of December 31, 2019 and 2018 , unrecognized tax benefits (including interest and penalties) were $1,002 million and $654 million , of which $355 million and $345 million would affect the effective income tax rate, respectively. In 2019 and 2018 , the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2019 and 2018 , the Company recognized net increases to unrecognized tax benefits for current year tax positions of $362 million and $18 million , respectively. The Company recognized a net reduction of $13 million during 2019 and a net increase of $38 million during 2018 in the unrecognized tax benefits related to tax positions taken in the prior years. The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2019 and 2018 , accrued interest and penalties related to unrecognized tax benefits were approximately $45 million and $42 million , respectively. In 2019 and 2018 , the Company recognized a net increase of approximately $3 million and $1 million of interest and penalties, respectively. The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S. The Company and its subsidiaries have open tax years, primarily from 2005 to 2018, with significant taxing jurisdictions, respectively, including Canada and the U.S. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely. Jurisdiction: Open Years United States - Federal 2014 - 2018 Canada 2005 - 2018 Germany 2013 - 2018 France 2013 - 2018 China 2015 - 2018 Ireland 2015 - 2018 Netherlands 2018 Australia 2011 - 2018 The Internal Revenue Service completed its examinations of the Company’s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations. The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the Internal Revenue Service has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements. The Company is currently under examination by the Canada Revenue Agency for four separate cycles: (a) years 2005 through 2006, (b) years 2007 through 2009, (c) years 2012 through 2013 and (d) years 2014 through 2015. The Company received from the Canada Revenue Agency a proposed audit adjustment for the years 2005 through 2009. The Company disagrees with the adjustments and has filed the respective Notices of Objection. The total proposed adjustment will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in material change to the provision for income taxes. The Canada Revenue Agency audits of the 2010 and 2011 tax years were closed in 2016, and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85 million and CAD 90 million , respectively. The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and will file an objection for 2013. Of the total proposed adjustments, all but CAD 3 million will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in a material change to the provision for income taxes. The Company’s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements. The Company’s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million , which includes penalties and interest. The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. As of December 31, 2017, Restricted cash of $77 million was deposited with a bank as collateral to secure a bank guarantee for the benefit of the Australian Government. On January 9, 2018, the cash collateral of $77 million of Restricted cash was returned to the Company in exchange for a $77 million letter of credit. The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2012 through 2017. Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements. The following table presents a reconciliation of the unrecognized tax benefits for 2019, 2018 and 2017 : (in millions) 2019 2018 2017 Balance, beginning of year $ 654 $ 598 $ 423 Additions based on tax positions related to the current year 361 18 145 Additions for tax positions of prior years 63 55 57 Reductions for tax positions of prior years (58 ) (11 ) (18 ) Lapse of statute of limitations (18 ) (6 ) (9 ) Balance, end of year $ 1,002 $ 654 $ 598 The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2019 could decrease by approximately $110 million in the next twelve months as a result of the resolution of certain tax audits and other events.

(LOSS) EARNINGS PER SHARE

(LOSS) EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
(LOSS) EARNINGS PER SHARE	(LOSS) EARNINGS PER SHARE (Loss) earnings per share attributable to Bausch Health Companies Inc. for 2019, 2018 and 2017 were calculated as follows: (in millions, except per share amounts) 2019 2018 2017 Net (loss) income attributable to Bausch Health Companies Inc. $ (1,788 ) $ (4,148 ) $ 2,404 Basic weighted-average number of common shares outstanding 352.1 351.3 350.2 Dilutive effect of stock options, RSUs and other — — 1.6 Diluted weighted-average number of common shares outstanding 352.1 351.3 351.8 (Loss) earnings per share attributable to Bausch Health Companies Inc. Basic $ (5.08 ) $ (11.81 ) $ 6.86 Diluted $ (5.08 ) $ (11.81 ) $ 6.83 In 2019 and 2018, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 5,106,000 and 3,763,000 common shares for 2019 and 2018 , respectively. Additionally, in 2019, 2018 and 2017 , stock options, time-based RSUs and performance-based RSUs to purchase approximately 2,598,000 , 4,185,000 and 7,050,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.

SUPPLEMENTAL CASH FLOW DISCLOSU

SUPPLEMENTAL CASH FLOW DISCLOSURES	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW DISCLOSURES	SUPPLEMENTAL CASH FLOW DISCLOSURES Supplemental cash flow disclosures for 2019, 2018 and 2017 are as follows: (in millions) 2019 2018 2017 Other Payments Interest paid $ 1,537 $ 1,665 $ 1,708 Income taxes paid $ 172 $ 138 $ 179

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	LEGAL PROCEEDINGS From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law. On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2019 , the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,397 million , inclusive of the settlement of the U.S. Securities Litigation (as discussed below) and related to other matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline. Governmental and Regulatory Inquiries SEC Investigation Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. The Company is cooperating with the SEC in this matter, has agreed to a tolling agreement with the SEC regarding certain potential claims and continues to engage in discussions with the SEC regarding resolution of the matter. Although the Company cannot predict the outcome or the duration of the SEC investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of the SEC investigation, the Company expects that it will likely result in damages, settlement payments, fines, penalties, consent orders or other administrative sanctions against the Company and/or certain of its former legacy directors and officers, any of which could be material. As a result, although no agreement has been reached, the Company has recorded an estimated liability based on these discussions which is included in the Company's accrued current loss contingencies. The final resolution may differ from the Company's current estimate and it could be material to the Company’s results of operations. AMF Investigation On April 12, 2016, the Company received a request letter from the Autorité des marchés financiers (the “AMF”) requesting documents concerning the work of the Company’s ad hoc committee of independent directors (established to review certain allegations regarding the Company’s former relationship with Philidor and related matters), the Company’s former relationship with Philidor, the Company's accounting practices and policies and other matters. The Company is cooperating with the AMF in this matter. In July 2018, the Company was advised by the AMF that it had issued a formal investigation order against it. The Company cannot predict whether any enforcement action against the Company will result from such investigation. Investigation by the U.S. Attorney's Office for the District of Massachusetts - re Arestin ® In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts. The materials requested pursuant to the subpoena include documents concerning the sales, marketing, coverage and reimbursement of Arestin ® , including related support services, and other matters. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation. Investigation by the U.S. Attorney's Office for the District of Massachusetts - re patient assistance and pricing In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, and, in June 2016, the Company received a follow-up subpoena. The materials requested, pursuant to the subpoenas and follow-up requests, include documents and witness interviews with respect to the Company’s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company’s pricing of its products. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation. Investigation by the U.S. Attorney's Office for the Southern District of New York In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York. The materials requested, pursuant to the subpoena and follow-up requests, include documents and witness interviews with respect to the Company’s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company’s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company’s pricing (including discounts and rebates), marketing and distribution of its products; the Company’s compliance program; and employee compensation. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation. Securities and RICO Class Actions and Related Matters U.S. Securities Litigation - Opt-Out Litigation On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On June 24, 2016, the lead plaintiff filed a consolidated complaint asserting claims under Sections 10(b) and 20(a) of the Exchange Act against the Company, and certain current or former officers and directors, as well as claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”) against the Company, certain current or former officers and directors, and certain other parties. The lead plaintiff seeks to bring these claims on behalf of a putative class of persons who purchased the Company’s equity securities and senior notes in the United States between January 4, 2013 and March 15, 2016, including all those who purchased the Company’s securities in the United States in the Company’s debt and stock offerings between July 2013 to March 2015. On September 13, 2016, the Company and the other defendants moved to dismiss the consolidated complaint. On April 28, 2017, the court dismissed certain claims arising out of the Company's private placement offerings and otherwise denied the motions to dismiss. On September 20, 2018, lead plaintiff filed an amended complaint, adding claims against ValueAct Capital Management L.P. and affiliated entities ("ValueAct"). On October 31, 2018, a third-party defendant, ValueAct, filed a motion to dismiss. On June 30, 2019, the Court denied the motion to dismiss and ValueAct has filed for interlocutory appeal of this decision. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million , subject to final court approval. Once approved by the court, the settlement will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing . The opt-out litigations related to this matter discussed above remain ongoing. On January 10, 2020, the Company made a payment of $200 million into an escrow fund under the terms of the settlement agreement. On January 27, 2020 the court preliminarily approved the settlement and scheduled the final settlement approval hearing for May 27, 2020. The balance of the settlement will be paid in accordance with the payment schedule outlined in the settlement agreement. The opt-out litigations discussed below remain ongoing. On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (“Timber Hill”), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company’s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order. In addition to the consolidated putative class action, thirty-three groups of individual investors in the Company’s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions pending in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (“Janus Aspen”); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (“Okumus”); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (“Lord Abbett”); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) ("Pentwater"); Public Employees’ Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (“Mississippi”); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (“Boeing”); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); Första AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (“NYCERS”); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (“Hound Partners”); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (“Blackrock”); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (“Prudential”); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) ("Senzar"); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (“Catalyst”); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (“Northwestern Mutual”); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (“Aly”); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (“Connecticut”); and Delaware Public Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (“Delaware”). These individual shareholder actions assert claims under Sections 10(b), 18, and 20(a) of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, and negligent misrepresentation under state law, based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. Some plaintiffs additionally assert claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act and one plaintiff asserts claims under the Connecticut Uniform Securities Act. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants’ motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (“Aly”) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On December 13, 2019, the Court granted the Company’s motion to dismiss the Catalyst complaint in its entirety. The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously. Canadian Securities Litigation In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O’Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined above. The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above. Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings. In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations. The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights (“CalSTRS”) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers’ Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations. On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company’s auditors. The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously. Insurance Coverage Lawsuit On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described above (under the 2015-2016 coverage period). RICO Class Actions Between May 27, 2016 and September 16, 2016, three virtually identical actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties, alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (“RICO”) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company branded drugs between January 2, 2013 and November 9, 2015. On November 30, 2016, the Court entered an order consolidating the three actions under the caption In re Valeant Pharmaceuticals International, Inc. Third-Party Payor Litigation, No. 3:16-cv-03087. A consolidated class action complaint was filed on December 14, 2016. The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured’s consent to renew the prescription. The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute. The Company moved to dismiss the consolidated complaint on February 13, 2017. On March 14, 2017, other defendants filed a motion to stay the RICO class action pending the resolution of criminal proceedings against Andrew Davenport and Gary Tanner. On August 9, 2017, the Court granted the motion to stay and entered an order staying all proceedings in the case and accordingly terminating other pending motions. On April 12, 2019, the court lifted the stay. On July 30, 2019, the plaintiffs filed an amended complaint. On August 28, 2019, the Company filed a motion to dismiss the amended complaint. Briefing on this motion concluded on October 25, 2019. The Company believes these claims are without merit and intends to defend itself vigorously. Hound Partners Lawsuit On October 19, 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County. This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18). This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The factual allegations made in this complaint are similar to those made in the District of New Jersey Hound Partners action. On March 29, 2019, the Company, certain individual defendants, and Plaintiffs submitted a consent order to stay further proceedings pending the completion of discovery in the federal opt-out case Hound Partners Offshore Funds, LP et al. v. Valeant Pharmaceuticals International, Inc. (Case No. 3:18-cv-08705). On October 9, 2019, the Court entered the consent order. The Company disputes the claims and intends to vigorously defend this matter. Derivative Lawsuits On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. The cases are Wessels v. Pearson (Case No. 3:19-cv-17833) and Shabbouei v. Pearson (Case No. 3:19-cv-17987). Plaintiffs in both cases assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The claims alleged in these cases are based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation , all of which occurred prior to 2017. The Shabbouei complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. On January 3, 2020, the parties submitted a letter to the Court requesting consolidation of the two derivative lawsuits. The Company disputes these claims and intends to defend itself vigorously. Antitrust Generic Pricing Antitrust Litigation The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (“Oceanside”), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (“Bausch Health US”), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (“Bausch Health Americas”) (for the purposes of this subsection, collectively, the “Company”), are defendants in multidistrict antitrust litigation (“MDL”) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation , pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The initial lawsuit to which the Company was added as a defendant in June 2018 was filed by a putative class of direct purchaser plaintiffs. In December 2018, certain direct purchaser plaintiffs that had opted out of this putative class filed an amended complaint in the MDL that added the Company, alleging similar claims as the direct purchaser plaintiffs’ putative class action complaint. In February 2019, the Company filed a motion to dismiss the individual claims brought against it and that motion remains pending. In October 2019, an end payer plaintiff that had opted out of the putative end payer class filed a complaint against the Company in the Eastern District of Pennsylvania alleging similar claims. In December 2019, end payer opt-out complaints also were filed against the Company in the Eastern District of Pennsylvania and in the Northern District of California. In December 2019, separate putative class action complaints were filed against the Company in the Eastern District of Pennsylvania by end payer and indirect reseller plaintiffs. In February 2020, a new putative class action complaint was filed against the Company in the Eastern District of Pennsylvania by direct purchaser plaintiffs. The cases have been consolidated into the MDL. There are also additional, separate complaints by other plaintiffs which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. In July 2019, 87 health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously. Glumetza Antitrust Litigation Between August and December 2019, six (6) putative antitrust class actions and two (2) non-class complaints were filed in the Northern District of California against the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (among other defendants) (the “California Actions”). One of these class actions has been voluntarily dismissed. Three of the remaining class actions were filed by plaintiffs seeking to represent a class of direct purchasers and two of the class actions were filed by end payer purchasers. The purported classes of direct purchasers and end payer purchasers filed consolidated amended complaints on November 25, 2019. The two non-class complaints were filed by direct purchasers. These actions have been consolidated and coordinated in In re Glumetza Antitrust Litigation , Case No. 3:19-cv-05822-WHA. In February 2020, an additional non-class complaint was filed in the Northern District of California and two (2) additional class actions were filed - one in the Northern District of California and one in the Southern District of Florida (the "Florida Action") (collectively, the "February 2020 Actions"). The February 2020 Actions are brought against the same defendants and allege the same anticompetitive conduct alleged in the California Actions. The Florida Action has been ordered to be transferred to the Northern District of California. Both class and non-class direct purchaser plaintiffs seek damages under federal antitrust laws and the end payer purchasers seek damages under state antitrust, consumer protection, and unjust enrichment laws. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza ® delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza ® or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for Glumetza ® and its generic equivalent both prior to and after generic entry. Motions to dismiss the California Actions are fully briefed and set for oral argument on February 20, 2020. The Company and its affiliates

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company has commitments related to capital expenditures of approximately $142 million as of December 31, 2019 . Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December 31, 2019 , the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $315 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following: • Under the terms of a June 2013 distribution and supply agreement with Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc., the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million , in the aggregate. • Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease (IBD) and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million , in the aggregate, as well as royalties on future sales. • Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $45 million , in the aggregate, as well as royalties on future sales. • Under the terms of a February 2018 agreement with Kaken Pharmaceutical Co., Ltd., the Company has acquired an exclusive license to develop and commercialize products containing an investigational compound, KP-470, a new chemical entity, which is being studied for the topical treatment of psoriasis and may be required to make potential development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $43 million , in the aggregate, as well as royalties on future sales. Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. Indemnification Provisions In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. As of December 31, 2019 and 2018 , no material amounts were accrued for the Company’s obligations under these indemnification provisions. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Reportable Segments The Company’s CEO, who is the Company’s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company’s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The following is a brief description of the Company’s segments: • The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products. • The Salix segment consists of sales in the U.S. of GI products. • The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices. • The Diversified Products segment consists of sales: (i) in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) in the U.S. of generic products, (iii) in the U.S. of dentistry products and (iv) of certain other businesses divested during 2017 that were not core to the Company's operations, including the Company's equity interests in Dendreon (June 28, 2017) and Sprout (December 20, 2017). As a result of the divestitures of Dendreon and Sprout, the Company exited the oncology and women's health businesses, respectively. Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures. Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, In-process research and development costs, Restructuring and integration costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment. Segment Revenues and Profit Segment revenues and profits for the years 2019 , 2018 and 2017 were as follows: (in millions) 2019 2018 2017 Revenues: Bausch + Lomb/International $ 4,739 $ 4,664 $ 4,795 Salix 2,022 1,749 1,566 Ortho Dermatologics 565 617 721 Diversified Products 1,275 1,350 1,642 Total revenues $ 8,601 $ 8,380 $ 8,724 Segment profit: Bausch + Lomb/International $ 1,332 $ 1,330 $ 1,412 Salix 1,349 1,149 935 Ortho Dermatologics 222 257 333 Diversified Products 932 1,012 1,115 Total segment profit 3,835 3,748 3,795 Corporate (609 ) (605 ) (562 ) Amortization of intangible assets (1,897 ) (2,644 ) (2,690 ) Goodwill impairments — (2,322 ) (312 ) Asset impairments (75 ) (568 ) (714 ) Restructuring and integration costs (31 ) (22 ) (52 ) Acquisition-related contingent consideration (12 ) 9 289 Other expense (income), net (1,414 ) 20 348 Operating (loss) income (203 ) (2,384 ) 102 Interest income 12 11 12 Interest expense (1,612 ) (1,685 ) (1,840 ) Loss on extinguishment of debt (42 ) (119 ) (122 ) Foreign exchange and other 8 23 107 Loss before benefit from income taxes $ (1,837 ) $ (4,154 ) $ (1,741 ) Capital Expenditures Capital expenditures by segment for the years 2019 , 2018 and 2017 were as follows: (in millions) 2019 2018 2017 Capital expenditures: Bausch + Lomb/International $ 225 $ 139 $ 159 Salix 2 2 3 Ortho Dermatologics 1 1 2 Diversified Products 2 2 4 230 144 168 Corporate 40 13 3 Total capital expenditures $ 270 $ 157 $ 171 Revenues by Product and by Product Category The top ten products represented 39% , 36% and 32% of total product sales for the years 2019, 2018 and 2017 , respectively. Revenues by segment and product category were as follows: (in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total 2019 2018 2017 2019 2018 2017 2019 2018 2017 2019 2018 2017 2019 2018 2017 Pharmaceuticals $ 885 $ 892 $ 956 $ 2,022 $ 1,752 $ 1,564 $ 355 $ 457 $ 567 $ 810 $ 927 $ 1,290 $ 4,072 $ 4,028 $ 4,377 Devices 1,524 1,505 1,421 — — — 193 135 111 — — — 1,717 1,640 1,532 OTC 1,452 1,412 1,529 — — — — — — — — — 1,452 1,412 1,529 Branded and Other Generics 801 784 819 — — — — — — 447 407 338 1,248 1,191 1,157 Other revenues 77 71 70 — (3 ) 2 17 25 43 18 16 14 112 109 129 $ 4,739 $ 4,664 $ 4,795 $ 2,022 $ 1,749 $ 1,566 $ 565 $ 617 $ 721 $ 1,275 $ 1,350 $ 1,642 $ 8,601 $ 8,380 $ 8,724 Geographic Information Revenues are attributed to a geographic region based on the location of the customer for the years 2019, 2018 and 2017 were as follows: (in millions) 2019 2018 2017 U.S. and Puerto Rico $ 5,164 $ 5,011 $ 5,225 China 368 361 331 Canada 339 319 326 Japan 241 226 223 Poland 231 218 201 Mexico 228 211 201 Egypt 218 178 152 France 201 205 188 Russia 180 154 200 Germany 150 170 157 United Kingdom 115 117 108 Spain 86 83 77 Italy 85 85 78 Other 995 1,042 1,257 $ 8,601 $ 8,380 $ 8,724 Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2019 and 2018 were as follows: (in millions) 2019 2018 U.S. and Puerto Rico $ 656 $ 593 Ireland 255 217 Canada 103 99 Poland 90 94 Germany 68 66 Egypt 62 50 Mexico 50 48 France 30 31 China 27 25 Serbia 27 28 Italy 22 23 Other 76 79 $ 1,466 $ 1,353 Major Customers Customers that accounted for 10% or more of total revenues were as follows: 2019 2018 2017 McKesson Corporation 17% 18% 19% AmerisourceBergen Corporation 16% 18% 15% Cardinal Health, Inc. 14% 13% 13%

SUPPLEMENTARY DATA (UNAUDITED)

SUPPLEMENTARY DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
SUPPLEMENTARY DATA (UNAUDITED)	SUPPLEMENTARY DATA (UNAUDITED) Selected unaudited quarterly consolidated financial data are shown below: 2019 (in millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Revenue $ 2,016 $ 2,152 $ 2,209 $ 2,224 Expenses 1,729 1,895 1,880 3,300 Operating income (loss) $ 287 $ 257 $ 329 $ (1,076 ) Net loss attributable to Bausch Health Companies Inc. $ (52 ) $ (171 ) $ (49 ) $ (1,516 ) Basic and Diluted loss per share attributable to Bausch Health Companies Inc.: $ (0.15 ) $ (0.49 ) $ (0.14 ) $ (4.30 ) Net cash provided by operating activities $ 413 $ 339 $ 515 $ 234 2018 (in millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Revenue $ 1,995 $ 2,128 $ 2,136 $ 2,121 Expenses 4,276 2,373 2,019 2,096 Operating (loss) income $ (2,281 ) $ (245 ) $ 117 $ 25 Net loss attributable to Bausch Health Companies Inc. $ (2,581 ) $ (873 ) $ (350 ) $ (344 ) Basic and Diluted loss per share attributable to Bausch Health Companies Inc.: $ (7.36 ) $ (2.49 ) $ (1.00 ) $ (0.98 ) Net cash provided by operating activities $ 438 $ 222 $ 522 $ 319

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (in millions) Balance at Beginning of Year Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End of Year Year ended December 31, 2019 Allowance for doubtful accounts $ 47 $ 10 $ (1 ) $ (8 ) $ 48 Deferred tax asset valuation allowance $ 2,913 $ 13 $ (95 ) $ — $ 2,831 Year ended December 31, 2018 Allowance for doubtful accounts $ 97 $ 4 $ (4 ) $ (50 ) $ 47 Deferred tax asset valuation allowance $ 2,001 $ 870 $ 42 $ — $ 2,913 Year ended December 31, 2017 Allowance for doubtful accounts $ 80 $ 33 $ 4 $ (20 ) $ 97 Deferred tax asset valuation allowance $ 1,857 $ 221 $ (77 ) $ — $ 2,001

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. In preparing the Company’s Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks.
Use of Estimates	On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted.
Reclassifications	Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Acquisitions and Acquisition-Related Contingent Consideration	Acquisitions Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. Acquisition-Related Contingent Consideration Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.
Fair Value of Derivative Instruments	Fair Value of Derivative Instruments The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period. The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the risk-free interest rate and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps, is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the year 2019 . The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities and trade receivables. The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months . Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.
Allowance for Credit Losses	Allowance for Credit Losses
Inventories	Inventories Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives: Land improvements 15 - 30 years Buildings and improvements Up to 40 years Machinery and equipment 3 - 20 years Other equipment 3 - 10 years Equipment on operating lease Up to 5 years Leasehold improvements Lesser of term of lease or 10 years
Intangible Assets	Intangible Assets Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives: Product brands 2 - 20 years Corporate brands 7 - 20 years Product rights 3 - 15 years Partner relationships 7 - 9 years Out-licensed technology and other 8 - 10 years
Divestitures of Products	Divestitures of Products The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net . Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.
IPR&D	IPR&D The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. IPR&D assets are tested for impairment at least annually or when triggering events are identified. The fair value of an IPR&D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. Indefinite-lived intangible assets, which includes acquired IPR&D and the corporate trademark acquired in the acquisition of Bausch & Lomb Holdings Incorporated (the ‘‘B&L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.
Goodwill	Goodwill Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values. Prior to January 1, 2018, the goodwill impairment test consisted of two steps. In step one, the Company compared the carrying value of each reporting unit to its fair value. In step two, if the carrying value of a reporting unit exceeded its fair value, the Company would measure goodwill impairment as the excess of the carryi ng value of the reporting unit’s goodwill over the fair value of its goodwill, if any. The fair value of goodwill was derived as the excess of the fair value of the reporting unit over the fair value of the reporting unit’s identifiable assets and liabilities. Effective January 1, 2018, the Company elected to early adopt guidance issued by the Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. Further, an entity is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.
Debt Discounts, Issuance Costs and Deferred Financing Costs	Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.
Foreign Currency Translation	Foreign Currency Translation The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders’ equity. Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized in Net (loss) income .
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. Based upon review of current customer contracts, the Company concluded the implementation of the new guidance did not have a material quantitative impact on its Consolidated Financial Statements as the timing of revenue recognition for product sales did not significantly change. The Company adopted this guidance using the modified retrospective approach, and therefore, revenue reported for the year 2017 has not been restated. Although the new guidance did result in additional disclosures as to the nature, amounts and concentrations of revenue, it did not have a material impact on the Company's significant accounting policies. The revenue recognition policies as enumerated below reflect the Company's accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition. The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 23, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Product Sales A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed further below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products. Product Sales Provisions As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period. Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. The following table presents the activity and ending balances of the Company’s variable consideration provisions for years ended December 31, 2019 and 2018 . (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balance, January 1, 2018 $ 167 $ 863 $ 1,094 $ 274 $ 148 $ 2,546 Current period provision 865 293 2,551 1,966 212 5,887 Payments and credits (857 ) (343 ) (2,621 ) (2,031 ) (197 ) (6,049 ) Reserve balance, December 31, 2018 175 813 1,024 209 163 2,384 Acquisition of Synergy — 3 12 — 1 16 Current period provision 776 113 2,265 1,938 195 5,287 Payments and credits (769 ) (238 ) (2,374 ) (1,979 ) (277 ) (5,637 ) Reserve balance, December 31, 2019 $ 182 $ 691 $ 927 $ 168 $ 82 $ 2,050 Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $29 million and $26 million as of December 31, 2019 and 2018 , respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets. The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or an adjustment related to past sales, or both. If the actual amounts paid vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variance becomes known. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration. Cash Discounts and Allowances Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability. Returns Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns. In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $84 million for the year 2019 . The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not differ from original estimates of provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems. Over the last several years the Company increased its focus on maximizing operational efficiencies and reducing product returns. The Company continually takes actions to address product returns including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions resulted in improved sales return experience related to current branded products and previously genericized products. As a result, for the year 2019 as compared to 2018 , the provision for sales returns improved by a net of $180 million . During the three months ended September 30, 2019 and 2018 we recorded a reduction in variable consideration for sales returns of approximately $80 million and $30 million , respectively, related to past sales. Rebates and Chargebacks Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates. The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $83 million for 2019 . Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods. Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share. Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or chargebacks. The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts due to the price increases implemented in each of the last three years, changes in the Company’s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs. Management’s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel. Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2019 and 2018 were not material to the Company’s revenues or earnings. Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company’s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management’s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any. Distribution Fees The Company sells product primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a product’s wholesaler acquisition cost (“WAC”) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $11 million and $31 million for the years 2019 and 2018 , respectively. Contract Assets and Contract Liabilities There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. Sales Commissions Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses. Financing Component
Research and Development Expenses	Research and Development Expenses Costs related to internal research and development programs, including costs associated with the development of acquired IPR&D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses . Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product. Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.
Legal Costs	Legal Costs
Advertising Costs	Advertising Costs
Share-Based Compensation	Share-Based Compensation
Interest Expense	Interest Expense
Income Taxes	Income Taxes Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future. In October 2016, the FASB issued guidance requiring an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset has been sold to an outside party. This guidance was effective for the Company January 1, 2018 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit and deferred income taxes as of the effective date. The Company recorded a net cumulative-effect adjustment of $1,209 million to increase deferred income tax assets and decrease the opening balance of Accumulated deficit for the income tax consequences deferred from past intra-entity transfers involving assets other than inventory. The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year . Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.
Earnings Per Share	Earnings Per Share Basic (loss) earnings per share attributable to Bausch Health Companies Inc. is calculated by dividing Net (loss) income attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted (loss) earnings per share attributable to Bausch Health Companies Inc. is calculated by dividing Net (loss) income attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock method.
Comprehensive Income	Comprehensive Income Comprehensive (loss) income comprises Net (loss) income and Other comprehensive income (loss) . Other comprehensive income (loss) includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders’ equity.
Contingencies	Contingencies In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities, and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a liability. These accruals are adjusted periodically as assessments change or additional information becomes available. If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.
Employee Benefit Plans	Employee Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.
Adoption of New Accounting Standards and Recently Issued Accounting Standards, Not Adopted as of December 31, 2019	Adoption of New Accounting Standards In February 2016, the FASB issued a new standard revising the accounting for leases to increase transparency and comparability among organizations that lease buildings, equipment and other assets by requiring the recognition of lease assets and lease liabilities on the balance sheet. Under the new standard, all leases are classified as either a finance lease or an operating lease. The classification is determined based on whether substantive control has been transferred to the lessee and its determination will govern the pattern of lease cost recognition. Finance leases are accounted for in substantially the same manner as capital leases under the former U.S. GAAP standard. Operating leases are accounted for in the statements of operations and statements of cash flows in a manner substantially consistent with operating leases under the former U.S. GAAP standard. However, as it relates to the balance sheet, operating lessees are, with limited exception, required to record a right-of-use asset and a corresponding lease liability, equal to the present value of the lease payments for each operating lease. Lessees are not required to recognize a right-of-use asset or lease liability for short-term leases, but instead recognizes lease payments as an expense on a straight-line basis over the lease term. The standard also requires lessees and lessors to provide additional qualitative and quantitative disclosures to help financial statement users assess the amounts, timing and uncertainty of cash flows arising from leases. The Company adopted the new standard effective January 1, 2019, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $302 million . In addition, approximately $20 million of restructuring liabilities associated with facility closures and deferred rents, included in Other non-current liabilities as of December 31, 2018, were reclassified to reduce right-of-use assets. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 13, "LEASES" for additional details and application of this standard. In August 2018, the FASB issued guidance aligning the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company has early-adopted this guidance prospectively for all implementation costs incurred after January 1, 2019. In 2019, implementation costs incurred in the Company's hosting arrangements which were capitalized were not material. Recently Issued Accounting Standards, Not Adopted as of December 31, 2019 In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance is effective for the Company beginning January 1, 2020. The application of this guidance is not expected to have a material effect on the Company's financial position, results of operations and cash flows. In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement. The guidance is effective for the Company beginning January 1, 2020. The application of this guidance is not expected to have a material effect on the Company's disclosures. In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted. The Company is evaluating the impact of adoption of this guidance on its disclosures. In December 2019, the FASB issued guidance simplifying the accounting for income taxes. The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted. The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.
Segment Reporting	Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of estimated useful lives of property, plant and equipment	Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives: Land improvements 15 - 30 years Buildings and improvements Up to 40 years Machinery and equipment 3 - 20 years Other equipment 3 - 10 years Equipment on operating lease Up to 5 years Leasehold improvements Lesser of term of lease or 10 years
Schedule of estimated useful lives of intangible assets	Amortization is calculated primarily using the straight-line method based on the following estimated useful lives: Product brands 2 - 20 years Corporate brands 7 - 20 years Product rights 3 - 15 years Partner relationships 7 - 9 years Out-licensed technology and other 8 - 10 years
Summary of variable consideration provisions	The following table presents the activity and ending balances of the Company’s variable consideration provisions for years ended December 31, 2019 and 2018 . (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balance, January 1, 2018 $ 167 $ 863 $ 1,094 $ 274 $ 148 $ 2,546 Current period provision 865 293 2,551 1,966 212 5,887 Payments and credits (857 ) (343 ) (2,621 ) (2,031 ) (197 ) (6,049 ) Reserve balance, December 31, 2018 175 813 1,024 209 163 2,384 Acquisition of Synergy — 3 12 — 1 16 Current period provision 776 113 2,265 1,938 195 5,287 Payments and credits (769 ) (238 ) (2,374 ) (1,979 ) (277 ) (5,637 ) Reserve balance, December 31, 2019 $ 182 $ 691 $ 927 $ 168 $ 82 $ 2,050

ACQUISITIONS AND LICENSING AG_2

ACQUISITIONS AND LICENSING AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Estimated fair values of assets acquired and liabilities assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date: (in millions) Accounts receivable $ 7 Inventories 24 Prepaid expenses and other current assets 5 Product brand intangible assets (estimated useful life - 7 years) 159 Accounts payable (1 ) Accrued expenses (17 ) Total identifiable net assets 177 Goodwill 3 Total fair value of consideration transferred $ 180

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis	The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and 2018 : 2019 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 2,696 $ 2,646 $ 50 $ — $ 197 $ 166 $ 31 $ — Liabilities: Acquisition-related contingent consideration $ 316 $ — $ — $ 316 $ 339 $ — $ — $ 339 Cross-currency swaps $ 13 $ — $ 13 $ — $ — $ — $ — $ —
Schedule of effect of hedging instruments on financial statements	The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for the year 2019 : (in millions) Loss recognized in Gain excluded from assessment of hedge effectiveness Location of gain in income of excluded component Cross-currency swaps $ 22 $ 9 Interest expense
Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs	The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for 2019 and 2018 : (in millions) 2019 2018 Beginning balance, January 1, $ 339 $ 387 Adjustments to Acquisition-related contingent consideration: Accretion for the time value of money $ 22 $ 24 Fair value adjustments due to changes in estimates of future payments (10 ) (33 ) Acquisition-related contingent consideration adjustments 12 (9 ) Payments / Settlements (36 ) (39 ) Foreign currency translation adjustment included in other comprehensive loss 1 — Ending balance, December 31, 316 339 Current portion 54 41 Non-current portion $ 262 $ 298
Schedule of assets and liabilities measured at fair value on a non-recurring basis	The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis: December 31, 2019 December 31, 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Other non-current assets: Non-current assets held for sale $ 39 $ — $ — $ 39 $ — $ — $ — $ —

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of the components of inventories	Inventories, net of allowance for obsolescence, as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Raw materials $ 319 $ 275 Work in process 149 95 Finished goods 639 564 $ 1,107 $ 934

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	The major components of property, plant and equipment as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Land $ 79 $ 81 Buildings 696 693 Machinery and equipment 1,606 1,527 Other equipment and leasehold improvements 369 366 Equipment on operating lease 56 46 Construction in progress 301 162 3,107 2,875 Less accumulated depreciation (1,641 ) (1,522 ) $ 1,466 $ 1,353

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of components of finite-lived intangible assets	The major components of intangible assets as of December 31, 2019 and 2018 consist of: Weighted- Average Remaining Useful Lives (Years) 2019 2018 (in millions) Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Gross Carrying Amount Accumulated Net Carrying Amount Finite-lived intangible assets: Product brands 7 $ 21,011 $ (13,544 ) $ 7,467 $ 20,891 $ (11,958 ) $ 8,933 Corporate brands 8 930 (338 ) 592 926 (263 ) 663 Product rights/patents 4 3,297 (2,887 ) 410 3,292 (2,658 ) 634 Partner relationships 2 166 (165 ) 1 168 (166 ) 2 Technology and other 3 209 (189 ) 20 208 (173 ) 35 Total finite-lived intangible assets 25,613 (17,123 ) 8,490 25,485 (15,218 ) 10,267 Acquired IPR&D not in service NA 13 — 13 36 — 36 B&L Trademark NA 1,698 — 1,698 1,698 — 1,698 $ 27,324 $ (17,123 ) $ 10,201 $ 27,219 $ (15,218 ) $ 12,001
Schedule of components of indefinite-lived intangible assets	The major components of intangible assets as of December 31, 2019 and 2018 consist of: Weighted- Average Remaining Useful Lives (Years) 2019 2018 (in millions) Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Gross Carrying Amount Accumulated Net Carrying Amount Finite-lived intangible assets: Product brands 7 $ 21,011 $ (13,544 ) $ 7,467 $ 20,891 $ (11,958 ) $ 8,933 Corporate brands 8 930 (338 ) 592 926 (263 ) 663 Product rights/patents 4 3,297 (2,887 ) 410 3,292 (2,658 ) 634 Partner relationships 2 166 (165 ) 1 168 (166 ) 2 Technology and other 3 209 (189 ) 20 208 (173 ) 35 Total finite-lived intangible assets 25,613 (17,123 ) 8,490 25,485 (15,218 ) 10,267 Acquired IPR&D not in service NA 13 — 13 36 — 36 B&L Trademark NA 1,698 — 1,698 1,698 — 1,698 $ 27,324 $ (17,123 ) $ 10,201 $ 27,219 $ (15,218 ) $ 12,001
Schedule of estimated aggregate amortization expense for each of the five succeeding years	Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows: (in millions) 2020 2021 2022 2023 2024 Thereafter Total Amortization $ 1,624 $ 1,375 $ 1,224 $ 1,079 $ 950 $ 2,238 $ 8,490
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amounts of goodwill during the years ended December 31, 2019, 2018 and 2017 were as follows: (in millions) Bausch + Lomb/ International Branded Rx U.S. Diversified Products Salix Ortho Dermatologics Diversified Products Total Balance, January 1, 2017 $ 5,499 $ 7,265 $ 3,030 $ — $ — $ — $ 15,794 Realignment of segment goodwill 264 (264 ) — — — — — Goodwill reclassified to assets held for sale and subsequently disposed (30 ) (61 ) (84 ) — — — (175 ) Impairment of the former Branded Rx reporting unit — (312 ) — — — — (312 ) Foreign exchange and other 283 3 — — — — 286 Balance, December 31, 2017 6,016 6,631 2,946 — — — 15,593 Impairment of the Salix and Ortho Dermatologics reporting units — (2,213 ) — — — — (2,213 ) Realignment of Global Solta reporting unit goodwill (82 ) 115 (33 ) — — — — Goodwill reclassified to assets held for sale and subsequently disposed (2 ) — — — — — (2 ) Realignment of segment goodwill — (4,533 ) (2,913 ) 3,156 1,267 3,023 — Impairment of the Dentistry reporting unit — — — — — (109 ) (109 ) Foreign exchange and other (127 ) — — — — — (127 ) Balance, December 31, 2018 5,805 — — 3,156 1,267 2,914 13,142 Acquisition of certain assets of Synergy — — — 3 — — 3 Goodwill reclassified to assets held for sale (Note 4) (18 ) — — — — — (18 ) Foreign exchange and other (1 ) — — — — — (1 ) Balance, December 31, 2019 $ 5,786 $ — $ — $ 3,159 $ 1,267 $ 2,914 $ 13,126

ACCRUED AND OTHER CURRENT LIA_2

ACCRUED AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of accrued and other current liabilities	Accrued and other current liabilities as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Legal matters and related fees $ 1,397 $ 11 Product rebates 898 998 Product returns 691 813 Interest 305 273 Employee compensation and benefit costs 304 301 Income taxes payable 196 167 Other 720 634 $ 4,511 $ 3,197

FINANCING ARRANGEMENTS (Tables)

FINANCING ARRANGEMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt	Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2019 and 2018 consists of the following: 2019 2018 (in millions) Maturity Principal Amount Net of Premiums, Discounts and Issuance Costs Principal Amount Net of Premiums, Discounts and Issuance Costs Senior Secured Credit Facilities: 2023 Revolving Credit Facility June 2023 — — 75 75 June 2025 Term Loan B Facility June 2025 3,869 3,768 4,394 4,269 November 2025 Term Loan B Facility November 2025 1,275 1,257 1,481 1,456 Senior Secured Notes: 6.50% Secured Notes March 2022 1,250 1,242 1,250 1,239 7.00% Secured Notes March 2024 2,000 1,983 2,000 1,979 5.50% Secured Notes November 2025 1,750 1,733 1,750 1,730 5.75% Secured Notes August 2027 500 493 — — Senior Unsecured Notes: 5.625% December 2021 — — 700 697 5.50% March 2023 402 400 1,000 995 5.875% May 2023 1,448 1,441 3,250 3,229 4.50% euro-denominated debt May 2023 1,682 1,674 1,720 1,709 6.125% April 2025 3,250 3,230 3,250 3,226 9.00% December 2025 1,500 1,473 1,500 1,469 9.25% April 2026 1,500 1,484 1,500 1,482 8.50% January 2027 1,750 1,756 750 738 7.00% January 2028 750 741 — — 5.00% January 2028 1,250 1,234 — — 7.25% May 2029 750 740 — — 5.25% January 2030 1,250 1,234 — — Other Various 12 12 12 12 Total long-term debt and other $ 26,188 25,895 $ 24,632 24,305 Less: Current portion of long-term debt and other 1,234 228 Non-current portion of long-term debt $ 24,661 $ 24,077
Schedule of aggregate maturities of long-term debt	ies and Mandatory PaymentsMaturities and mandatory payments of debt obligations for the five succeeding years ending December 31 and t

PENSION AND POSTRETIREMENT EM_2

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Schedule of amounts recognized in accumulated other comprehensive loss	The amounts included in Accumulated other comprehensive loss as of December 31, 2019 , and 2018 were as follows: Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 2019 2018 Unrecognized actuarial losses $ (20 ) $ (31 ) $ (65 ) $ (50 ) $ (2 ) $ (1 ) Unrecognized prior service credits $ — $ — $ 26 $ 27 $ 14 $ 17
Components of net periodic benefit cost	The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2019 , 2018 and 2017 : Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2017 2019 2018 2017 2019 2018 2017 Service cost $ 2 $ 2 $ 2 $ 3 $ 3 $ 3 $ — $ — $ — Interest cost 8 7 8 5 5 5 1 1 2 Expected return on plan assets (13 ) (15 ) (13 ) (5 ) (5 ) (5 ) — — — Amortization of net loss — — — 1 1 2 — — — Amortization of prior service credit — — — (1 ) (1 ) (1 ) (2 ) (2 ) (3 ) Other — — — 1 — — — — — Net periodic (benefit) cost $ (3 ) $ (6 ) $ (3 ) $ 4 $ 3 $ 4 $ (1 ) $ (1 ) $ (1 )
Components of the change in projected benefit obligations, change in plan assets and funded status	The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2019 and 2018 : Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 2019 2018 Change in Projected Benefit Obligation Projected benefit obligation, beginning of year $ 214 $ 234 $ 235 $ 254 $ 41 $ 48 Service cost 2 2 3 3 — — Interest cost 8 7 5 5 1 1 Employee contributions — — — — 1 1 Settlements — — (2 ) (2 ) — — Benefits paid (15 ) (16 ) (8 ) (5 ) (4 ) (5 ) Actuarial losses (gains) 18 (13 ) 30 (10 ) 2 (4 ) Currency translation adjustments — — (4 ) (10 ) — — Projected benefit obligation, end of year 227 214 259 235 41 41 Change in Plan Assets Fair value of plan assets, beginning of year 187 206 147 155 — — Actual return on plan assets 42 (11 ) 17 (2 ) — — Employee contributions — — — — 1 1 Company contributions 2 8 10 7 3 4 Settlements — — (2 ) (2 ) — — Benefits paid (15 ) (16 ) (8 ) (5 ) (4 ) (5 ) Currency translation adjustments — — (3 ) (6 ) — — Fair value of plan assets, end of year 216 187 161 147 — — Funded Status at end of year $ (11 ) $ (27 ) $ (98 ) $ (88 ) $ (41 ) $ (41 ) Recognized as: Accrued and other current liabilities $ — $ — $ (2 ) $ (2 ) $ (5 ) $ (5 ) Other non-current liabilities $ (11 ) $ (27 ) $ (96 ) $ (86 ) $ (36 ) $ (36 )
Schedule of underfunded plans	Information for the underfunded pension benefit plans is as follows: U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 Projected benefit obligation $ 227 $ 214 $ 259 $ 235 Accumulated benefit obligation 227 214 251 225 Fair value of plan assets 216 187 161 147
Future benefit payments for the pension benefit plans	Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: (in millions) Pension Benefit Plans U.S. Postretirement Benefit Plan U.S. Plan Non-U.S. Plans 2020 $ 14 $ 5 $ 5 2021 18 6 4 2022 18 6 4 2023 17 6 4 2024 16 6 3 2025-2029 77 33 13
Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations	The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2019, 2018 and 2017 were as follows: Pension Benefit Plans U.S. Postretirement Benefit Plan 2019 2018 2017 2019 2018 2017 For Determining Net Periodic (Benefit) Cost U.S. Plans: Discount rate 4.25 % 3.56 % 4.04 % 4.16 % 3.47 % 3.85 % Expected rate of return on plan assets 7.25 % 7.50 % 7.50 % — — — Rate of compensation increase — — — — — — Non-U.S. Plans: Discount rate 2.39 % 2.29 % 2.08 % Expected rate of return on plan assets 3.46 % 3.66 % 3.84 % Rate of compensation increase 2.89 % 2.87 % 2.64 % Pension Benefit Plans U.S. Postretirement Benefit Plan 2019 2018 2019 2018 For Determining Benefit Obligation U.S. Plans: Discount rate 3.16 % 4.25 % 3.04 % 4.16 % Rate of compensation increase — — — — Non-U.S. Plans: Discount rate 1.68 % 2.39 % Rate of compensation increase 3.05 % 2.89 %
Actual asset allocations	The following presents the actual asset allocation as of December 31, 2019 and 2018 : 2019 2018 U.S. Plan Equity securities 55 % 52 % Fixed income securities 44 % 47 % Other 1 % 1 % Non-U.S. Plans Cash and cash equivalents 6 % 5 % Equity securities 25 % 20 % Fixed income securities 64 % 69 % Other 6 % 6 %
Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition	The table below presents total plan assets by investment category as of December 31, 2019 and 2018 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2019 and 2018 . Pension Benefit Plans - U.S. Plans December 31, 2019 December 31, 2018 (in millions) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash and cash equivalents $ 1 $ — $ — $ 1 $ 2 $ — $ — $ 2 Commingled funds: Equity securities: U.S. broad market — 64 — 64 — 51 — 51 Emerging markets — 15 — 15 — 13 — 13 Worldwide developed markets — 26 — 26 — 21 — 21 Other assets — 15 — 15 — 13 — 13 Fixed income securities: Investment grade — 95 — 95 — 87 — 87 $ 1 $ 215 $ — $ 216 $ 2 $ 185 $ — $ 187 Pension Benefit Plans - Non-U.S. Plans December 31, 2019 December 31, 2018 (in millions) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents $ — $ 9 $ — $ 9 $ — $ 7 $ — $ 7 Commingled funds: Equity securities: Emerging markets — 2 — 2 — 1 — 1 Worldwide developed markets — 38 — 38 — 29 — 29 Fixed income securities: Investment grade — 9 — 9 — 9 — 9 Global high yield — 3 — 3 — 2 — 2 Government bond funds 1 90 — 91 — 90 — 90 Other assets — 8 1 9 — 9 — 9 $ 1 $ 159 $ 1 $ 161 $ — $ 147 $ — $ 147

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Summary of right-of-use assets and right-of-use liabilities	Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2019 as follows: (in millions) Right-of-use assets included in: Other non-current assets $ 271 Lease liabilities included in: Accrued and other current liabilities $ 53 Other non-current liabilities 240 Total lease liabilities $ 293
Summary of lease expenses	Lease expense for the year 2019 includes: (in millions) Operating lease costs $ 62 Variable operating lease costs $ 16
Summary of other operating lease information	Other information related to operating leases for 2019 is as follows: (dollars in millions) Cash paid from operating cash flows for amounts included in the measurement of lease liabilities $ 73 Right-of-use assets obtained in exchange for new operating lease liabilities $ 47 Weighted-average remaining lease term 8.2 years Weighted-average discount rate 6.2 %
Summary of operating lease future payments, after adoption of 842	As of December 31, 2019 , future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows: (in millions) 2020 $ 70 2021 55 2022 42 2023 37 2024 30 Thereafter 149 Total 383 Less: Imputed interest 90 Present value of remaining lease payments 293 Less: Current portion 53 Non-current portion $ 240
Summary of operating lease future payments, before adoption of 842	Accordingly, rental expense related to operating lease agreements was $92 million and $102 million for 2018 and 2017, respectively, and the Company is providing the following table of future payments under noncancelable operating leases as of December 31, 2018, for each of the five succeeding years ending December 31 and thereafter as previously disclosed under prior accounting guidance: (in millions) 2019 2020 2021 2022 2023 Thereafter Total Future payments $ 78 $ 60 $ 44 $ 39 $ 32 $ 166 $ 419

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of the components and classification of share-based compensation expense	The components and classification of share-based compensation expense related to stock options and RSUs for the years 2019 , 2018 and 2017 were as follows: (in millions) 2019 2018 2017 Stock options $ 21 $ 23 $ 18 RSUs 81 64 69 Share-based compensation expense $ 102 $ 87 $ 87 Research and development expenses $ 9 $ 9 $ 8 Selling, general and administrative expenses 93 78 79 Share-based compensation expense $ 102 $ 87 $ 87
Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model	The fair values of all stock options granted for the years 2019 , 2018 and 2017 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: 2019 2018 2017 Expected stock option life (years) 3.0 3.0 3.0 Expected volatility 46.5 % 54.0 % 67.3 % Risk-free interest rate 2.5 % 2.7 % 1.8 % Expected dividend yield — % — % — %
Summary of stock option activity	The following table summarizes stock option activity during 2019 : (in millions, except per share amounts) Options Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2019 5.9 $ 27.88 Granted 1.7 $ 23.19 Exercised (0.3 ) $ 16.03 Expired or forfeited (0.2 ) $ 37.27 Outstanding, December 31, 2019 7.1 $ 26.99 7.5 $ 61 Vested and expected to vest, December 31, 2019 6.7 $ 27.43 7.4 $ 57 Vested and exercisable, December 31, 2019 3.6 $ 34.27 6.5 $ 24
Summary of non-vested time-based RSU activity	The following table summarizes non-vested time-based RSU activity during 2019 : (in millions, except per share amounts) Time-Based RSUs Weighted- Average Grant-Date Fair Value Per Share Non-vested, January 1, 2019 5.8 $ 18.29 Granted 3.1 $ 24.13 Vested (1.9 ) $ 17.88 Forfeited (0.9 ) $ 23.77 Non-vested, December 31, 2019 6.1 $ 20.54
Schedule of assumptions used to calculate the fair values of performance-based RSUs	The fair values of TSR performance-based RSUs granted during 2019 , 2018 and 2017 were estimated with the following assumptions: 2019 2018 2017 Contractual term (years) 3.0 3.0 3.0 Expected Company share volatility 46.5% 54.2% 67.2% - 77.2% Risk-free interest rate 2.5% 2.7% 1.7% - 1.8%
Summary of non-vested performance-based RSU activity	The following table summarizes non-vested performance-based RSU activity during 2019 : (in millions, except per share amounts) Performance-based RSUs Weighted- Average Grant-Date Fair Value Per Share Non-vested, January 1, 2019 1.5 $ 34.06 Granted 1.0 $ 29.52 Vested (0.3 ) $ 48.42 Forfeited (0.2 ) $ 91.76 Non-vested, December 31, 2019 2.0 $ 25.80

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of the components of accumulated other comprehensive loss	Accumulated other comprehensive loss as of December 31, 2019 and 2018 consists of: (in millions) 2019 2018 Foreign currency translation adjustment $ (2,046 ) $ (2,111 ) Pension adjustment, net of tax (40 ) (26 ) $ (2,086 ) $ (2,137 )

RESEARCH AND DEVELOPMENT (Table

RESEARCH AND DEVELOPMENT (Tables)	12 Months Ended
	Dec. 31, 2019
Research and Development [Abstract]
Summary of research and development	Research and development costs for the years 2019 , 2018 and 2017 consists of: (in millions) 2019 2018 2017 Product related research and development $ 434 $ 376 $ 328 Quality assurance 37 37 33 Research and development $ 471 $ 413 $ 361

OTHER EXPENSE (INCOME), NET (Ta

OTHER EXPENSE (INCOME), NET (Tables)	12 Months Ended
	Dec. 31, 2019
Other Income and Expenses [Abstract]
Schedule of other nonoperating income (expense)	Other expense (income), net for the years 2019 , 2018 and 2017 consists of: (in millions) 2019 2018 2017 Gain on the Skincare Sale $ — $ — $ (309 ) Gain on the iNova Sale — — (309 ) Gain on the Dendreon Sale — — (97 ) Loss on the Sprout Sale — — 98 Net (gain) loss on other sales of assets (31 ) 6 37 Litigation and other matters 1,401 (27 ) 226 Acquired in-process research and development costs 41 1 5 Acquisition-related costs 8 1 — Other, net (5 ) (1 ) 1 Other expense (income), net $ 1,414 $ (20 ) $ (348 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Components of loss before recovery of income taxes	The components of Loss before benefit from income taxes for 2019 , 2018 and 2017 consist of: (in millions) 2019 2018 2017 Domestic $ (2,396 ) $ (1,475 ) $ (2,032 ) Foreign 559 (2,679 ) 291 $ (1,837 ) $ (4,154 ) $ (1,741 )
Components of benefits from income taxes	The components of Benefit from income taxes for 2019 , 2018 and 2017 consist of: (in millions) 2019 2018 2017 Current: Domestic $ (12 ) $ — $ (20 ) Foreign (116 ) (327 ) (146 ) (128 ) (327 ) (166 ) Deferred: Domestic (5 ) 17 (2 ) Foreign 187 320 4,313 182 337 4,311 $ 54 $ 10 $ 4,145
Reconciliation of reported recovery of income taxes from the expected amount calculated by applying the Canadian statutory rate to income before recovery of income taxes	The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2019 , 2018 and 2017 as follows: (in millions) 2019 2018 2017 Loss before benefit from income taxes $ (1,837 ) $ (4,154 ) $ (1,741 ) Benefit from income taxes Expected benefit from income taxes at Canadian statutory rate $ 494 $ 1,117 $ 468 Non-deductible amount of share-based compensation (7 ) (10 ) (37 ) Adjustments to tax attributes (99 ) (4 ) (242 ) Impact of changes in enacted income tax rates — — 747 Change in valuation allowance related to foreign tax credits and NOLs 21 (3 ) 139 Change in valuation allowance on Canadian deferred tax assets and tax rate changes (142 ) (875 ) (360 ) Change in uncertain tax positions (350 ) (47 ) (65 ) Foreign tax rate differences 186 (3 ) 933 Non-deductible portion of Goodwill impairments — (488 ) (139 ) Tax differences on divestitures of businesses — — 203 Tax benefit on intra-entity transfers — 356 2,480 Other (49 ) (33 ) 18 $ 54 $ 10 $ 4,145
Schedule of tax effect of major items recorded as deferred tax assets and liabilities	Deferred tax assets and liabilities as of December 31, 2019 and 2018 consist of: (in millions) 2019 2018 Deferred tax assets: Tax loss carryforwards $ 2,911 $ 2,886 Provisions 641 519 Research and development tax credits 155 143 Scientific Research and Experimental Development pool 52 52 Tax credit carryforwards 25 46 Deferred revenue 5 4 Unrealized FX on U.S. dollar debt and other financing cost 94 262 Prepaid expenses 41 44 Share-based compensation 19 24 Other 23 — Total deferred tax assets 3,966 3,980 Less valuation allowance (2,831 ) (2,913 ) Net deferred tax assets 1,135 1,067 Deferred tax liabilities: Intangible assets 53 163 Plant, equipment and technology 56 55 Outside basis differences 41 29 Other — 29 Total deferred tax liabilities 150 276 Net deferred tax asset (liability) $ 985 $ 791
Summary of open tax years by jurisdiction	Jurisdiction: Open Years United States - Federal 2014 - 2018 Canada 2005 - 2018 Germany 2013 - 2018 France 2013 - 2018 China 2015 - 2018 Ireland 2015 - 2018 Netherlands 2018 Australia 2011 - 2018
Reconciliation of the beginning and ending amounts of unrecognized tax benefits	The following table presents a reconciliation of the unrecognized tax benefits for 2019, 2018 and 2017 : (in millions) 2019 2018 2017 Balance, beginning of year $ 654 $ 598 $ 423 Additions based on tax positions related to the current year 361 18 145 Additions for tax positions of prior years 63 55 57 Reductions for tax positions of prior years (58 ) (11 ) (18 ) Lapse of statute of limitations (18 ) (6 ) (9 ) Balance, end of year $ 1,002 $ 654 $ 598

(LOSS) EARNINGS PER SHARE (Tabl

(LOSS) EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of calculation of earnings per share	(Loss) earnings per share attributable to Bausch Health Companies Inc. for 2019, 2018 and 2017 were calculated as follows: (in millions, except per share amounts) 2019 2018 2017 Net (loss) income attributable to Bausch Health Companies Inc. $ (1,788 ) $ (4,148 ) $ 2,404 Basic weighted-average number of common shares outstanding 352.1 351.3 350.2 Dilutive effect of stock options, RSUs and other — — 1.6 Diluted weighted-average number of common shares outstanding 352.1 351.3 351.8 (Loss) earnings per share attributable to Bausch Health Companies Inc. Basic $ (5.08 ) $ (11.81 ) $ 6.86 Diluted $ (5.08 ) $ (11.81 ) $ 6.83

SUPPLEMENTAL CASH FLOW DISCLO_2

SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Disclosures	Supplemental cash flow disclosures for 2019, 2018 and 2017 are as follows: (in millions) 2019 2018 2017 Other Payments Interest paid $ 1,537 $ 1,665 $ 1,708 Income taxes paid $ 172 $ 138 $ 179

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of segment revenues and profit	Segment revenues and profits for the years 2019 , 2018 and 2017 were as follows: (in millions) 2019 2018 2017 Revenues: Bausch + Lomb/International $ 4,739 $ 4,664 $ 4,795 Salix 2,022 1,749 1,566 Ortho Dermatologics 565 617 721 Diversified Products 1,275 1,350 1,642 Total revenues $ 8,601 $ 8,380 $ 8,724 Segment profit: Bausch + Lomb/International $ 1,332 $ 1,330 $ 1,412 Salix 1,349 1,149 935 Ortho Dermatologics 222 257 333 Diversified Products 932 1,012 1,115 Total segment profit 3,835 3,748 3,795 Corporate (609 ) (605 ) (562 ) Amortization of intangible assets (1,897 ) (2,644 ) (2,690 ) Goodwill impairments — (2,322 ) (312 ) Asset impairments (75 ) (568 ) (714 ) Restructuring and integration costs (31 ) (22 ) (52 ) Acquisition-related contingent consideration (12 ) 9 289 Other expense (income), net (1,414 ) 20 348 Operating (loss) income (203 ) (2,384 ) 102 Interest income 12 11 12 Interest expense (1,612 ) (1,685 ) (1,840 ) Loss on extinguishment of debt (42 ) (119 ) (122 ) Foreign exchange and other 8 23 107 Loss before benefit from income taxes $ (1,837 ) $ (4,154 ) $ (1,741 )
Schedule of capital expenditures, depreciation and amortization by segment	Capital expenditures by segment for the years 2019 , 2018 and 2017 were as follows: (in millions) 2019 2018 2017 Capital expenditures: Bausch + Lomb/International $ 225 $ 139 $ 159 Salix 2 2 3 Ortho Dermatologics 1 1 2 Diversified Products 2 2 4 230 144 168 Corporate 40 13 3 Total capital expenditures $ 270 $ 157 $ 171
Schedule of revenues by product and by product category	Revenues by segment and product category were as follows: (in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total 2019 2018 2017 2019 2018 2017 2019 2018 2017 2019 2018 2017 2019 2018 2017 Pharmaceuticals $ 885 $ 892 $ 956 $ 2,022 $ 1,752 $ 1,564 $ 355 $ 457 $ 567 $ 810 $ 927 $ 1,290 $ 4,072 $ 4,028 $ 4,377 Devices 1,524 1,505 1,421 — — — 193 135 111 — — — 1,717 1,640 1,532 OTC 1,452 1,412 1,529 — — — — — — — — — 1,452 1,412 1,529 Branded and Other Generics 801 784 819 — — — — — — 447 407 338 1,248 1,191 1,157 Other revenues 77 71 70 — (3 ) 2 17 25 43 18 16 14 112 109 129 $ 4,739 $ 4,664 $ 4,795 $ 2,022 $ 1,749 $ 1,566 $ 565 $ 617 $ 721 $ 1,275 $ 1,350 $ 1,642 $ 8,601 $ 8,380 $ 8,724
Schedule of revenues and long-lived assets by geographic region	Revenues are attributed to a geographic region based on the location of the customer for the years 2019, 2018 and 2017 were as follows: (in millions) 2019 2018 2017 U.S. and Puerto Rico $ 5,164 $ 5,011 $ 5,225 China 368 361 331 Canada 339 319 326 Japan 241 226 223 Poland 231 218 201 Mexico 228 211 201 Egypt 218 178 152 France 201 205 188 Russia 180 154 200 Germany 150 170 157 United Kingdom 115 117 108 Spain 86 83 77 Italy 85 85 78 Other 995 1,042 1,257 $ 8,601 $ 8,380 $ 8,724
Schedule of assets by geographic region	Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2019 and 2018 were as follows: (in millions) 2019 2018 U.S. and Puerto Rico $ 656 $ 593 Ireland 255 217 Canada 103 99 Poland 90 94 Germany 68 66 Egypt 62 50 Mexico 50 48 France 30 31 China 27 25 Serbia 27 28 Italy 22 23 Other 76 79 $ 1,466 $ 1,353
Schedule of external customers that accounted for 10% or more of total revenues	Customers that accounted for 10% or more of total revenues were as follows: 2019 2018 2017 McKesson Corporation 17% 18% 19% AmerisourceBergen Corporation 16% 18% 15% Cardinal Health, Inc. 14% 13% 13%

SUPPLEMENTARY DATA (UNAUDITED)

SUPPLEMENTARY DATA (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial information	Selected unaudited quarterly consolidated financial data are shown below: 2019 (in millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Revenue $ 2,016 $ 2,152 $ 2,209 $ 2,224 Expenses 1,729 1,895 1,880 3,300 Operating income (loss) $ 287 $ 257 $ 329 $ (1,076 ) Net loss attributable to Bausch Health Companies Inc. $ (52 ) $ (171 ) $ (49 ) $ (1,516 ) Basic and Diluted loss per share attributable to Bausch Health Companies Inc.: $ (0.15 ) $ (0.49 ) $ (0.14 ) $ (4.30 ) Net cash provided by operating activities $ 413 $ 339 $ 515 $ 234 2018 (in millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Revenue $ 1,995 $ 2,128 $ 2,136 $ 2,121 Expenses 4,276 2,373 2,019 2,096 Operating (loss) income $ (2,281 ) $ (245 ) $ 117 $ 25 Net loss attributable to Bausch Health Companies Inc. $ (2,581 ) $ (873 ) $ (350 ) $ (344 ) Basic and Diluted loss per share attributable to Bausch Health Companies Inc.: $ (7.36 ) $ (2.49 ) $ (1.00 ) $ (0.98 ) Net cash provided by operating activities $ 438 $ 222 $ 522 $ 319

DESCRIPTION OF BUSINESS - Narra

DESCRIPTION OF BUSINESS - Narrative (Details)	Dec. 31, 2019country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of countries in which entity operates (more than)	100

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)wholesaler	Dec. 31, 2018USD ($)	Dec. 31, 2017
Concentrations of Credit Risk
Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)	3 months
Percentage of net trade receivables accounted for by largest wholesale customers	41.00%
Allowance for doubtful accounts	$ 48	$ 47
Argentina, Brazil, Egypt, Greece, Turkey, Ukraine and Venezuela
Concentrations of Credit Risk
Net trade receivable	$ 128	$ 105
Past due period for receivables to be negligible (less than)	90 days
Period net trade receivable balance outstanding (more than)	90 days
Portion of net trade receivables that is past due	$ 1
Trade receivables | Three largest U.S. wholesaler customers | Credit concentration
Concentrations of Credit Risk
Number of largest wholesale customers | wholesaler	3
Amoun | Revenue
Concentrations of Credit Risk
Concentration risk, percentage	3.00%	2.00%	2.00%

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2019
Minimum | Land improvements
Property, plant and equipment [Line Items]
Estimated useful lives	15 years
Minimum | Machinery and equipment
Property, plant and equipment [Line Items]
Estimated useful lives	3 years
Minimum | Other equipment
Property, plant and equipment [Line Items]
Estimated useful lives	3 years
Maximum | Land improvements
Property, plant and equipment [Line Items]
Estimated useful lives	30 years
Maximum | Buildings and improvements
Property, plant and equipment [Line Items]
Estimated useful lives	40 years
Maximum | Machinery and equipment
Property, plant and equipment [Line Items]
Estimated useful lives	20 years
Maximum | Other equipment
Property, plant and equipment [Line Items]
Estimated useful lives	10 years
Maximum | Equipment on operating lease
Property, plant and equipment [Line Items]
Estimated useful lives	5 years
Maximum | Leasehold improvements
Property, plant and equipment [Line Items]
Estimated useful lives	10 years

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2019
Product brands
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	7 years
Corporate brands
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	8 years
Product rights
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	4 years
Partner relationships
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	2 years
Out-licensed technology and other
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Minimum | Product brands
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	2 years
Minimum | Corporate brands
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	7 years
Minimum | Product rights
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Minimum | Partner relationships
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	7 years
Minimum | Out-licensed technology and other
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	8 years
Maximum | Product brands
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years
Maximum | Corporate brands
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years
Maximum | Product rights
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	15 years
Maximum | Partner relationships
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	9 years
Maximum | Out-licensed technology and other
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	10 years

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 2,384	$ 2,546
Acquisition of Synergy	16
Current period provision	5,287	5,887
Payments and credits	(5,637)	(6,049)
Balance at End of Year	2,050	2,384
Discounts and Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	175	167
Acquisition of Synergy	0
Current period provision	776	865
Payments and credits	(769)	(857)
Balance at End of Year	182	175
Returns
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	813	863
Acquisition of Synergy	3
Current period provision	113	293
Payments and credits	(238)	(343)
Balance at End of Year	691	813
Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	1,024	1,094
Acquisition of Synergy	12
Current period provision	2,265	2,551
Payments and credits	(2,374)	(2,621)
Balance at End of Year	927	1,024
Chargebacks
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	209	274
Acquisition of Synergy	0
Current period provision	1,938	1,966
Payments and credits	(1,979)	(2,031)
Balance at End of Year	168	209
Distribution Fees
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	163	148
Acquisition of Synergy	1
Current period provision	195	212
Payments and credits	(277)	(197)
Balance at End of Year	$ 82	$ 163

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Cooperative advertising credits included in rebates	$ 2,050				$ 2,384				$ 2,050	$ 2,384	$ 2,546
Settlement period for cash discounts and allowances									1 month
1% change in estimated return rates, Impact on pre-tax earnings									$ 84
Net improvement in provision									180	180
Reduction in variable consideration provision, adjustment		$ 80				$ 30
1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings									83
Price appreciation credits	2,224	$ 2,209	$ 2,152	$ 2,016	2,121	$ 2,136	$ 2,128	$ 1,995	8,601	8,380	$ 8,724
Price Appreciation Credit
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Price appreciation credits									$ 11	31
Minimum
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Payment terms									30 days
Maximum
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Payment terms									90 days
Rebates, Advertising Credits Portion
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Cooperative advertising credits included in rebates	$ 29				$ 26				$ 29	$ 26

SIGNIFICANT ACCOUNTING POLICI_9

SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)	Dec. 31, 2019
Minimum
Lessee, Lease, Description [Line Items]
Lease term	1 year
Lease renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term	20 years
Lease renewal term	5 years

SIGNIFICANT ACCOUNTING POLIC_10

SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Advertising expenses	$ 544	$ 481	$ 462

SIGNIFICANT ACCOUNTING POLIC_11

SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Capitalized interest	$ 34	$ 34

SIGNIFICANT ACCOUNTING POLIC_12

SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase to deferred income taxes	$ 1,690	$ 1,676
Tax benefit recognition, measurement percentage (greater than)	50.00%
Minimum period to classify uncertain tax position liabilities as long term liabilities	1 year
Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase to deferred income taxes			$ 1,209

SIGNIFICANT ACCOUNTING POLIC_13

SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Threshold percentage for amortization of net actuarial gains and losses	10.00%

SIGNIFICANT ACCOUNTING POLIC_14

SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use asset	$ 271	$ 302
Lease liability	293	302
Other non-current liabilities adjustment, upon adoption of ASU	$ (851)		$ (581)
Restatement Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use asset		(20)
Other non-current liabilities adjustment, upon adoption of ASU		$ 20

ACQUISITIONS AND LICENSING AG_3

ACQUISITIONS AND LICENSING AGREEMENTS - Narrative (Details) business in Thousands	Mar. 06, 2019USD ($)	Oct. 16, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)business	Dec. 31, 2018USD ($)business	Dec. 31, 2017USD ($)business	Dec. 31, 2019USD ($)	Sep. 30, 2018USD ($)	Mar. 31, 2017USD ($)	Feb. 21, 2017USD ($)
Business Combinations
Other expense				$ 1,414,000,000	$ (20,000,000)	$ (348,000,000)
Reduction of additional paid-in capital					$ 18,000,000	$ 9,000,000
Number of other material business combinations | business				0
Number of material business combinations | business					0	0
Payment for contingent consideration liability				$ 35,000,000	$ 37,000,000	$ 45,000,000
Additional Paid-In Capital
Business Combinations
Reduction of additional paid-in capital					15,000,000	$ 2,000,000
Synergy
Business Combinations
Cash payments to acquire certain assets and assumed liabilities	$ 180,000,000
Revenue of acquiree since acquisition date			$ 55,000,000
Operating results of acquiree since acquisition			$ 0
Pro-forma revenue				0	0
Pro-forma operating results				0	$ 0
Other expense				$ 8,000,000
Medpharma
Business Combinations
Cash payments to acquire certain assets and assumed liabilities		$ 18,000,000
Percentage interest acquired		40.00%
Medpharma | Additional Paid-In Capital
Business Combinations
Reduction of additional paid-in capital		$ 15,000,000
EyeGate | Development and Regulatory Milestones
Business Combinations
Upfront payment									$ 4,000,000
Possible contingent consideration (up to)										$ 34,000,000
Payment for contingent consideration liability							$ 3,000,000
Carrying value, contingent consideration, liability								$ 0
EyeGate | Sales Based Milestone Payments
Business Combinations
Possible contingent consideration (up to)										$ 65,000,000

ACQUISITIONS AND LICENSING AG_4

ACQUISITIONS AND LICENSING AGREEMENTS - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Mar. 06, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Combinations
Goodwill		$ 13,126	$ 13,142	$ 15,593	$ 15,794
Synergy
Business Combinations
Accounts receivable	$ 7
Inventories	24
Prepaid expenses and other current assets	5
Product brand intangible assets (estimated useful life - 7 years)	159
Accounts payable	(1)
Accrued expenses	(17)
Total identifiable net assets	177
Goodwill	3
Total fair value of consideration transferred	$ 180
Estimated useful lives	7 years

DIVESTITURES - Narrative (Detai

DIVESTITURES - Narrative (Details) divestiture in Millions, $ in Millions	Dec. 20, 2017USD ($)	Nov. 09, 2017USD ($)	Sep. 29, 2017USD ($)	Jun. 28, 2017USD ($)	Mar. 03, 2017USD ($)	Nov. 08, 2017USD ($)	Dec. 31, 2019USD ($)countryproduct	Dec. 31, 2018USD ($)divestiture	Dec. 31, 2017USD ($)
Asset acquisitions and disposition
Number of material divestitures | divestiture								0
Impairment write-down							$ 8
Number of countries in which entity operates (more than) | country							100
Impairment of finite-lived intangible assets							$ 5
Held For Sale
Asset acquisitions and disposition
Impairment write-down								$ 5	$ 114
Certain Products For Disposal, September 2019 | Held For Sale
Asset acquisitions and disposition
Disposal group, revenue							14	19
Impairment write-down							8
CeraVe, AcneFree, AMBI Skincare Brand
Asset acquisitions and disposition
Gain (loss) on sale of business							0	0	309
CeraVe, AcneFree, AMBI Skincare Brand | Held For Sale
Asset acquisitions and disposition
Net cash proceeds					$ 1,300
Gain (loss) on sale of business									309
Dendreon
Asset acquisitions and disposition
Gain (loss) on sale of business							0	0	97
Dendreon | Held For Sale
Asset acquisitions and disposition
Net cash proceeds				$ 845
Gain (loss) on sale of business									97
iNova
Asset acquisitions and disposition
Gain (loss) on sale of business							$ 0	0	309
iNova | Held For Sale
Asset acquisitions and disposition
Net cash proceeds			$ 938
Gain (loss) on sale of business									309
Number of countries in which entity operates (more than) | country							15
Obagi Medical Products, Inc. | Held For Sale
Asset acquisitions and disposition
Impairment of finite-lived intangible assets						$ 103
Obagi Medical Products, Inc. | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Asset acquisitions and disposition
Net cash proceeds		$ 190
Gain (loss) on sale of business									(13)
Sprout
Asset acquisitions and disposition
Gain (loss) on sale of business							$ 0	$ 0	(98)
Loan term	5 years
Related party loan	$ 25
Sprout | Minimum
Asset acquisitions and disposition
Purchase obligation (no less than)	$ 200
Sprout | Held For Sale
Asset acquisitions and disposition
Impairment write-down									351
Sprout | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Asset acquisitions and disposition
Gain (loss) on sale of business									$ (98)
Royalty percentage	6.00%
Diversified Products | Certain Products For Disposal, September 2019 | Held For Sale
Asset acquisitions and disposition
Number of products for disposal | product							1

RESTRUCTURING AND INTEGRATION_2

RESTRUCTURING AND INTEGRATION COSTS - Narrative (Details) - Restructuring and Integration-Related Costs - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cost-rationalization and integration initiatives
Remaining restructuring liabilities	$ 27
Restructuring costs	31	$ 22	$ 52
Severance costs	11	11	16
Facility closure costs	11	10	20
Other costs	9	1
Restructuring payments	$ 31	$ 33	85
Integration consulting, duplicate labor, transition service, and other			$ 16

FAIR VALUE MEASUREMENTS - Asset

FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Net Investment Hedging | Currency Swap | Designated as Hedging Instrument
Liabilities:
Cross-currency swaps	$ 13
Recurring basis
Assets:
Cash equivalents	2,696	$ 197
Liabilities:
Acquisition-related contingent consideration	316	339
Recurring basis | Net Investment Hedging | Currency Swap | Designated as Hedging Instrument
Liabilities:
Cross-currency swaps	13	0
Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Cash equivalents	2,646	166
Liabilities:
Acquisition-related contingent consideration	0	0
Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Net Investment Hedging | Currency Swap | Designated as Hedging Instrument
Liabilities:
Cross-currency swaps	0	0
Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	50	31
Liabilities:
Acquisition-related contingent consideration	0	0
Recurring basis | Significant Other Observable Inputs (Level 2) | Net Investment Hedging | Currency Swap | Designated as Hedging Instrument
Liabilities:
Cross-currency swaps	13	0
Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	0	0
Liabilities:
Acquisition-related contingent consideration	316	339
Recurring basis | Significant Unobservable Inputs (Level 3) | Net Investment Hedging | Currency Swap | Designated as Hedging Instrument
Liabilities:
Cross-currency swaps	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Cross

FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments or receipts in settlement of cross-currency swaps	$ 0
Currency Swap | Net Investment Hedging | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate notional amounts	1,250,000,000
Fair value cross-currency swaps liability, net	13,000,000
Fair value cross-currency swaps liability	22,000,000
Fair value cross-currency swaps asset	$ 9,000,000

FAIR VALUE MEASUREMENTS - Cro_2

FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Currency Swap - Net Investment Hedging - Designated as Hedging Instrument $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Loss recognized in Other comprehensive loss	$ 22
Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain excluded from assessment of hedge effectiveness	$ 9

FAIR VALUE MEASUREMENTS - Ass_2

FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance, January 1,	$ 339	$ 387
Acquisition-related contingent consideration adjustments	12	(9)
Payments / Settlements	(36)	(39)
Foreign currency translation adjustment included in other comprehensive loss	1	0
Ending balance, December 31,	316	339
Current portion	54	41
Non-current portion	262	298
Accretion for the time value of money
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration adjustments	22	24
Fair value adjustments due to changes in estimates of future payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration adjustments	$ (10)	$ (33)
Minimum | Measurement Input, Discount Rate | Significant Unobservable Inputs (Level 3) | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, contingent consideration obligations, discount rate	0.05
Maximum | Measurement Input, Discount Rate | Significant Unobservable Inputs (Level 3) | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, contingent consideration obligations, discount rate	0.25

FAIR VALUE MEASUREMENTS - Ass_3

FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Other non-current assets:
Non-current assets held for sale	$ 39	$ 0
Quoted Prices in Active Markets for Identical Assets (Level 1)
Other non-current assets:
Non-current assets held for sale	0	0
Significant Other Observable Inputs (Level 2)
Other non-current assets:
Non-current assets held for sale	0	0
Significant Unobservable Inputs (Level 3)
Other non-current assets:
Non-current assets held for sale	$ 39	$ 0

FAIR VALUE MEASUREMENTS - Ass_4

FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of long-lived assets	$ 8
Held For Sale
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of long-lived assets		$ 5	$ 114
Held For Sale | Certain Products For Disposal, September 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of long-lived assets	8
Non-recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-current assets held for sale	$ 39	$ 0

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Non-recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	$ 27,520	$ 23,357

INVENTORIES - Summary of Invent

INVENTORIES - Summary of Inventories, Net (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 319	$ 275
Work in process	149	95
Finished goods	639	564
Inventories, net	$ 1,107	$ 934

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	$ 3,107	$ 2,875
Less accumulated depreciation	(1,641)	(1,522)
Property, plant and equipment, net	1,466	1,353
Land
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	79	81
Buildings
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	696	693
Machinery and equipment
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	1,606	1,527
Other equipment and leasehold improvements
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	369	366
Equipment on operating lease
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	56	46
Construction in progress
Property, plant and equipment [Line Items]
Property, plant and equipment, gross	$ 301	$ 162

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 178	$ 175	$ 168

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 25,613	$ 25,485
Accumulated Amortization and Impairments	(17,123)	(15,218)
Net Carrying Amount	8,490	10,267
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount	27,324	27,219
Intangible Assets, Net (Excluding Goodwill)	10,201	12,001
Acquired IPR&D not in service
Indefinite-lived Intangible Assets [Line Items]
Net Carrying Amount	13	36
B&L Trademark
Indefinite-lived Intangible Assets [Line Items]
Net Carrying Amount	$ 1,698	1,698
Product brands
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Lives (Years)	7 years
Gross Carrying Amount	$ 21,011	20,891
Accumulated Amortization and Impairments	(13,544)	(11,958)
Net Carrying Amount	$ 7,467	8,933
B&L Trademark
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Lives (Years)	8 years
Gross Carrying Amount	$ 930	926
Accumulated Amortization and Impairments	(338)	(263)
Net Carrying Amount	$ 592	663
Product rights/patents
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Lives (Years)	4 years
Gross Carrying Amount	$ 3,297	3,292
Accumulated Amortization and Impairments	(2,887)	(2,658)
Net Carrying Amount	$ 410	634
Partner relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Lives (Years)	2 years
Gross Carrying Amount	$ 166	168
Accumulated Amortization and Impairments	(165)	(166)
Net Carrying Amount	$ 1	2
Technology and other
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Lives (Years)	3 years
Gross Carrying Amount	$ 209	208
Accumulated Amortization and Impairments	(189)	(173)
Net Carrying Amount	$ 20	$ 35

INTANGIBLE ASSETS AND GOODWIL_3

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)

Oct. 01, 2019

Oct. 01, 2018

Jan. 01, 2018

Oct. 01, 2017

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Sep. 30, 2017

Jun. 30, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Mar. 01, 2018

Dec. 31, 2016

Finite-Lived Intangible Assets [Line Items]

Impairment of intangible assets

$ 58,000,000

Impairment of long-lived assets

8,000,000

Impairment of finite-lived intangible assets

5,000,000

Impairment of indefinite-lived intangible assets

4,000,000

Carrying value of intangible assets, net

$ 10,201,000,000

$ 12,001,000,000

10,201,000,000

$ 12,001,000,000

Finite-lived intangible assets

8,490,000,000

10,267,000,000

8,490,000,000

10,267,000,000

Net (loss) income attributable to Bausch Health Companies Inc.

$ (1,516,000,000)

$ (49,000,000)

$ (171,000,000)

$ (52,000,000)

$ (344,000,000)

$ (350,000,000)

$ (873,000,000)

$ (2,581,000,000)

(1,788,000,000)

(4,148,000,000)

$ 2,404,000,000

Decrease to earnings per share, basic and diluted (in dollars per share)

$ 4.30

$ 0.14

$ 0.49

$ 0.15

$ 0.98

$ 1

$ 2.49

$ 7.36

Goodwill reallocated into (out of)

$ 13,126,000,000

$ 13,142,000,000

13,126,000,000

13,142,000,000

15,593,000,000

$ 15,794,000,000

Goodwill impairments

$ 0

0

2,322,000,000

312,000,000

Accumulated goodwill impairment charges to date

3,711,000,000

3,711,000,000

Salix Reporting Unit

Finite-Lived Intangible Assets [Line Items]

Goodwill reallocated into (out of)

$ 5,127,000,000

Goodwill impairments

0

Total identifiable net assets

10,660,000,000

Aggregate purchase price, net

$ 13,404,000,000

Ortho Dermatologics Reporting Unit

Finite-Lived Intangible Assets [Line Items]

Goodwill impairments

$ 0

2,213,000,000

Percentage of fair value in excess of carrying value

5.00%

5.00%

Dentistry Reporting Unit

Finite-Lived Intangible Assets [Line Items]

Goodwill impairments

$ 109,000,000

109,000,000

Reporting Units Excluding Dentistry

Finite-Lived Intangible Assets [Line Items]

Goodwill impairments

$ 0

Reporting Units Excluding Ortho Dermatologics and Dentistry

Finite-Lived Intangible Assets [Line Items]

Percentage of fair value in excess of carrying value

15.00%

Baush and Lomb/International Segment | Scenario, Adjustment

Finite-Lived Intangible Assets [Line Items]

Goodwill reallocated into (out of)

$ 264,000,000

Branded Rx Segment

Finite-Lived Intangible Assets [Line Items]

Goodwill impairments

$ 312,000,000

Branded Rx Segment | Scenario, Adjustment

Finite-Lived Intangible Assets [Line Items]

Goodwill reallocated into (out of)

$ 115,000,000

Branded Rx Segment | Salix Reporting Unit

Finite-Lived Intangible Assets [Line Items]

Goodwill impairments

$ 1,970,000,000

Branded Rx Segment | Ortho Dermatologics Reporting Unit

Finite-Lived Intangible Assets [Line Items]

Goodwill impairments

$ 243,000,000

Bausch Lomb/International And U.S. Diversified Products Segments | Scenario, Adjustment

Finite-Lived Intangible Assets [Line Items]

Goodwill reallocated into (out of)

$ (115,000,000)

Maximum

Finite-Lived Intangible Assets [Line Items]

Reporting unit, impairment test, long-term growth rates

2.00%

Reporting unit, impairment test, estimated cash flows, discount rate

9.80%

Minimum

Finite-Lived Intangible Assets [Line Items]

Reporting unit, impairment test, long-term growth rates

1.50%

Reporting unit, impairment test, estimated cash flows, discount rate

9.00%

Product rights/patents

Finite-Lived Intangible Assets [Line Items]

Impairment of finite-lived intangible assets

55,000,000

95,000,000

Finite-lived intangible assets

410,000,000

634,000,000

$ 410,000,000

$ 634,000,000

Estimated useful lives

4 years

Product rights/patents | Maximum

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives

15 years

Product rights/patents | Minimum

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives

3 years

Certain Product Brands

Finite-Lived Intangible Assets [Line Items]

Finite-lived intangible assets

$ 7,618,000,000

Estimated useful lives

4 years

7 years

Corporate brands

Finite-Lived Intangible Assets [Line Items]

Finite-lived intangible assets

592,000,000

$ 663,000,000

$ 592,000,000

$ 663,000,000

Estimated useful lives

8 years

Corporate brands | Maximum

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives

20 years

Corporate brands | Minimum

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives

7 years

Held For Sale

Finite-Lived Intangible Assets [Line Items]

Impairment of long-lived assets

5,000,000

$ 114,000,000

Held For Sale | Sprout

Finite-Lived Intangible Assets [Line Items]

Impairment of long-lived assets

351,000,000

Acquired IPR&D

Finite-Lived Intangible Assets [Line Items]

Impairment of indefinite-lived intangible assets

28,000,000

3,000,000

Uceris

Finite-Lived Intangible Assets [Line Items]

Impairment of intangible assets

$ 263,000,000

348,000,000

Carrying value of intangible assets, net

47,000,000

$ 47,000,000

Arestin

Finite-Lived Intangible Assets [Line Items]

Impairment of intangible assets

$ 132,000,000

Other Product Lines

Finite-Lived Intangible Assets [Line Items]

Impairment of finite-lived intangible assets

151,000,000

Salix | Corporate brands

Finite-Lived Intangible Assets [Line Items]

Finite-lived intangible assets

$ 569,000,000

Estimated useful lives

10 years

17 years

Xifaxan

Finite-Lived Intangible Assets [Line Items]

Carrying value of intangible assets, net

$ 4,309,000,000

4,309,000,000

Xifaxan | Intangible Assets, Amortization Period

Finite-Lived Intangible Assets [Line Items]

Net (loss) income attributable to Bausch Health Companies Inc.

$ 473,000,000

$ 143,000,000

Decrease to earnings per share, basic and diluted (in dollars per share)

$ 1.34

$ 0.41

INTANGIBLE ASSETS AND GOODWIL_4

INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Estimated aggregate amortization expense
2020	$ 1,624
2021	1,375
2022	1,224
2023	1,079
2024	950
Thereafter	2,238
Net Carrying Amount	$ 8,490	$ 10,267

INTANGIBLE ASSETS AND GOODWIL_5

INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) - USD ($)	Oct. 01, 2019	Oct. 01, 2018	Jan. 01, 2017	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Change in the carrying amount of goodwill
Balance at the beginning of the period			$ 15,794,000,000		$ 13,142,000,000	$ 15,593,000,000	$ 15,794,000,000
Acquisition of certain assets of Synergy					3,000,000
Goodwill reclassified to assets held for sale					(18,000,000)	(2,000,000)	(175,000,000)
Impairments	$ 0				0	(2,322,000,000)	(312,000,000)
Realignment of segment goodwill			0
Foreign exchange and other					(1,000,000)	(127,000,000)	286,000,000
Balance at the end of the period					13,126,000,000	13,142,000,000	15,593,000,000
Ortho Dermatologics Reporting Unit
Change in the carrying amount of goodwill
Impairments				$ 0		(2,213,000,000)
Dentistry Reporting Unit
Change in the carrying amount of goodwill
Impairments		$ (109,000,000)				(109,000,000)
Bausch Lomb/ International
Change in the carrying amount of goodwill
Balance at the beginning of the period			5,499,000,000		5,805,000,000	6,016,000,000	5,499,000,000
Realignment of Global Solta reporting unit goodwill						(82,000,000)
Goodwill reclassified to assets held for sale					(18,000,000)	(2,000,000)	(30,000,000)
Realignment of segment goodwill			264,000,000
Foreign exchange and other					(1,000,000)	(127,000,000)	283,000,000
Balance at the end of the period					5,786,000,000	5,805,000,000	6,016,000,000
Branded Rx
Change in the carrying amount of goodwill
Balance at the beginning of the period			7,265,000,000		0	6,631,000,000	7,265,000,000
Realignment of Global Solta reporting unit goodwill						115,000,000
Goodwill reclassified to assets held for sale							(61,000,000)
Impairments							(312,000,000)
Realignment of segment goodwill			(264,000,000)			(4,533,000,000)
Foreign exchange and other							3,000,000
Balance at the end of the period					0	0	6,631,000,000
Branded Rx | Ortho Dermatologics Reporting Unit
Change in the carrying amount of goodwill
Impairments						(2,213,000,000)
U.S. Diversified Products
Change in the carrying amount of goodwill
Balance at the beginning of the period			$ 3,030,000,000		0	2,946,000,000	3,030,000,000
Realignment of Global Solta reporting unit goodwill						(33,000,000)
Goodwill reclassified to assets held for sale							(84,000,000)
Realignment of segment goodwill						(2,913,000,000)
Foreign exchange and other							0
Balance at the end of the period					0	0	$ 2,946,000,000
Salix
Change in the carrying amount of goodwill
Balance at the beginning of the period					3,156,000,000
Acquisition of certain assets of Synergy					3,000,000
Realignment of segment goodwill						3,156,000,000
Balance at the end of the period					3,159,000,000	3,156,000,000
Ortho Dermatologics
Change in the carrying amount of goodwill
Balance at the beginning of the period					1,267,000,000
Realignment of segment goodwill						1,267,000,000
Balance at the end of the period					1,267,000,000	1,267,000,000
Diversified Products
Change in the carrying amount of goodwill
Balance at the beginning of the period					2,914,000,000
Realignment of segment goodwill						3,023,000,000
Balance at the end of the period					$ 2,914,000,000	2,914,000,000
Diversified Products | Dentistry Reporting Unit
Change in the carrying amount of goodwill
Impairments						$ (109,000,000)

ACCRUED AND OTHER CURRENT LIA_3

ACCRUED AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Legal matters and related fees	$ 1,397	$ 11
Product rebates	898	998
Product returns	691	813
Interest	305	273
Employee compensation and benefit costs	304	301
Income taxes payable	196	167
Other	720	634
Accrued and other current liabilities	$ 4,511	$ 3,197

FINANCING ARRANGEMENTS - Schedu

FINANCING ARRANGEMENTS - Schedule of Long-term Debt (Details) - USD ($)	Dec. 31, 2019	Dec. 30, 2019	Mar. 08, 2019	Dec. 31, 2018	Jun. 01, 2018	Mar. 26, 2018	Dec. 18, 2017	Mar. 21, 2017	Jan. 01, 2017	Mar. 27, 2015	Jan. 30, 2015	Dec. 02, 2013
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 26,188,000,000			$ 24,632,000,000
Total long-term debt and other	25,895,000,000			24,305,000,000
Less: Current portion of long-term debt and other	1,234,000,000			228,000,000
Non-current portion of long-term debt	24,661,000,000			24,077,000,000
Term Loan B Facility Due June 2025
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	3,869,000,000			4,394,000,000
Total long-term debt and other	$ 3,768,000,000			4,269,000,000
Stated interest rate	4.74%
Term Loan B Facility Due November 2025
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,275,000,000			1,481,000,000
Total long-term debt and other	$ 1,257,000,000			1,456,000,000
Stated interest rate	4.49%
Senior Secured Notes 6.50% Due March 2022
Long-term debt, net of unamortized debt discount [Line Items]
Stated interest rate	6.50%							6.50%
Senior Secured Notes 7.00% Due March 2024
Long-term debt, net of unamortized debt discount [Line Items]
Stated interest rate	7.00%							7.00%
Senior Secured Notes 5.50% Due November 2025
Long-term debt, net of unamortized debt discount [Line Items]
Stated interest rate	5.50%
Senior Secured Notes 5.75% Due August 2027
Long-term debt, net of unamortized debt discount [Line Items]
Stated interest rate	5.75%
9.00% Senior Unsecured Notes due December 2025
Long-term debt, net of unamortized debt discount [Line Items]
Stated interest rate							9.00%
Senior Secured Notes | Senior Secured Notes 6.50% Due March 2022
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,250,000,000			1,250,000,000
Total long-term debt and other	1,242,000,000			1,239,000,000
Senior Secured Notes | Senior Secured Notes 7.00% Due March 2024
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	2,000,000,000			2,000,000,000
Total long-term debt and other	1,983,000,000			1,979,000,000
Senior Secured Notes | Senior Secured Notes 5.50% Due November 2025
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	1,750,000,000			1,750,000,000
Total long-term debt and other	1,733,000,000			1,730,000,000
Senior Secured Notes | Senior Secured Notes 5.75% Due August 2027
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	500,000,000			0
Total long-term debt and other	493,000,000			0
Senior Unsecured Notes | 5.625 % Senior Unsecured Notes due December 2021
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	0			700,000,000
Total long-term debt and other	$ 0			697,000,000
Stated interest rate	5.625%		5.625%									5.625%
Senior Unsecured Notes | 5.50% Senior Unsecured Notes due March 2023
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 402,000,000			1,000,000,000
Total long-term debt and other	$ 400,000,000			995,000,000
Stated interest rate	5.50%		5.50%								5.50%
Senior Unsecured Notes | 5.875% Senior Unsecured Notes due May 2023
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,448,000,000			3,250,000,000
Total long-term debt and other	$ 1,441,000,000			3,229,000,000
Stated interest rate	5.875%		5.875%							5.875%
Senior Unsecured Notes | 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,682,000,000			1,720,000,000
Total long-term debt and other	$ 1,674,000,000			1,709,000,000
Stated interest rate	4.50%									4.50%
Senior Unsecured Notes | 6.125% Senior Unsecured Notes due April 2025
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 3,250,000,000			3,250,000,000
Total long-term debt and other	$ 3,230,000,000			3,226,000,000
Stated interest rate	6.125%									6.125%
Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,500,000,000			1,500,000,000
Total long-term debt and other	$ 1,473,000,000			1,469,000,000
Stated interest rate	9.00%						9.00%
Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,500,000,000			1,500,000,000
Total long-term debt and other	$ 1,484,000,000			1,482,000,000
Stated interest rate	9.25%					9.25%
Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,750,000,000			750,000,000
Total long-term debt and other	$ 1,756,000,000			738,000,000
Stated interest rate	8.50%				8.50%
Senior Unsecured Notes | 7.00% Senior Unsecured Notes Due January 2028
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 750,000,000			0
Total long-term debt and other	$ 741,000,000			0
Stated interest rate	7.00%
Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,250,000,000			0
Total long-term debt and other	$ 1,234,000,000			0
Stated interest rate	5.00%	5.00%
Senior Unsecured Notes | 7.25% Senior Unsecured Notes Due May 2029
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 750,000,000			0
Total long-term debt and other	$ 740,000,000			0
Stated interest rate	7.25%
Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 1,250,000,000			0
Total long-term debt and other	$ 1,234,000,000			0
Stated interest rate	5.25%	5.25%
Senior Unsecured Notes | Other
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	$ 12,000,000			12,000,000
Total long-term debt and other	12,000,000			12,000,000
Revolving credit facility
Long-term debt, net of unamortized debt discount [Line Items]
Total long-term debt and other									$ 9,939,000,000
Revolving credit facility | 2023 Revolving Credit Facility Due June 2023
Long-term debt, net of unamortized debt discount [Line Items]
Principal Amount	0			75,000,000
Total long-term debt and other	$ 0			$ 75,000,000
Stated interest rate	4.74%

FINANCING ARRANGEMENTS - Covena

FINANCING ARRANGEMENTS - Covenant Compliance (Details)	Dec. 31, 2019
Revolving credit facility
Debt Instrument [Line Items]
Secured leverage ratio	4

FINANCING ARRANGEMENTS - Senior

FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Mar. 28, 2017	Jan. 01, 2017
Debt Instrument [Line Items]
Long-term debt	$ 25,895,000,000	$ 24,305,000,000
Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 1,190,000,000	$ 1,500,000,000
Long-term debt				9,939,000,000
Amount outstanding				$ 875,000,000

FINANCING ARRANGEMENTS - Seni_2

FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2017 Activity (Details) - USD ($)	Mar. 08, 2019	Mar. 21, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 01, 2018	Mar. 28, 2017	Jan. 01, 2017
Debt Instrument [Line Items]
Repayments of long-term debt			$ 4,406,000,000	$ 10,101,000,000	$ 14,203,000,000
Loss on extinguishment of debt	$ 8,000,000		42,000,000	119,000,000	122,000,000
Revolving credit facility
Debt Instrument [Line Items]
Repayments of long-term debt				$ 571,000,000
Repayments of lines of credit		$ 350,000,000	$ 806,000,000
Maximum borrowing capacity							$ 1,190,000,000	$ 1,500,000,000
Senior Credit Facilities
Debt Instrument [Line Items]
Repayments of long-term debt, using sale proceeds					3,221,000,000
Repayments of long-term debt, using cash on hand					786,000,000
Loss on extinguishment of debt					66,000,000
2023 Revolving Credit Facility Due June 2023 | Revolving credit facility
Debt Instrument [Line Items]
Aggregate principal amount		4,962,000,000
Stated interest rate			4.74%
Maximum borrowing capacity						$ 1,225,000,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Repurchased face amount		$ 1,100,000,000
Stated interest rate		6.75%
Revolving Credit Facility Due April 2020 | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 3,000,000

FINANCING ARRANGEMENTS - Seni_3

FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details) - USD ($)

May 23, 2019

Mar. 08, 2019

Nov. 27, 2018

Jun. 01, 2018

Mar. 26, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 27, 2019

Mar. 31, 2019

Mar. 28, 2017

Mar. 21, 2017

Jan. 01, 2017

Mar. 27, 2015

Debt Instrument [Line Items]

Repayments of long-term debt

$ 4,406,000,000

$ 10,101,000,000

$ 14,203,000,000

Proceeds from issuance of long-term debt

5,960,000,000

8,944,000,000

9,424,000,000

Loss on extinguishment of debt

$ 8,000,000

$ 42,000,000

119,000,000

$ 122,000,000

Debt issuance cost

$ 25,000,000

$ 74,000,000

Payments of debt restructuring costs

4,000,000

Senior Unsecured Notes

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 32,000,000

$ 26,000,000

Series F Tranche B Term Loan Facility

Debt Instrument [Line Items]

Repayments of long-term debt

3,315,000,000

Loss on extinguishment of debt

$ 48,000,000

Term Loan B Facility Due June 2025

Debt Instrument [Line Items]

Debt instrument, term

7 years

7 years

Aggregate principal amount

$ 1,500,000,000

$ 4,565,000,000

Stated interest rate

4.74%

5.375% Senior Notes due March 2020 | Senior Unsecured Notes

Debt Instrument [Line Items]

Repayments of long-term debt

$ 691,000,000

Aggregate principal amount

$ 2,000,000,000

Stated interest rate

5.375%

5.375%

6.75% Senior Notes due in August 2021 | Senior Unsecured Notes

Debt Instrument [Line Items]

Repayments of long-term debt

$ 578,000,000

Stated interest rate

6.75%

7.25% Senior Notes due in July 2022 | Senior Unsecured Notes

Debt Instrument [Line Items]

Repayments of long-term debt

$ 550,000,000

Stated interest rate

7.25%

6.375% Senior Notes due in October 2020 | Senior Unsecured Notes

Debt Instrument [Line Items]

Repayments of long-term debt

$ 146,000,000

Stated interest rate

6.375%

8.50% Senior Unsecured Notes Due January 2027 | Senior Unsecured Notes

Debt Instrument [Line Items]

Aggregate principal amount

$ 750,000,000

$ 1,000,000,000

Stated interest rate

8.50%

8.50%

Proceeds from issuance of long-term debt

$ 750,000,000

7.50% Senior Notes due July 2021 | Senior Unsecured Notes

Debt Instrument [Line Items]

Repayments of long-term debt

$ 1,483,000,000

Stated interest rate

7.50%

Loss on extinguishment of debt

$ 43,000,000

Repurchased face amount

$ 17,000,000

Revolving credit facility

Debt Instrument [Line Items]

Repayments of long-term debt

$ 571,000,000

Maximum borrowing capacity

$ 1,190,000,000

$ 1,500,000,000

Revolving credit facility | 2023 Revolving Credit Facility Due June 2023

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 1,225,000,000

Aggregate principal amount

$ 4,962,000,000

Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold

91 days

Alternate term, principal amount maturity threshold

$ 1,000,000,000

Stated interest rate

4.74%

FINANCING ARRANGEMENTS - Seni_4

FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details) - USD ($)	Mar. 21, 2017	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2017
Debt Instrument [Line Items]
Long-term debt		$ 25,895,000,000	$ 24,305,000,000
Term Loan B Facility Due June 2025
Debt Instrument [Line Items]
Long-term debt		3,768,000,000	4,269,000,000
Term Loan B Facility Due November 2025
Debt Instrument [Line Items]
Long-term debt		1,257,000,000	1,456,000,000
Revolving credit facility
Debt Instrument [Line Items]
Repayments of lines of credit	$ 350,000,000	806,000,000
Long-term debt				$ 9,939,000,000
Revolving credit facility | 2023 Revolving Credit Facility Due June 2023
Debt Instrument [Line Items]
Long-term debt		0	$ 75,000,000
Remaining availability		1,055,000,000
Letter of Credit | 2023 Revolving Credit Facility Due June 2023
Debt Instrument [Line Items]
Long-term debt		$ 170,000,000

FINANCING ARRANGEMENTS - Curren

FINANCING ARRANGEMENTS - Current Description Of Senior Secured Credit Facilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Federal funds effective rate	26.90%	26.90%	26.90%
Revolving credit facility
Debt Instrument [Line Items]
Quarterly amortization payments	$ 1,126,000,000
Incremental credit facility borrowings	$ 1,000,000,000
Incremental borrowings interest rate	28.50%
Secured leverage ratio (not greater than)	4
Interest coverage ratio (not less than)	2
Revolving credit facility | Secured Debt
Debt Instrument [Line Items]
Secured leverage ratio (not greater than)	3.50
Revolving credit facility | Unsecured Debt
Debt Instrument [Line Items]
Total leverage ratio (not greater than)	6.50
Senior Credit Facilities
Debt Instrument [Line Items]
Variable interest rate	0.00%
2023 Revolving Credit Facility Due June 2023 | Revolving credit facility
Debt Instrument [Line Items]
Stated interest rate	4.74%
2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility
Debt Instrument [Line Items]
Commitment fee, unutilized commitments, percentage	0.25%
2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility
Debt Instrument [Line Items]
Commitment fee, unutilized commitments, percentage	0.50%
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses	100.00%
Percentage of cash proceeds from incurrence of debt	100.00%
Percentage of annual excess cash flow	50.00%
Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments	100.00%
Term Loan B Facility Due June 2025
Debt Instrument [Line Items]
Stated interest rate	4.74%
Annual amortization rate, percentage	5.00%
Term Loan B Facility Due November 2025
Debt Instrument [Line Items]
Stated interest rate	4.49%
Annual amortization rate, percentage	5.00%
Federal Funds Effective Swap Rate | Senior Secured Credit Facilities
Debt Instrument [Line Items]
Variable interest rate	0.50%
Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility
Debt Instrument [Line Items]
Variable interest rate	1.50%
Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility
Debt Instrument [Line Items]
Variable interest rate	2.00%
Base Rate or Prime Rate | Term Loan B Facility Due June 2025
Debt Instrument [Line Items]
Variable interest rate	2.00%
Base Rate or Prime Rate | Term Loan B Facility Due November 2025
Debt Instrument [Line Items]
Variable interest rate	1.75%
Eurodollar | Senior Credit Facilities
Debt Instrument [Line Items]
Federal funds effective rate	1.00%
Variable interest rate	1.00%
Eurodollar | Senior Credit Facilities | Minimum
Debt Instrument [Line Items]
Variable interest rate	1.00%
Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum
Debt Instrument [Line Items]
Variable interest rate	0.00%
Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility
Debt Instrument [Line Items]
Variable interest rate	2.50%
Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility
Debt Instrument [Line Items]
Variable interest rate	3.00%
Eurodollar | Term Loan B Facility Due June 2025
Debt Instrument [Line Items]
Variable interest rate	3.00%
Eurodollar | Term Loan B Facility Due November 2025
Debt Instrument [Line Items]
Variable interest rate	2.75%
Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023
Debt Instrument [Line Items]
Variable interest rate	1.00%
Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum
Debt Instrument [Line Items]
Variable interest rate	0.00%

FINANCING ARRANGEMENTS - Seni_5

FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)	May 23, 2019	Mar. 08, 2019	Dec. 30, 2018	Jun. 01, 2018	Mar. 26, 2018	Nov. 21, 2017	Oct. 17, 2017	Mar. 21, 2017	Apr. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 27, 2015	Dec. 02, 2013
Debt Instrument [Line Items]
Redemption price percentage due to change in control (as a percent)										101.00%
Repayments of long-term debt										$ 4,406,000,000	$ 10,101,000,000	$ 14,203,000,000
Loss on extinguishment of debt		$ 8,000,000								$ 42,000,000	119,000,000	$ 122,000,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Redemption price percentage due to change in control (as a percent)										101.00%
Loss on extinguishment of debt	$ 32,000,000				$ 26,000,000
Revolving credit facility
Debt Instrument [Line Items]
Repayments of lines of credit								$ 350,000,000		$ 806,000,000
Repayments of long-term debt											$ 571,000,000
Senior Secured Notes 6.50% Due March 2022
Debt Instrument [Line Items]
Stated interest rate								6.50%		6.50%
Aggregate principal amount								$ 1,250,000,000
Repurchased face amount								$ 1,100,000,000
Senior Secured Notes 7.00% Due March 2024
Debt Instrument [Line Items]
Stated interest rate								7.00%		7.00%
Aggregate principal amount								$ 2,000,000,000
Redemption price percentage (as a percent)								100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings								40.00%
Senior Secured Notes 5.50% Due November 2025
Debt Instrument [Line Items]
Stated interest rate										5.50%
Senior Secured Notes 5.50% Due November 2025 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate							5.50%
Aggregate principal amount						$ 750,000,000
Redemption price percentage (as a percent)							100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings							40.00%
Senior Secured Notes 5.50% Due November 2025 | Senior Secured Notes
Debt Instrument [Line Items]
Aggregate principal amount							$ 1,000,000,000
Repurchased face amount							$ 1,000,000,000
Series F Tranche B Term Loan Facility
Debt Instrument [Line Items]
Repayments of lines of credit						$ 750,000,000
Repayments of long-term debt				$ 3,315,000,000
Loss on extinguishment of debt				$ 48,000,000
Senior Secured 5.75% Notes due August 2027 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate		5.75%
Aggregate principal amount		$ 500,000,000
Redemption price percentage (as a percent)		100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings		40.00%
5.75% Senior Secured Notes due 2027 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate				8.50%						8.50%
Aggregate principal amount				$ 750,000,000									$ 1,000,000,000
Redemption price percentage (as a percent)				100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings				40.00%
5.875% Senior Unsecured Notes due May 2023 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate		5.875%								5.875%				5.875%
Aggregate principal amount														$ 3,250,000,000
Repayments of long-term debt	$ 1,118,000,000	$ 584,000,000
5.625 % Senior Unsecured Notes due December 2021 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate		5.625%								5.625%					5.625%
Aggregate principal amount															$ 900,000,000
Repayments of long-term debt		$ 518,000,000	$ 200,000,000						$ 182,000,000
Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Aggregate principal amount									$ 1,500,000,000

FINANCING ARRANGEMENTS - Seni_6

FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)	Jan. 16, 2020USD ($)	Dec. 30, 2019USD ($)	Oct. 03, 2019USD ($)	May 23, 2019USD ($)	Mar. 08, 2019USD ($)	Dec. 30, 2018USD ($)	Jun. 01, 2018USD ($)	Mar. 26, 2018USD ($)	Dec. 18, 2017USD ($)	Mar. 27, 2015USD ($)	Apr. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Mar. 31, 2019USD ($)	Mar. 27, 2015EUR (€)	Jan. 30, 2015USD ($)	Dec. 02, 2013USD ($)
Debt Instrument [Line Items]
Redemption price percentage due to change in control (as a percent)												101.00%
Repayments of long-term debt												$ 4,406,000,000	$ 10,101,000,000	$ 14,203,000,000
Loss on extinguishment of debt					$ 8,000,000							42,000,000	$ 119,000,000	$ 122,000,000
Salix
Debt Instrument [Line Items]
Restricted cash										$ 10,340,000,000
5.50% Senior Unsecured Notes due March 2023
Debt Instrument [Line Items]
Aggregate principal amount																	$ 1,000,000,000
Senior Unsecured Notes due 2023 | Subsequent event
Debt Instrument [Line Items]
Repurchased face amount	$ 1,240,000,000
9.00% Senior Unsecured Notes due December 2025
Debt Instrument [Line Items]
Stated interest rate									9.00%
Settled Litigation | New Jersey | Valeant US Securities Litigation
Debt Instrument [Line Items]
Litigation, amount agreed to pay												$ 1,210,000,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Redemption price percentage due to change in control (as a percent)												101.00%
Loss on extinguishment of debt				$ 32,000,000				$ 26,000,000
Senior Unsecured Notes | 5.625 % Senior Unsecured Notes due December 2021
Debt Instrument [Line Items]
Stated interest rate					5.625%							5.625%						5.625%
Aggregate principal amount																		$ 900,000,000
Repayments of long-term debt					$ 518,000,000	$ 200,000,000					$ 182,000,000
Senior Unsecured Notes | 5.50% Senior Unsecured Notes due March 2023
Debt Instrument [Line Items]
Stated interest rate					5.50%							5.50%					5.50%
Repayments of long-term debt				382,000,000	$ 216,000,000
Senior Unsecured Notes | 5.375% Senior Notes due March 2020
Debt Instrument [Line Items]
Stated interest rate							5.375%			5.375%						5.375%
Aggregate principal amount										$ 2,000,000,000
Repayments of long-term debt							$ 691,000,000
Senior Unsecured Notes | 5.875% Senior Unsecured Notes due May 2023
Debt Instrument [Line Items]
Stated interest rate					5.875%					5.875%		5.875%				5.875%
Aggregate principal amount										$ 3,250,000,000
Repayments of long-term debt				$ 1,118,000,000	$ 584,000,000
Senior Unsecured Notes | 5.875% Senior Unsecured Notes due May 2023 | Subsequent event
Debt Instrument [Line Items]
Repayments of long-term debt	$ 1,240,000,000
Senior Unsecured Notes | 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023
Debt Instrument [Line Items]
Stated interest rate										4.50%		4.50%				4.50%
Aggregate principal amount | €																€ 1,500,000,000
Senior Unsecured Notes | 6.125% Senior Unsecured Notes due April 2025
Debt Instrument [Line Items]
Stated interest rate										6.125%		6.125%				6.125%
Aggregate principal amount										$ 3,250,000,000
Redemption price percentage (as a percent)										100.00%
Senior Unsecured Notes | Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Repayments of long-term debt			$ 100,000,000
Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025
Debt Instrument [Line Items]
Stated interest rate									9.00%			9.00%
Aggregate principal amount									$ 1,500,000,000
Repurchased face amount									$ 1,500,000,000
Redemption price percentage (as a percent)									100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings									40.00%
Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026
Debt Instrument [Line Items]
Stated interest rate								9.25%				9.25%
Aggregate principal amount								$ 1,500,000,000
Repurchased face amount								$ 1,500,000,000
Redemption price percentage (as a percent)								100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings								40.00%
Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027
Debt Instrument [Line Items]
Stated interest rate							8.50%					8.50%
Aggregate principal amount							$ 750,000,000								$ 1,000,000,000
Redemption price percentage (as a percent)							100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings							40.00%
Senior Unsecured Notes | 7.00% Senior Unsecured Notes due 2028
Debt Instrument [Line Items]
Stated interest rate				7.00%
Aggregate principal amount				$ 750,000,000
Redemption price percentage (as a percent)				100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings				40.00%
Senior Unsecured Notes | 7.25% Senior Unsecured Notes due 2029
Debt Instrument [Line Items]
Stated interest rate				7.25%
Aggregate principal amount				$ 750,000,000
Redemption price percentage (as a percent)				100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings				40.00%
Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028
Debt Instrument [Line Items]
Stated interest rate		5.00%										5.00%
Aggregate principal amount		$ 1,250,000,000
Redemption price percentage (as a percent)		100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings		40.00%
Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030
Debt Instrument [Line Items]
Stated interest rate		5.25%										5.25%
Aggregate principal amount		$ 1,250,000,000
Redemption price percentage (as a percent)		100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings		40.00%

FINANCING ARRANGEMENTS - Weight

FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Weighted average interest rate	6.21%	6.23%

FINANCING ARRANGEMENTS - Maturi

FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
2020	$ 1,240
2021	103
2022	1,553
2023	2,595
2024	2,303
Thereafter	18,394
Total gross maturities	26,188	$ 24,632
Unamortized discounts	(293)
Total long-term debt and other	$ 25,895	$ 24,305

FINANCING ARRANGEMENTS - Matu_2

FINANCING ARRANGEMENTS - Maturities, Narrative (Details)	Jan. 16, 2020USD ($)
Senior Unsecured Notes due 2023 | Subsequent event
Debt Instrument [Line Items]
Repurchased face amount	$ 1,240,000,000

PENSION AND POSTRETIREMENT EM_3

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019USD ($)defined_benefit_plan	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Future benefit payments period		10 years
Contributions recognized		$ 41	$ 36	$ 22
Pension Benefit Plans | Ireland
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of defined benefit plans | defined_benefit_plan		2
Percentage of expected return on plan assets		3.50%
Percentage allocation of fund		95.00%	95.00%
Pension Benefit Plans | Ireland | Scenario, Forecast
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Percentage of expected return on plan assets	3.00%
Pension Benefit Plans | Ireland, Germany, and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Expected unrecognized prior service credits during next year		$ 1
Expected unrecognized loss during next year		2
Estimated company contributions in next fiscal year		$ 9
Percentage of expected return on plan assets		3.46%	3.66%	3.84%
Pension Benefit Plans | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Estimated company contributions in next fiscal year		$ 3
Percentage of expected return on plan assets		7.25%	7.50%	7.50%
Pension Benefit Plans | United States | Scenario, Forecast
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Percentage of expected return on plan assets	6.25%
Postretirement Benefit Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contribution maximum age		65 years
Estimated company contributions in next fiscal year		$ 5
Percentage of expected return on plan assets		0.00%	0.00%	0.00%
Postretirement Benefit Plan | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Expected unrecognized prior service credits during next year		$ 3

PENSION AND POSTRETIREMENT EM_4

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
U.S. Postretirement Benefit Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial losses	$ (2)	$ (1)
Unrecognized prior service credits	14	17
United States | Pension Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial losses	(20)	(31)
Unrecognized prior service credits	0	0
Ireland, Germany, and Japan | Pension Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial losses	(65)	(50)
Unrecognized prior service credits	$ 26	$ 27

PENSION AND POSTRETIREMENT EM_5

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
U.S. Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	$ 0
Interest cost	1	1	2
Expected return on plan assets	0	0	0
Amortization of net loss	0	0	0
Amortization of prior service credit	(2)	(2)	(3)
Other	0	0	0
Net periodic (benefit) cost	(1)	(1)	(1)
United States | Pension Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	2	2	2
Interest cost	8	7	8
Expected return on plan assets	(13)	(15)	(13)
Amortization of net loss	0	0	0
Amortization of prior service credit	0	0	0
Other	0	0	0
Net periodic (benefit) cost	(3)	(6)	(3)
Ireland, Germany, and Japan | Pension Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	3	3	3
Interest cost	5	5	5
Expected return on plan assets	(5)	(5)	(5)
Amortization of net loss	1	1	2
Amortization of prior service credit	(1)	(1)	(1)
Other	1	0	0
Net periodic (benefit) cost	$ 4	$ 3	$ 4

PENSION AND POSTRETIREMENT EM_6

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
U.S. Postretirement Benefit Plan
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	$ 41	$ 48
Service cost	0	0	$ 0
Interest cost	1	1	2
Employee contributions	1	1
Settlements	0	0
Benefits paid	(4)	(5)
Actuarial losses (gains)	2	(4)
Currency translation adjustments	0	0
Projected benefit obligation, end of year	41	41	48
Change in Plan Assets
Fair value of plan assets, beginning of year	0	0
Actual return on plan assets	0	0
Employee contributions	1	1
Company contributions	3	4
Settlements	0	0
Benefits paid	(4)	(5)
Currency translation adjustments	0	0
Fair value of plan assets, end of year	0	0	0
Funded Status at end of year	(41)	(41)
Recognized as:
Accrued and other current liabilities	(5)	(5)
Other non-current liabilities	(36)	(36)
United States | Pension Benefit Plans
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	214	234
Service cost	2	2	2
Interest cost	8	7	8
Employee contributions	0	0
Settlements	0	0
Benefits paid	(15)	(16)
Actuarial losses (gains)	18	(13)
Currency translation adjustments	0	0
Projected benefit obligation, end of year	227	214	234
Change in Plan Assets
Fair value of plan assets, beginning of year	187	206
Actual return on plan assets	42	(11)
Employee contributions	0	0
Company contributions	2	8
Settlements	0	0
Benefits paid	(15)	(16)
Currency translation adjustments	0	0
Fair value of plan assets, end of year	216	187	206
Funded Status at end of year	(11)	(27)
Recognized as:
Accrued and other current liabilities	0	0
Other non-current liabilities	(11)	(27)
Ireland, Germany, and Japan | Pension Benefit Plans
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	235	254
Service cost	3	3	3
Interest cost	5	5	5
Employee contributions	0	0
Settlements	(2)	(2)
Benefits paid	(8)	(5)
Actuarial losses (gains)	30	(10)
Currency translation adjustments	(4)	(10)
Projected benefit obligation, end of year	259	235	254
Change in Plan Assets
Fair value of plan assets, beginning of year	147	155
Actual return on plan assets	17	(2)
Employee contributions	0	0
Company contributions	10	7
Settlements	(2)	(2)
Benefits paid	(8)	(5)
Currency translation adjustments	(3)	(6)
Fair value of plan assets, end of year	161	147	$ 155
Funded Status at end of year	(98)	(88)
Recognized as:
Accrued and other current liabilities	(2)	(2)
Other non-current liabilities	$ (96)	$ (86)

PENSION AND POSTRETIREMENT EM_7

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
United States
Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets
Projected benefit obligation	$ 227	$ 214
Accumulated benefit obligation	227	214
Fair value of plan assets	216	187
Ireland, Germany, and Japan
Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets
Projected benefit obligation	259	235
Accumulated benefit obligation	251	225
Fair value of plan assets	$ 161	$ 147

PENSION AND POSTRETIREMENT EM_8

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details) $ in Millions	Dec. 31, 2019USD ($)
Pension Benefit Plans | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2020	$ 14
2021	18
2022	18
2023	17
2024	16
2025-2029	77
Pension Benefit Plans | Ireland, Germany, and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2020	5
2021	6
2022	6
2023	6
2024	6
2025-2029	33
U.S. Postretirement Benefit Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2020	5
2021	4
2022	4
2023	4
2024	3
2025-2029	$ 13

PENSION AND POSTRETIREMENT EM_9

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Pension Benefit Plans | United States
Defined Benefit Plan Disclosure [Line Items]
Discount rate - for determining net periodic (benefit) cost	4.25%	3.56%	4.04%
Expected rate of return on plan assets - for determining net periodic (benefit) cost	7.25%	7.50%	7.50%
Rate of compensation increase	0.00%	0.00%	0.00%
Discount rate - for determining benefit obligation	3.16%	4.25%
Rate of compensation increase - for determining benefit obligation	0.00%	0.00%
Pension Benefit Plans | Ireland, Germany, and Japan
Defined Benefit Plan Disclosure [Line Items]
Discount rate - for determining net periodic (benefit) cost	2.39%	2.29%	2.08%
Expected rate of return on plan assets - for determining net periodic (benefit) cost	3.46%	3.66%	3.84%
Rate of compensation increase	2.89%	2.87%	2.64%
Discount rate - for determining benefit obligation	1.68%	2.39%
Rate of compensation increase - for determining benefit obligation	3.05%	2.89%
U.S. Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate - for determining net periodic (benefit) cost	4.16%	3.47%	3.85%
Expected rate of return on plan assets - for determining net periodic (benefit) cost	0.00%	0.00%	0.00%
Rate of compensation increase	0.00%	0.00%	0.00%
Discount rate - for determining benefit obligation	3.04%	4.16%
Rate of compensation increase - for determining benefit obligation	0.00%	0.00%

PENSION AND POSTRETIREMENT E_10

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) - Pension Benefit Plans	Dec. 31, 2019	Dec. 31, 2018
United States | Equity securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	55.00%	52.00%
United States | Fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	44.00%	47.00%
United States | Other
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	1.00%	1.00%
Ireland, Germany, and Japan | Cash and cash equivalents
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	6.00%	5.00%
Ireland, Germany, and Japan | Equity securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	25.00%	20.00%
Ireland, Germany, and Japan | Fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	64.00%	69.00%
Ireland, Germany, and Japan | Other
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, percentage of actual plan asset allocations	6.00%	6.00%

PENSION AND POSTRETIREMENT E_11

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details) - Pension Benefit Plans - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	$ 216	$ 187	$ 206
Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	216	187
Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	161	147
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	1	2
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	1	0
Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	215	185
Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	159	147
Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	1	0
Cash and cash equivalents | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	1	2
Cash and cash equivalents | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	9	7
Cash and cash equivalents | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	1	2
Cash and cash equivalents | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Cash and cash equivalents | Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Cash and cash equivalents | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	9	7
Cash and cash equivalents | Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Cash and cash equivalents | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
U.S. broad market | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	64	51
U.S. broad market | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
U.S. broad market | Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	64	51
U.S. broad market | Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Emerging markets | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	15	13
Emerging markets | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	2	1
Emerging markets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Emerging markets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Emerging markets | Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	15	13
Emerging markets | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	2	1
Emerging markets | Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Emerging markets | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Worldwide developed markets | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	26	21
Worldwide developed markets | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	38	29
Worldwide developed markets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Worldwide developed markets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Worldwide developed markets | Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	26	21
Worldwide developed markets | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	38	29
Worldwide developed markets | Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Worldwide developed markets | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Other assets | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	15	13
Other assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Other assets | Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	15	13
Other assets | Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Investment grade | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	95	87
Investment grade | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	9	9
Investment grade | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Investment grade | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Investment grade | Significant Other Observable Inputs (Level 2) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	95	87
Investment grade | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	9	9
Investment grade | Significant Unobservable Inputs (Level 3) | Recurring basis | United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Investment grade | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Global high yield | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	3	2
Global high yield | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Global high yield | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	3	2
Global high yield | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Government bond funds | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	91	90
Government bond funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	1	0
Government bond funds | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	90	90
Government bond funds | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Other assets | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	9	9
Other assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	0	0
Other assets | Significant Other Observable Inputs (Level 2) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	8	9
Other assets | Significant Unobservable Inputs (Level 3) | Recurring basis | Ireland and Japan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	$ 1	$ 0

LEASES - Right-of-use Assets an

LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019
Right-of-use assets included in:
Other non-current assets	$ 271	$ 302
Lease liabilities included in:
Accrued and other current liabilities	53
Other non-current liabilities	240
Present value of remaining lease payments	$ 293	$ 302

LEASES - Narrative (Details)

LEASES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Leases [Abstract]
Finance leases	$ 0
Sub-lease income	0
Short-term lease expense	0
Right-of-use assets obtained in exchange for new operating lease liabilities, excluding amount recognized upon adoption of new accounting standard	47
Right-of-use assets obtained in exchange for new operating lease liabilities, upon adoption of new accounting standard	$ 282
Rental expense related to operating lease		$ 92	$ 102

LEASES - Lease Expenses (Detail

LEASES - Lease Expenses (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating lease costs	$ 62
Variable operating lease costs	$ 16

LEASES - Lease Additional Infor

LEASES - Lease Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities	$ 73
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 47
Weighted-average remaining lease term	8 years 2 months 12 days
Weighted-average discount rate	6.20%

LEASES - Lease Future Payments,

LEASES - Lease Future Payments, Topic 842 (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
2020	$ 70
2021	55
2022	42
2023	37
2024	30
Thereafter	149
Total	383
Less: Imputed interest	90
Present value of remaining lease payments	293	$ 302
Less: Current portion	53
Non-current portion	$ 240

LEASES - Lease Future Payment_2

LEASES - Lease Future Payments, Topic 840 (Details) $ in Millions	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 78
2020	60
2021	44
2022	39
2023	32
Thereafter	166
Total	$ 419

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) - Omnibus Incentive Plan 2014 - USD ($)	Apr. 30, 2018	Dec. 31, 2019	May 31, 2014
Components and classification of share-based compensation expense
Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)			18,000,000
Shares reserved for future issuance (in shares)			20,000,000
Number of additional shares available for issuance (in shares)	11,900,000
Number of shares available for future grants (in shares)		9,864,000
Nonemployee Director
Components and classification of share-based compensation expense
Aggregate fair market value on awards granted during any calendar year	$ 750,000

SHARE-BASED COMPENSATION - Summ

SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Components and classification of share-based compensation expense
Share-based compensation	$ 102	$ 87	$ 87
Research and development expenses
Components and classification of share-based compensation expense
Share-based compensation	9	9	8
Selling, general and administrative expenses
Components and classification of share-based compensation expense
Share-based compensation	93	78	79
Stock options
Components and classification of share-based compensation expense
Share-based compensation	21	23	18
RSUs
Components and classification of share-based compensation expense
Share-based compensation	$ 81	$ 64	$ 69

SHARE-BASED COMPENSATION - Stoc

SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stock options
Method and assumptions on valuation of stock options
Expected stock option life (years)	3 years	3 years	3 years
Expected volatility	46.50%	54.00%	67.30%
Risk-free interest rate	2.50%	2.70%	1.80%
Expected dividend yield	0.00%	0.00%	0.00%
Options
Beginning of the period (in shares)	5.9
Granted (in shares)	1.7
Exercised (in shares)	(0.3)
Expired or forfeited (in shares)	(0.2)
End of the period (in shares)	7.1	5.9
Vested and expected to vest at the end of the period (in shares)	6.7
Vested and exercisable at the end of the period (in shares)	3.6
Weighted- Average Exercise Price Per Share
Beginning of the period (in dollars per share)	$ 27.88
Granted (in dollars per share)	23.19
Exercised (in dollars per share)	16.03
Expired or forfeited (in dollars per share)	37.27
End of the period (in dollars per share)	26.99	$ 27.88
Vested and expected to vest at the end of the period (in dollars per share)	27.43
Vested and exercisable at the end of the period (in dollars per share)	$ 34.27
Weighted- Average Remaining Contractual Term (Years)
Outstanding at the end of the period	7 years 6 months
Vested and expected to vest at the end of the period	7 years 4 months 24 days
Vested and exercisable at the end of the period	6 years 6 months
Aggregate Intrinsic Value
Outstanding at the end of the period	$ 61
Vested and expected to vest at the end of the period	57
Vested and exercisable at the end of the period	$ 24
Additional disclosures
Weighted-average grant date fair value of stock options (in dollars per share)	$ 8.45	$ 7.83	$ 5.97
Intrinsic value of stock options exercised in the period	$ 3	$ 1	$ 1
Proceeds from exercise of stock options	5	2	1
Remaining unrecognized compensation expense related to non-vested awards	$ 11
Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized	1 year 6 months
Fair value of stock options vested	$ 18	$ 17	$ 20
Vesting Period One
Share-based compensation
Vesting period	3 years
Vesting Period One | Stock options
Share-based compensation
Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant	33.00%
Vesting Period Two
Share-based compensation
Vesting period	4 years
Vesting Period Two | Stock options
Share-based compensation
Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant	25.00%

SHARE-BASED COMPENSATION - RSUs

SHARE-BASED COMPENSATION - RSUs (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
RSUs
Share-based compensation
Percentage of vesting rights	33.00%
Vesting period	3 years
Time-Based RSUs
Share-based compensation
Remaining unrecognized compensation expense related to non-vested awards	$ 56
Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized	1 year 7 months 6 days
Total fair value	$ 34	$ 30	$ 58
RSUs
Beginning of the period (in shares)	5,800,000
Granted (in shares)	3,100,000
Vested (in shares)	(1,900,000)
Forfeited (in shares)	(900,000)
End of the period (in shares)	6,100,000	5,800,000
Weighted- Average Grant-Date Fair Value Per Share
Beginning of the period (in dollars per share)	$ 18.29
Granted (in dollars per share)	24.13
Vested (in dollars per share)	17.88
Forfeited (in dollars per share)	23.77
End of the period (in dollars per share)	$ 20.54	$ 18.29
Performance-Based Restricted Stock Units
Share-based compensation
Remaining unrecognized compensation expense related to non-vested awards	$ 28
Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized	1 year 7 months 6 days
Maximum common shares issuable upon vesting (in shares)	3,486,000
RSUs
Beginning of the period (in shares)	1,500,000
Granted (in shares)	959,000
Vested (in shares)	(300,000)
Forfeited (in shares)	(200,000)
End of the period (in shares)	2,000,000	1,500,000
Weighted- Average Grant-Date Fair Value Per Share
Beginning of the period (in dollars per share)	$ 34.06
Granted (in dollars per share)	29.52
Vested (in dollars per share)	48.42
Forfeited (in dollars per share)	91.76
End of the period (in dollars per share)	$ 25.80	$ 34.06
Method and assumptions on valuation of stock options
Contractual term (years)	3 years	3 years	3 years
Expected Company share volatility	46.50%	54.20%
Expected Company share volatility, minimum			67.20%
Expected Company share volatility, maximum			77.20%
Risk-free interest rate	2.50%	2.70%
Risk-free interest rate, minimum			1.70%
Risk-free interest rate, maximum			1.80%
Performance-Based Restricted Stock Units | Chief Executive Officer
Share-based compensation
Aggregate value of long term incentive awards		$ 10
Number of shares canceled (in shares)		933,000
TSR Performance-Based Restricted Stock Units
RSUs
Granted (in shares)	454,000
Weighted- Average Grant-Date Fair Value Per Share
Granted (in dollars per share)	$ 34.53
ROTC Performance-Based Restricted Stock Units
RSUs
Granted (in shares)	505,000
Weighted- Average Grant-Date Fair Value Per Share
Granted (in dollars per share)	$ 25.03

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ 1,136	$ 2,815	$ 5,944	$ 3,258
Foreign currency translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(2,046)	(2,111)
Pension adjustment, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(40)	(26)
Ending Balance
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ (2,086)	$ (2,137)	$ (1,896)	$ (2,108)

RESEARCH AND DEVELOPMENT - Sche

RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Research and Development [Abstract]
Product related research and development	$ 434	$ 376	$ 328
Quality assurance	37	37	33
Research and development	$ 471	$ 413	$ 361

OTHER EXPENSE (INCOME), NET - S

OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Other Income And Expenses [Line Items]
Net (gain) loss on other sales of assets	$ (31)	$ 6	$ 37
Litigation and other matters	1,401	(27)	226
Acquired in-process research and development costs	41	1	5
Acquisition-related costs	8	1	0
Other, net	(5)	(1)	1
Other expense (income), net	1,414	(20)	(348)
Skincare Brand
Schedule Of Other Income And Expenses [Line Items]
(Gain) loss on sale	0	0	(309)
iNova
Schedule Of Other Income And Expenses [Line Items]
(Gain) loss on sale	0	0	(309)
Dendreon
Schedule Of Other Income And Expenses [Line Items]
(Gain) loss on sale	0	0	(97)
Sprout
Schedule Of Other Income And Expenses [Line Items]
(Gain) loss on sale	$ 0	$ 0	$ 98

OTHER EXPENSE (INCOME), NET - N

OTHER EXPENSE (INCOME), NET - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Other Income And Expenses [Line Items]
Favorable (unfavorable) adjustment, litigation and other matters	$ (1,401)	$ 27	$ (226)
Milestone achievement, included in net gain (loss) on other sales of assets	31	(6)	(37)
Upfront payments, included in acquired in-process research and development costs	41	1	5
Licensing Agreements
Schedule Of Other Income And Expenses [Line Items]
Upfront payments, included in acquired in-process research and development costs	38
Milestone Payment Related To Certain Product
Schedule Of Other Income And Expenses [Line Items]
Milestone achievement, included in net gain (loss) on other sales of assets	$ 20
Salix Ltd. SEC Investigation Litigation
Schedule Of Other Income And Expenses [Line Items]
Favorable (unfavorable) adjustment, litigation and other matters		$ 40
Allergan Shareholder Class Actions | Valeant Co Parties
Schedule Of Other Income And Expenses [Line Items]
Litigation and other matters			96
Solodyn Antitrust Class Actions
Schedule Of Other Income And Expenses [Line Items]
Litigation and other matters			93
Mimetogen Pharmaceuticals Litigation
Schedule Of Other Income And Expenses [Line Items]
Litigation and other matters			$ 20

INCOME TAXES - Components of Be

INCOME TAXES - Components of Benefit from Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Components of loss before benefit of income taxes
Domestic	$ (2,396)	$ (1,475)	$ (2,032)
Foreign	559	(2,679)	291
Loss before benefit from income taxes	(1,837)	(4,154)	(1,741)
Current:
Domestic	(12)	0	(20)
Foreign	(116)	(327)	(146)
Total	(128)	(327)	(166)
Deferred:
Domestic	(5)	17	(2)
Foreign	187	320	4,313
Total	182	337	4,311
(Provision for) benefit from income taxes	$ 54	$ 10	$ 4,145

INCOME TAXES - Schedule of Effe

INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Expected Canadian statutory rate	26.90%	26.90%	26.90%
Loss before benefit from income taxes	$ (1,837)	$ (4,154)	$ (1,741)
Benefit from income taxes
Expected benefit from income taxes at Canadian statutory rate	494	1,117	468
Non-deductible amount of share-based compensation	(7)	(10)	(37)
Adjustments to tax attributes	(99)	(4)	(242)
Impact of changes in enacted income tax rates	0	0	747
Change in valuation allowance related to foreign tax credits and NOLs	21	(3)	139
Change in valuation allowance on Canadian deferred tax assets and tax rate changes	(142)	(875)	(360)
Change in uncertain tax positions	(350)	(47)	(65)
Foreign tax rate differences	186	(3)	933
Non-deductible portion of Goodwill impairments	0	(488)	(139)
Tax differences on divestitures of businesses	0	0	203
Tax benefit on intra-entity transfers	0	356	2,480
Other	(49)	(33)	18
(Provision for) benefit from income taxes	$ 54	$ 10	$ 4,145

INCOME TAXES - Tax Effect of Ma

INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Tax loss carryforwards	$ 2,911	$ 2,886
Provisions	641	519
Research and development tax credits	155	143
Scientific Research and Experimental Development pool	52	52
Tax credit carryforwards	25	46
Deferred revenue	5	4
Unrealized FX on U.S. dollar debt and other financing cost	94	262
Prepaid expenses	41	44
Share-based compensation	19	24
Other	23	0
Total deferred tax assets	3,966	3,980
Less valuation allowance	(2,831)	(2,913)
Net deferred tax assets	1,135	1,067
Deferred tax liabilities:
Intangible assets	53	163
Plant, equipment and technology	56	55
Outside basis differences	41	29
Other	0	29
Total deferred tax liabilities	150	276
Net deferred tax asset	$ 985	$ 791

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) $ in Millions, $ in Millions	Aug. 08, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2019USD ($)subsidiary	Dec. 31, 2019CAD ($)subsidiary	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jan. 09, 2018USD ($)
Income Tax [Line Items]
Tax Act - provisional net tax benefits						$ 975
Tax Act - re-measurement of certain deferred tax assets and liabilities, income tax expense (benefit)						774
Tax Act - one-time transition tax on certain foreign earnings, income tax expense (benefit)						88
Tax Act - decrease in deferred tax asset attributable to certain legal accruals, income tax expense (benefit)						10
Tax Act - Outside basis differences in certain foreign subsidiaries, provisional income tax expense (benefit)		$ (299)					$ 299
Net benefit related to the carryback of losses		400				400
Reversal of previously established deferred tax liability, benefit						1,900
Valuation allowance against deferred tax assets			$ 2,831		$ 2,913
Provisional deferred tax benefit related to intentions to amend prior tax filings						84
Unrecognized tax benefits including interest and penalties			1,002		654
Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate			355		345
Unrecognized tax benefits, net increase for tax positions of current year			362		18
Unrecognized tax benefits, net decrease for tax positions of prior years			13
Unrecognized tax benefits, net increase for tax positions of prior years					38
Accrued interest and penalties related to unrecognized tax benefits			$ 45		42
Net increase (decrease) recognized in interest and penalties					3	1
Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more) | subsidiary			1	1
Restricted cash		$ 77	$ 1		2	77		$ 77
Letter of credit								$ 77
Possible decrease in unrecognized tax benefits realized in next twelve months			110
Tax Year 2013
Income Tax [Line Items]
Notice of tax assessment, aggregate amount of possible loss				$ 90
Canadian Federal and Provincial
Income Tax [Line Items]
Increase (decrease) in valuation allowance			(82)		912
Accumulated losses available for federal and provincial purposes			7,441		5,655
Unclaimed investment tax credits and research and development credits			34		34
Valuation allowance against deferred tax assets			2,461		2,470
Canadian Federal and Provincial | Pooled Scientific Research and Experimental Development
Income Tax [Line Items]
Tax credit carryforward			192		192
United States - Federal
Income Tax [Line Items]
Accumulated losses available for federal and provincial purposes			636		1,552
Unclaimed investment tax credits and research and development credits			106		97
Foreign tax credits reversal						$ 342
United States - Federal | Revenue Commissioners, Ireland
Income Tax [Line Items]
Accumulated losses available for federal and provincial purposes			$ 6,765
Ireland | Revenue Commissioners, Ireland
Income Tax [Line Items]
Accumulated losses available for federal and provincial purposes					$ 5,495
Ireland | Canada Revenue Agency
Income Tax [Line Items]
Estimate of possible loss, amount not subject to full valuation allowance				3
Ireland | Australian Taxation Office
Income Tax [Line Items]
Notice of tax assessment, aggregate amount of possible loss	$ 117
Ireland | Tax Year 2012 | Canada Revenue Agency
Income Tax [Line Items]
Notice of tax assessment, aggregate amount of possible loss				$ 85

INCOME TAXES - Federal Income T

INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)	12 Months Ended
	Dec. 31, 2019
United States - Federal | Minimum
Income Taxes
Open Years	2014
United States - Federal | Maximum
Income Taxes
Open Years	2018
Canada | Minimum
Income Taxes
Open Years	2005
Canada | Maximum
Income Taxes
Open Years	2018
Germany | Minimum
Income Taxes
Open Years	2013
Germany | Maximum
Income Taxes
Open Years	2018
France | Minimum
Income Taxes
Open Years	2013
France | Maximum
Income Taxes
Open Years	2018
China | Minimum
Income Taxes
Open Years	2015
China | Maximum
Income Taxes
Open Years	2018
Ireland | Minimum
Income Taxes
Open Years	2015
Ireland | Maximum
Income Taxes
Open Years	2018
Netherlands
Income Taxes
Open Years	2018
Australia | Minimum
Income Taxes
Open Years	2011
Australia | Maximum
Income Taxes
Open Years	2018

INCOME TAXES - Reconciliation S

INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of year	$ 654	$ 598	$ 423
Additions based on tax positions related to the current year	361	18	145
Additions for tax positions of prior years	63	55	57
Reductions for tax positions of prior years	(58)	(11)	(18)
Lapse of statute of limitations	(18)	(6)	(9)
Balance, end of year	$ 1,002	$ 654	$ 598

(LOSS) EARNINGS PER SHARE - Sch

(LOSS) EARNINGS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net (loss) income attributable to Bausch Health Companies Inc.	$ (1,516)	$ (49)	$ (171)	$ (52)	$ (344)	$ (350)	$ (873)	$ (2,581)	$ (1,788)	$ (4,148)	$ 2,404
Basic weighted-average number of common shares outstanding (in shares)									352.1	351.3	350.2
Dilutive effect of stock options, RSUs and other (in shares)									0	0	1.6
Diluted weighted-average number of common shares outstanding (in shares)									352.1	351.3	351.8
(Loss) earnings per share attributable to Bausch Health Companies Inc.
Basic (in dollars per share)									$ (5.08)	$ (11.81)	$ 6.86
Diluted (in dollars per share)									$ (5.08)	$ (11.81)	$ 6.83

(LOSS) EARNINGS PER SHARE - Nar

(LOSS) EARNINGS PER SHARE - Narrative (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)	5,106	3,763
Stock options, Time-based RSUs, Performance-based RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)	2,598	4,185	7,050

SUPPLEMENTAL CASH FLOW DISCLO_3

SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Payments
Interest paid	$ 1,537	$ 1,665	$ 1,708
Income taxes paid	$ 172	$ 138	$ 179

LEGAL PROCEEDINGS - Narrative (

LEGAL PROCEEDINGS - Narrative (Details) $ in Millions

Jan. 10, 2020USD ($)

Nov. 25, 2019case

Aug. 19, 2019USD ($)

Jan. 28, 2019USD ($)

Dec. 07, 2017insurance_policy_period

Mar. 24, 2017case

Feb. 19, 2020case

Sep. 30, 2019

Jan. 31, 2019case

Apr. 30, 2018USD ($)

Sep. 16, 2016action

Dec. 31, 2019USD ($)case

Dec. 31, 2019USD ($)groupcaseaction

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2015case

Sep. 13, 2019shareholder

Sep. 10, 2019shareholder

Feb. 15, 2019entity

Dec. 30, 2016case

Mar. 31, 2015manufacturer

Legal proceedings and other matters

Legal matters and related fees | $

$ 1,397

$ 1,397

$ 11

Payments for legal settlements | $

$ 15

$ 224

$ 221

Insurance Coverage Lawsuit

Legal proceedings and other matters

Number of distinct insurance policy periods | insurance_policy_period

2

Derivative Lawsuits

Legal proceedings and other matters

Number of alleged stockholders filed lawsuits | shareholder

2

2

Glumetza Antitrust Litigation

Legal proceedings and other matters

Recent suits filed

6

Glumetza Antitrust Litigation, Non-Class Complaints

Legal proceedings and other matters

Recent suits filed

2

2

Sandoz Litigation

Legal proceedings and other matters

Stay of the approval period

30 months

Shower to Shower Product Liability Litigation

Legal proceedings and other matters

Number of lawsuits

165

165

Shower to Shower Product Liability Litigation | Pending Litigation

Legal proceedings and other matters

Number of lawsuits

12

12

Johnson & Johnson Talcum Powder Litigation

Legal proceedings and other matters

Recent suits filed

2

Number of lawsuits

1

6

6

3

Number of cases voluntarily dismissed

4

Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation

Legal proceedings and other matters

Number of lawsuits

2

2

Number of cases not voluntarily dismissed

3

Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue

Legal proceedings and other matters

Number of lawsuits

1

1

Doctors Allergy Formula, LLC Litigation

Legal proceedings and other matters

Damages sought | $

$ 23

Litigation with Former Salix CEO

Legal proceedings and other matters

Damages sought | $

$ 30

Contact Lens Antitrust Class Actions | Settled Litigation

Legal proceedings and other matters

Litigation, amount agreed to pay | $

$ 10

Number of manufacturers | manufacturer

3

Investigation by the State of Texas | Settled Litigation

Legal proceedings and other matters

Litigation, amount agreed to pay | $

$ 10

Mississippi Attorney General Consumer Protection Action Litigation | Settled Litigation

Legal proceedings and other matters

Litigation, amount agreed to pay | $

$ 0

New Jersey | Unfavorable Regulatory Action

Legal proceedings and other matters

Recent suits filed | action

3

New Jersey | Valeant US Securities Litigation

Legal proceedings and other matters

Number of groups of investors | group

33

New Jersey | Valeant US Securities Litigation | Settled Litigation

Legal proceedings and other matters

Litigation, amount agreed to pay | $

$ 1,210

New Jersey | Johnson & Johnson Talcum Powder Litigation

Legal proceedings and other matters

Number of lawsuits

4

4

Canada

Legal proceedings and other matters

Recent suits filed

6

Canada | Violation of Canadian Provincial Securities Legislation

Legal proceedings and other matters

Number of additional suits filed, but not served | action

2

Number of entities, exercised opt-out right, pursuing action | entity

1

Canada | Shower to Shower Product Liability Litigation

Legal proceedings and other matters

Number of lawsuits

2

2

Delaware | Johnson & Johnson Talcum Powder Litigation

Legal proceedings and other matters

Number of cases voluntarily dismissed

122

Claims dismissed, refiling period

60 days

Claims dismissed, number of cases refiled

0

0

British Columbia | Shower to Shower Product Liability Litigation

Legal proceedings and other matters

Number of lawsuits

1

1

Quebec | Shower to Shower Product Liability Litigation

Legal proceedings and other matters

Number of lawsuits

1

1

Subsequent event | Glumetza Antitrust Litigation

Legal proceedings and other matters

Recent suits filed

2

Subsequent event | New Jersey | Valeant US Securities Litigation

Legal proceedings and other matters

Payments for legal settlements | $

$ 200

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details)	Dec. 31, 2019USD ($)
Other commitments
Capital expenditures	$ 142,000,000
Milestone payments in terms of collaboration and license agreements, aggregate	315,000,000
Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.
Other commitments
Milestone payments in terms of collaboration and license agreements, aggregate	70,000,000
Mitsubishi Tanabe Pharma Corporation
Other commitments
Milestone payments in terms of collaboration and license agreements, aggregate	60,000,000
Novaliq GmbH
Other commitments
Milestone payments in terms of collaboration and license agreements, aggregate	45,000,000
Kaken Pharmaceutical Co., Ltd.
Other commitments
Milestone payments in terms of collaboration and license agreements, aggregate	$ 43,000,000

SEGMENT INFORMATION - Segment R

SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details) - USD ($)	Oct. 01, 2019	Mar. 08, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment reporting information
Revenue			$ 2,224,000,000	$ 2,209,000,000	$ 2,152,000,000	$ 2,016,000,000	$ 2,121,000,000	$ 2,136,000,000	$ 2,128,000,000	$ 1,995,000,000	$ 8,601,000,000	$ 8,380,000,000	$ 8,724,000,000
Operating (loss) income			$ (1,076,000,000)	$ 329,000,000	$ 257,000,000	$ 287,000,000	$ 25,000,000	$ 117,000,000	$ (245,000,000)	$ (2,281,000,000)	(203,000,000)	(2,384,000,000)	102,000,000
Amortization of intangible assets											(1,897,000,000)	(2,644,000,000)	(2,690,000,000)
Goodwill impairments	$ 0										0	(2,322,000,000)	(312,000,000)
Asset impairments											(75,000,000)	(568,000,000)	(714,000,000)
Restructuring and integration costs											(31,000,000)	(22,000,000)	(52,000,000)
Acquisition-related contingent consideration											(12,000,000)	9,000,000	289,000,000
Other expense (income), net											(1,414,000,000)	20,000,000	348,000,000
Interest income											12,000,000	11,000,000	12,000,000
Interest expense											(1,612,000,000)	(1,685,000,000)	(1,840,000,000)
Loss on extinguishment of debt		$ 8,000,000									42,000,000	119,000,000	122,000,000
Foreign exchange and other											8,000,000	23,000,000	107,000,000
Loss before benefit from income taxes											(1,837,000,000)	(4,154,000,000)	(1,741,000,000)
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											270,000,000	157,000,000	171,000,000
Baush and Lomb/International
Segment reporting information
Revenue											4,739,000,000	4,664,000,000	4,795,000,000
Salix
Segment reporting information
Revenue											2,022,000,000	1,749,000,000	1,566,000,000
Ortho Dermatologics
Segment reporting information
Revenue											565,000,000	617,000,000	721,000,000
Diversified Products
Segment reporting information
Revenue											1,275,000,000	1,350,000,000	1,642,000,000
Operating Segments
Segment reporting information
Revenue											8,601,000,000	8,380,000,000	8,724,000,000
Operating (loss) income											3,835,000,000	3,748,000,000	3,795,000,000
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											230,000,000	144,000,000	168,000,000
Operating Segments | Baush and Lomb/International
Segment reporting information
Revenue											4,739,000,000	4,664,000,000	4,795,000,000
Operating (loss) income											1,332,000,000	1,330,000,000	1,412,000,000
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											225,000,000	139,000,000	159,000,000
Operating Segments | Salix
Segment reporting information
Revenue											2,022,000,000	1,749,000,000	1,566,000,000
Operating (loss) income											1,349,000,000	1,149,000,000	935,000,000
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											2,000,000	2,000,000	3,000,000
Operating Segments | Ortho Dermatologics
Segment reporting information
Revenue											565,000,000	617,000,000	721,000,000
Operating (loss) income											222,000,000	257,000,000	333,000,000
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											1,000,000	1,000,000	2,000,000
Operating Segments | Diversified Products
Segment reporting information
Revenue											1,275,000,000	1,350,000,000	1,642,000,000
Operating (loss) income											932,000,000	1,012,000,000	1,115,000,000
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											2,000,000	2,000,000	4,000,000
Corporate
Segment reporting information
Operating (loss) income											(609,000,000)	(605,000,000)	(562,000,000)
Capital Expenditures, and Depreciation and Amortization
Total capital expenditures											$ 40,000,000	$ 13,000,000	$ 3,000,000

SEGMENT INFORMATION - Revenues

SEGMENT INFORMATION - Revenues by Product Category (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)product	Dec. 31, 2018USD ($)product	Dec. 31, 2017USD ($)product
Revenue from External Customer [Line Items]
Number of products represented of total revenue | product									10	10	10
Revenue	$ 2,224	$ 2,209	$ 2,152	$ 2,016	$ 2,121	$ 2,136	$ 2,128	$ 1,995	$ 8,601	$ 8,380	$ 8,724
Pharmaceuticals
Revenue from External Customer [Line Items]
Revenue									4,072	4,028	4,377
Devices
Revenue from External Customer [Line Items]
Revenue									1,717	1,640	1,532
OTC
Revenue from External Customer [Line Items]
Revenue									1,452	1,412	1,529
Branded and Other Generics
Revenue from External Customer [Line Items]
Revenue									1,248	1,191	1,157
Other revenues
Revenue from External Customer [Line Items]
Revenue									112	109	129
Baush and Lomb/International
Revenue from External Customer [Line Items]
Revenue									4,739	4,664	4,795
Baush and Lomb/International | Pharmaceuticals
Revenue from External Customer [Line Items]
Revenue									885	892	956
Baush and Lomb/International | Devices
Revenue from External Customer [Line Items]
Revenue									1,524	1,505	1,421
Baush and Lomb/International | OTC
Revenue from External Customer [Line Items]
Revenue									1,452	1,412	1,529
Baush and Lomb/International | Branded and Other Generics
Revenue from External Customer [Line Items]
Revenue									801	784	819
Baush and Lomb/International | Other revenues
Revenue from External Customer [Line Items]
Revenue									77	71	70
Salix
Revenue from External Customer [Line Items]
Revenue									2,022	1,749	1,566
Salix | Pharmaceuticals
Revenue from External Customer [Line Items]
Revenue									2,022	1,752	1,564
Salix | Devices
Revenue from External Customer [Line Items]
Revenue									0	0	0
Salix | OTC
Revenue from External Customer [Line Items]
Revenue									0	0	0
Salix | Branded and Other Generics
Revenue from External Customer [Line Items]
Revenue									0	0	0
Salix | Other revenues
Revenue from External Customer [Line Items]
Revenue									0	(3)	2
Ortho Dermatologics
Revenue from External Customer [Line Items]
Revenue									565	617	721
Ortho Dermatologics | Pharmaceuticals
Revenue from External Customer [Line Items]
Revenue									355	457	567
Ortho Dermatologics | Devices
Revenue from External Customer [Line Items]
Revenue									193	135	111
Ortho Dermatologics | OTC
Revenue from External Customer [Line Items]
Revenue									0	0	0
Ortho Dermatologics | Branded and Other Generics
Revenue from External Customer [Line Items]
Revenue									0	0	0
Ortho Dermatologics | Other revenues
Revenue from External Customer [Line Items]
Revenue									17	25	43
Diversified Products
Revenue from External Customer [Line Items]
Revenue									1,275	1,350	1,642
Diversified Products | Pharmaceuticals
Revenue from External Customer [Line Items]
Revenue									810	927	1,290
Diversified Products | Devices
Revenue from External Customer [Line Items]
Revenue									0	0	0
Diversified Products | OTC
Revenue from External Customer [Line Items]
Revenue									0	0	0
Diversified Products | Branded and Other Generics
Revenue from External Customer [Line Items]
Revenue									447	407	338
Diversified Products | Other revenues
Revenue from External Customer [Line Items]
Revenue									$ 18	$ 16	$ 14
Revenues | Product Concentration Risk
Revenue from External Customer [Line Items]
Concentration risk, percentage									39.00%	36.00%	32.00%

SEGMENT INFORMATION - Geographi

SEGMENT INFORMATION - Geographic Information, Revenue (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues and long-lived assets by geographic region
Revenue	$ 2,224	$ 2,209	$ 2,152	$ 2,016	$ 2,121	$ 2,136	$ 2,128	$ 1,995	$ 8,601	$ 8,380	$ 8,724
U.S. and Puerto Rico
Revenues and long-lived assets by geographic region
Revenue									5,164	5,011	5,225
China
Revenues and long-lived assets by geographic region
Revenue									368	361	331
Canada
Revenues and long-lived assets by geographic region
Revenue									339	319	326
Japan
Revenues and long-lived assets by geographic region
Revenue									241	226	223
Poland
Revenues and long-lived assets by geographic region
Revenue									231	218	201
Mexico
Revenues and long-lived assets by geographic region
Revenue									228	211	201
Egypt
Revenues and long-lived assets by geographic region
Revenue									218	178	152
France
Revenues and long-lived assets by geographic region
Revenue									201	205	188
Russia
Revenues and long-lived assets by geographic region
Revenue									180	154	200
Germany
Revenues and long-lived assets by geographic region
Revenue									150	170	157
United Kingdom
Revenues and long-lived assets by geographic region
Revenue									115	117	108
Spain
Revenues and long-lived assets by geographic region
Revenue									86	83	77
Italy
Revenues and long-lived assets by geographic region
Revenue									85	85	78
Other
Revenues and long-lived assets by geographic region
Revenue									$ 995	$ 1,042	$ 1,257

SEGMENT INFORMATION - Geograp_2

SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Revenues and long-lived assets by geographic region
Long-lived assets	$ 1,466	$ 1,353
U.S. and Puerto Rico
Revenues and long-lived assets by geographic region
Long-lived assets	656	593
Ireland
Revenues and long-lived assets by geographic region
Long-lived assets	255	217
Canada
Revenues and long-lived assets by geographic region
Long-lived assets	103	99
Poland
Revenues and long-lived assets by geographic region
Long-lived assets	90	94
Germany
Revenues and long-lived assets by geographic region
Long-lived assets	68	66
Egypt
Revenues and long-lived assets by geographic region
Long-lived assets	62	50
Mexico
Revenues and long-lived assets by geographic region
Long-lived assets	50	48
France
Revenues and long-lived assets by geographic region
Long-lived assets	30	31
China
Revenues and long-lived assets by geographic region
Long-lived assets	27	25
Serbia
Revenues and long-lived assets by geographic region
Long-lived assets	27	28
Italy
Revenues and long-lived assets by geographic region
Long-lived assets	22	23
Other
Revenues and long-lived assets by geographic region
Long-lived assets	$ 76	$ 79

SEGMENT INFORMATION - Major Cus

SEGMENT INFORMATION - Major Customers (Details) - Customer concentration - Revenues	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
McKesson Corporation
Segment reporting information
Concentration risk, percentage	17.00%	18.00%	19.00%
AmerisourceBergen Corporation
Segment reporting information
Concentration risk, percentage	16.00%	18.00%	15.00%
Cardinal Health, Inc.
Segment reporting information
Concentration risk, percentage	14.00%	13.00%	13.00%

SUPPLEMENTARY DATA (UNAUDITED_2

SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 2,224	$ 2,209	$ 2,152	$ 2,016	$ 2,121	$ 2,136	$ 2,128	$ 1,995	$ 8,601	$ 8,380	$ 8,724
Expenses	3,300	1,880	1,895	1,729	2,096	2,019	2,373	4,276	8,804	10,764	8,622
Operating (loss) income	(1,076)	329	257	287	25	117	(245)	(2,281)	(203)	(2,384)	102
Net loss attributable to Bausch Health Companies Inc.	$ (1,516)	$ (49)	$ (171)	$ (52)	$ (344)	$ (350)	$ (873)	$ (2,581)	(1,788)	(4,148)	2,404
Basic and Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)	$ (4.30)	$ (0.14)	$ (0.49)	$ (0.15)	$ (0.98)	$ (1)	$ (2.49)	$ (7.36)
Net cash provided by operating activities	$ 234	$ 515	$ 339	$ 413	$ 319	$ 522	$ 222	$ 438	$ 1,501	$ 1,501	$ 2,290

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS - Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 2,384	$ 2,546
Charged to Other Accounts	5,287	5,887
Deductions	(5,637)	(6,049)
Balance at End of Year	2,050	2,384	$ 2,546
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	47	97	80
Charged to Costs and Expenses	10	4	33
Charged to Other Accounts	(1)	(4)	4
Deductions	(8)	(50)	(20)
Balance at End of Year	48	47	97
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	2,913	2,001	1,857
Charged to Costs and Expenses	13	870	221
Charged to Other Accounts	(95)	42	(77)
Deductions	0	0	0
Balance at End of Year	$ 2,831	$ 2,913	$ 2,001